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Abstract
Development of risk models for the prediction of new or
worsening acute kidney injury on or during hospital
admission: a cohort and nested study
Michael Bedford,1* Paul Stevens,1 Simon Coulton,2 Jenny Billings,2
Marc Farr,3 Toby Wheeler,1 Maria Kalli,4 Tim Mottishaw5
and Chris Farmer1
1Kent Kidney Research Group, Kent and Canterbury Hospital, East Kent Hospitals University NHS
Foundation Trust, Canterbury, UK
2Centre for Health Services Studies, University of Kent, Canterbury, UK
3Department of Information, Kent and Canterbury Hospital, East Kent Hospitals University NHS
Foundation Trust, Canterbury, UK
4Canterbury Christ Church University Business School, Canterbury Christ Church University,
Canterbury, UK
5Strategic Development, Royal Victoria Hospital, East Kent Hospitals University NHS Foundation
Trust, Canterbury, UK
*Corresponding author michael.bedford@nhs.net
Background: Acute kidney injury (AKI) is a common clinical problem with significant morbidity and
mortality. All hospitalised patients are at risk. AKI is often preventable and reversible; however, the
2009 National Confidential Enquiry into Patient Outcome and Death highlighted systematic failings of
identification and management, and recommended risk assessment of all emergency admissions.
Objectives: To develop three predictive models to stratify the risk of (1) AKI on arrival in hospital;
(2) developing AKI during admission; and (3) worsening AKI if already present; and also to (4) develop a
clinical algorithm for patients admitted to hospital and explore effective methods of delivery of this
information at the point of care.
Study design: Quantitative methodology (1) to formulate predictive risk models and (2) to validate the
models in both our population and a second population. Qualitative methodology to plan clinical decision
support system (CDSS) development and effective integration into clinical care.
Settings and participants: Quantitative analysis – the study population comprised hospital admissions to
three acute hospitals of East Kent Hospitals University NHS Foundation Trust in 2011, excluding maternity
and elective admissions. For validation in a second population the study included hospital admissions to
Medway NHS Foundation Trust. Qualitative analysis – the sample consisted of six renal consultants
(interviews) and six outreach nurses (focus group), with representation from all sites.
Data collection: Data (comprising age, sex, comorbidities, hospital admission and outpatient history,
relevant pathology tests, drug history, baseline creatinine and chronic kidney disease stage, proteinuria,
operative procedures and microbiology) were collected from the hospital data warehouse and the
pathology and surgical procedure databases.
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Data analysis: Quantitative – both traditional and Bayesian regression methods were used. Traditional
methods were performed using ordinal logistic regression with univariable analyses to inform the
development of multivariable analyses. Backwards selection was used to retain only statistically significant
variables in the final models. The models were validated using actual and predicted probabilities, an area
under the receiver operating characteristic (AUROC) curve analysis and the Hosmer–Lemeshow test.
Qualitative – content analysis was employed.
Main outcome measures: (1) A clinical pratice algorithm to guide clinical alerting and risk modeling for
AKI in emergency hospital admissions; (2) identification of the key variables that are associated with the
risk of AKI; (3) validated risk models for AKI in acute hospital admissions; and (4) a qualitative analysis
providing guidance as to the best approach to the implementation of clinical alerting to highlight patients
at risk of AKI in hospitals.
Findings: Quantitative – we have defined a clinical practice algorithm for risk assessment within the first
24 hours of hospital admission. Bayesian methodology enabled prediction of low risk but could not reliably
identify high-risk patients. Traditional methods identified key variables, which predict AKI both on
admission and at 72 hours post admission. Validation demonstrated an AUROC curve of 0.75 and 0.68,
respectively. Predicting worsening AKI during admission was unsuccessful. Qualitative – analysis of AKI
alerting gave valuable insights in terms of user friendliness, information availability, clinical communication
and clinical responsibility, and has informed CDSS development.
Conclusions: This study provides valuable evidence of relationships between key variables and AKI.
We have developed a clinical algorithm and risk models for risk assessment within the first 24 hours of
hospital admission. However, the study has its limitations, and further analysis and testing, including
continuous modelling, non-linear modelling and interaction exploration, may further refine the models.
The qualitative study has highlighted the complexity regarding the implementation and delivery of alerting
systems in clinical practice.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
Patients admitted to hospital are at risk of damage to kidney function, termed acute kidney injury (AKI),either from their illness or as a result of subsequent treatment. Kidney injury can lead to serious health
issues and even death. It is essential that patients at risk, and those who develop kidney injury, are
recognised early and treated effectively. However, the 2009 National Confidential Enquiry into Patient
Outcome and Death highlighted systematic failings of identification and subsequent management of
kidney injury in hospital. The report recommended risk assessment for all patients admitted to hospital.
We extracted data on hospital admissions during 2011 to a large NHS trust. Data comprised age, sex,
chronic medical conditions, hospital admission and outpatient history, relevant blood tests, medication
history, kidney functions, urine protein testing and operations. These data were used successfully to
develop mathematical risk models to predict AKI on admission to hospital and at 72 hours post admission.
These models were checked in a second local population and also in a further population with different
demographic characteristics, suggesting that these models may be transferable across the NHS. We were
unable to develop a model to predict worsening AKI.
We also conducted a focus group and individual interviews about an alerting system already in place for
AKI, to assess the most effective way to incorporate risk alerting into everyday clinical practice. This analysis
has provided valuable insights into the delivery of information and alerting in clinical practice.
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Scientific summary
Background
Acute kidney injury (AKI) is a global health issue and is a common clinical problem characterised by an acute
decline in renal function, the results of which range from small changes in serum creatinine to anuric renal
failure requiring renal replacement therapy. Its prevalence (5–7% among inpatients) is increasing, associated
with an ageing population and increasing comorbidity. Patients with AKI have significantly increased
in-hospital and 12-month mortality, length of stay, admission to intensive therapy unit, 30-day readmission
and increase in care on discharge. All hospitalised patients are at risk of AKI, resulting from their presenting
disease or subsequent iatrogenic injury. AKI is often preventable and reversible; however, the 2009 National
Confidential Enquiry into Patient Outcome and Death [Stewart J, Findlay G, Smith N, Kelly K, Mason M.
Adding Insult to Injury. A Review of the Care of Patients Who Died in Hospital with a Primary Diagnosis of
Acute Kidney Injury (Acute Renal Failure). London: National Confidential Enquiry into Patient Outcome and
Death; 2009] highlighted systematic failings of identification and management, and recommended risk
assessment of all emergency admissions. The National Institute for Health and Care Excellence (NICE) clinical
guideline 169 (NICE. Acute Kidney Injury: Prevention, Detection and Management of Acute Kidney Injury up
to the Point of Renal Replacement Therapy. Clinical Guideline 169. London: NICE; 2013) recommends
research to assess the risk of AKI to drive prevention and early recognition.
Objectives
1. Identification of AKI: accurately identify and report patients with AKI.
2. Develop predictive models: based on factors identified in primary and secondary care records and the
admission characteristics of each patient, develop three predictive models to stratify the risk of
(1) AKI on arrival in hospital; (2) developing AKI during the admission; and (3) worsening AKI if it is
already present.
3. Produce a clinical algorithm: use the predictive model to develop an algorithm for all patients admitted
to hospital to stratify them according to risk of developing AKI.
4. Integration into clinical practice: define the most effective way to incorporate the risk model into a
clinical decision support system (CDSS) that can be integrated into everyday clinical practice. This will
inform the follow-on study from this project.
Study design
This study involved both quantitative and qualitative methodology. Quantitative methodology was used to
(1) formulate the predictive risk model and (2) validate the risk model in the East Kent population and a
second population and NHS trust (Medway NHS Foundation Trust). Qualitative methodology was employed
to plan CDSS development and effectively integrate it into everyday clinical care.
Setting
The study population comprised all patients presenting to the three acute hospitals of East Kent Hospitals
University NHS Foundation Trust (EKHUFT) (Kent and Canterbury Hospital in Canterbury, William Harvey
Hospital in Ashford and Queen Elizabeth the Queen Mother Hospital in Margate) in the calendar year
2011. The renal tertiary referral centre is based at Kent and Canterbury Hospital. The secondary validation
population included all patients presenting to Medway NHS Foundation Trust.
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Participants
Quantitative analysis
For risk model development and validation in the first population, the study included hospital admissions to
EKHUFT during 2011, excluding maternity admissions and elective admissions. For validation in the second
population, the study included hospital admission to Medway NHS Foundation Trust over the same time
period and with the same exclusions.
Qualitative analysis
The sample consisted of six renal consultants for the individual interviews and six outreach nurses who
attended the focus group. All consultants worked across the three hospitals within the trust and there was
representation from all hospitals from the outreach nurses.
Data collection
Data were extracted from four primary databases at EKHUFT: the hospital episode database (age, sex,
comorbidities, hospital admission and outpatient history); the pathology database (relevant pathology tests,
e.g. C-reactive protein (CRP) levels, white blood cell count (WBC), microbiology tests, proteinuria testing,
and including level of creatinine to define AKI and chronic kidney disease stage); the electronic discharge
notification database (drug history); and the operation database (operative procedures).
Data analysis
Quantitative
We investigated the use of both Bayesian and traditional regression methods to develop the risk models.
In the Bayesian methods we worked out the likelihood function of the data, placed a prior distribution
over all of the unknown parameters and used the Bayes theorem to calculate the posterior distribution
over all parameters. We selected a normal distribution prior for the unknown coefficients, and within that
incorporated the stochastic search variable selection approach described in George and McCullogh
(George CI, McCulloch RE. Variable selection via Gibbs sampling. J Am Stat Assoc 1993;88:88–9). To
proceed to the calculation of the posterior and to inference we used Markov chain Monte Carlo methods
and coded/constructed a Gibbs sampler. We ran the sampler for 200,000 iterations, with the first 10,000
iterations as burn-in.
The traditional methods were performed using ordinal logistic regression and employed a robust standard
error to account for multiple admissions for some patients. Initially, the individual association between each
factor and AKI stage was examined individually in a series of univariable analyses. Subsequently, the joint
association between the factors and AKI stage was examined in a multivariable analysis. A backwards
selection procedure was used to retain only the statistically significant variables in the final models.
The developed models were validated in both the EKHUFT data set and a second population data set at
Medway NHS Foundation Trust. The first approach split the validation data set into risk groups based on the
predicted probabilities. Within each risk category, the actual occurrence of AKI was assessed and compared
with the predictions. This method assesses both the discrimination and calibration of the model. Second,
we assessed the discrimination between high- and low-risk cases by calculating the area under the receiver
operating characteristic (ROC) curve. A final set of analyses examined the difference in the observed
outcome and that predicted by the model using the Hosmer–Lemeshow test.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxii
Qualitative
The analytical approach taken for the focus group and interviews was that of Flick’s content analysis
(Flick U. Introduction to Qualitative Research. Thousand Oaks, CA: Sage Publications; 1998), whereby
themes and subthemes are categorised within a pre-existing template (usually the instrumentation).
Findings
Quantitative
We have defined a clear clinical practice algorithm for risk assessment within the first 24 hours of hospital
admission. Quantitative analysis has identified key variables from a large data set which would be useful
for predicting AKI in patients admitted to hospital. Bayesian methodology enabled prediction of those at
low risk of AKI on admission but could not reliably identify high-risk patients. Traditional methods to assess
risk at admission (model 1) and at 24 hours (model 2) identified a number of key variables which predict
AKI at both 24 hours and 72 hours post admission. Subsequent validation demonstrated areas under the
ROC of 0.75 and 0.68, respectively. However, modelling was unable to reliably predict those with
worsening AKI (ROC of 0.53).
The predictive variables included in the first model for the prediction of AKI at the point of admission to
hospital were age, previous hospital admissions, primary diagnosis, Charlson Comorbidity Index score
and laboratory variables, including levels of CRP, haemoglobin (Hb), glycated haemoglobin and troponin,
proteinuria and baseline estimated glomerular filtration rate. Other variables included medications and
microbiology, including blood culture and mid-stream specimen urine or catheter specimen urine. For the
second model predicting new AKI at 72 hours, the results were similar; however, Hb was not a significant
predictor, but levels of potassium or magnesium and WBCs were. In the second model, microbiology
and medications were not significant.
Qualitative
The qualitative analysis gave valuable insights into the use of a clinical alerting system for AKI already in
operation in clinical practice in the hospitals. The analysis suggested that initial responses to the system
appeared encouraging; however, there were some issues highlighted with regard to the user-friendliness
of the system and the advantages and disadvantages of the timing of access to clinical alerts. The users
also voiced concerns with regard to clinical communication and clinical responsibility. Despite being of
small scale, which may limit its generalisability, this work has informed the development of a new alerting
system and pathway of care for AKI at the trust, which will be employed to deliver the risk modelling from
this study into clinical practice.
Conclusion
In our studies we have been able to demonstrate that routinely available data can be used to highlight
patients at risk of AKI both at the point of admission to hospital and following admission. However, the
methodology used has its limitations, and further analysis and testing, including continuous modelling,
non-linear modelling and interaction exploration, may refine the model further. This study provides
valuable evidence of the relationships between key variables available from hospital electronic records and
AKI. Some of the models may be refined further once physiological data become more commonly available
across the NHS. We have provided a clear clinical algorithm for risk assessment within the first 24 hours
of hospital admission and thereafter. The clinical algorithm includes a decision matrix and the application
of the multivariable analysis to patient data. The qualitative element of this study has also highlighted
the complexity of the implementation and delivery of alerting systems to the clinical front line.
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Recommendations for future research
The next stage of this work is to test these risk models in terms of their clinical, logistic and economic
impact in routine clinical practice in a clinical intervention pilot study.
There should also be further work to investigate the development of clinical risk models in different
settings (e.g. elective surgery or radiocontrast investigations) within clinical practice, as we believe that a
number of risk models need be to employed across the different settings within the secondary care
environment. There should also be work to investigate the development of risk models to predict
the presence of AKI in patients presenting to their general practitioner in primary care to guide testing in
this setting.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
What is acute kidney injury?
Acute kidney injury (AKI), previously known as acute renal failure, is an all too common clinical problem
characterised by an acute decline in renal function, the results of which range from minimal alteration in
serum creatinine to anuric renal failure necessitating renal replacement therapy (RRT). This abrupt rise
in serum creatinine results from an insult or injury that causes a functional or structural change in the
kidney. The aetiologies and risk factors for AKI are numerous, but now well defined.1–4 Even without
the need for RRT, AKI may impact on a patient’s clinical course with complications such as fluid overload,
acidosis and hyperkalaemia, all of which may lead to an increase in morbidity, length of stay and,
ultimately, mortality in both the long and short term. Renal outcomes include full renal recovery, no renal
recovery, development of chronic kidney disease (CKD) and progression of pre-existing CKD.5–9
Acute kidney injury is increasingly well recognised as a public health issue and is both a consequence and
a predictor of CKD.10–12 Its prevalence (4.9% among hospitalised patients in the USA) is increasing,13 owing
to an ageing population and the growing burden of the same risk factors contributing to the rise in CKD
(including obesity, diabetes and hypertension), and also to better recognition.
Conceptual model
The conceptual model of CKD is well established, and continues to inform clinical medicine, research and
public health.14–16 In contrast, the concept of acute kidney diseases and disorders (AKD) is relatively new and
attempts to map itself onto the widely accepted CKD concept. The definition of AKI, in contradistinction to
CKD, describes an abrupt, time-limited reduction of function which has at least the potential to recover.
Both AKI and CKD describe decreased function which can lead to complications, including end-stage renal
disease (ESRD) and mortality. Risk factors for AKI and CKD are similar, and there is a conceptual overlap
and interplay between the two. AKI and CKD are both risk factors for each other, and also worsen the
prognosis of each other.
Underlying biology
If we now consider the situation at a biological level, in the elderly CKD population several factors could
lead to increased susceptibility to AKI. Changes in the renal vasculature occur with age, just as in other
vascular beds, often owing to comorbidity, but also in the absence of comorbidity.17 It is suggested that
these changes eventually cause cortical glomerulosclerosis, interstitial fibrosis and tubular atrophy,
and compensatory hypertrophy and hyperfiltration of glomeruli in the medulla, contributing to the
development of CKD.18 With increasing age and CKD, function in both proximal and distal tubules is
compromised, hampering the ability to control fluid and electrolyte balance and affecting tubuloglomerular
feedback.17,19 These changes, related to age and CKD, may exacerbate clinical events such as dehydration
and drug toxicity, which carry a high risk of AKI.18
Contrary to the idea that the diseased kidney is at increased risk of AKI is the ‘intact nephron’
hypothesis.20,21 In surviving nephrons of a kidney with CKD there remains homogeneity of function and
regulatory capacity. The kidney responds in a predictable and organised manner to maintain homeostasis
in the face of a number of challenges. There may be fewer functional nephrons available, and a reduced
reserve, but available nephrons are functionally intact. This is evident until the late stages of the disease
and should, therefore, not produce an increased risk of AKI; however, it may impart an increased severity
when it develops, which is therefore more likely to be clinically evident. There is also the concept of
priming or conditioning, where the ischaemic or diseased kidney in CKD is more ‘used to’ insults and can,
therefore, maintain function.
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Given that people with CKD have an increased burden of vascular disease, it may be that less of a vascular
insult is required to provoke AKI. There are supportive data from animal models of AKI which suggest that
AKI is a form of ‘vasomotor nephropathy’.22,23 People with CKD and a greater burden of vascular disease
may have increased severity of AKI when it develops, which is more likely to be clinically apparent and
require hospitalisation and, thus, be captured in epidemiological studies. Patients without CKD, and with
less vascular disease, may have less severe AKI, which manifests as ‘silent and discrete’ episodes in the
community and may not be captured in existing epidemiological studies, thereby indicating an increased
incidence of AKI in CKD.
Further prospective studies are required to assess the true incidence of AKI in patients with CKD and
correct more accurately for comorbidity and hospitalisation.
But what happens following AKI? Renal tissue has the ability to recover from sublethal or lethal cellular
damage.24–27 However, function may not be fully restored, which results in the development of CKD.26 It is
suggested that kidney function can be directly related to a cycle of cell injury and recovery following AKI
(Figure 1a).28 This involves renal tubular epithelial cells, damage to which is thought to be extended by
renal vascular endothelial injury and dysfunction. It is believed that endothelial repair is important to overall
renal recovery and may impact on long-term function.29 This model, however, considers acute tubular
necrosis (ATN) as the cause of AKI. What happens most frequently is limited to the very early part of this
process. In patients developing CKD (Figure 1b), the initiating insult leading to damage, inflammation and
repair (initiation) may result in fibrosis (extension) and then further damage in a self-perpetuating cycle of
progression (maintenance) to ESRD. Early intervention at the stages of initiation and extension may prevent
CKD and ESRD, while later intervention during the maintenance stage may only delay progression, with
the extent of delay determined by the success or otherwise of intervention. Patients with AKI may or may
not have pre-existing CKD (Figure 1c). Okusa et al.30 (pathophysiological concepts from Sutton et al.28)
Days
100
0
G
F
R
 (
%
)
(a)
In
itia
tio
n
AKI may lead to self-perpetuating
 cycle of inflammation and repair
with fibrosis leading to CKD
Re
pa
ir
Extension
Maintenance
Pre-renal
Initiation
Cellular
 phases
of AKI
Repair
Maintenance
Extension
FIGURE 1 Conceptual model of GFR and cellular pathology over time in AKI, CKD, and AKI and CKD. (a) Model
of AKI over time: the cellular phases of AKI leading to repair, highlighting the possibility of initiating a
self-perpetuating cycle of inflammation producing fibrosis leading to CKD; (b) model of CKD over time: the phases
of cellular injury in CKD. Following an initial insult there is initiation of the inflammatory response with repair.
This may then lead to the extension phase with added fibrosis. Past a point of no return, the disease process
embarks upon a self-perpetuating cycle of cellular damage and fibrosis (maintenance phase) leading to
deterioration in GFR, and progression to ESRD. The figure also shows the effect of intervention on the disease
process; and (c) AKI and CKD: the effect of episodes of AKI on the progression of CKD, with three possible
outcomes: complete recovery, stepwise progression and inexorable decline. D, damage; F, fibrosis; GFR, glomerular
filtration rate; I, inflammation, R, repair. (continued )
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FIGURE 1 Conceptual model of GFR and cellular pathology over time in AKI, CKD, and AKI and CKD. (a) Model
of AKI over time: the cellular phases of AKI leading to repair, highlighting the possibility of initiating a
self-perpetuating cycle of inflammation producing fibrosis leading to CKD; (b) model of CKD over time: the phases
of cellular injury in CKD. Following an initial insult there is initiation of the inflammatory response with repair.
This may then lead to the extension phase with added fibrosis. Past a point of no return, the disease process
embarks upon a self-perpetuating cycle of cellular damage and fibrosis (maintenance phase) leading to
deterioration in GFR, and progression to ESRD. The figure also shows the effect of intervention on the disease
process; and (c) AKI and CKD: the effect of episodes of AKI on the progression of CKD, with three possible
outcomes: complete recovery, stepwise progression and inexorable decline. D, damage; F, fibrosis; GFR, glomerular
filtration rate; I, inflammation, R, repair.
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suggest that, following AKI, there are four possible outcomes: (1) full recovery; (2) incomplete recovery
resulting in CKD; (3) exacerbation of pre-existing CKD accelerating progression to ESRD; and
(4) non-recovery of function leading to ESRD. Recovery from AKI may also be incomplete, leading to
step-down in glomerular filtration rate (GFR) falling short of CKD. The fact that patients experiencing AKI
are likely to also have risk factors for CKD could suggest that patients without a known background CKD
who develop AKI already have unrecognised renal disease and reduced functional reserve, which has not
yet manifested as CKD. These patients are programmed to develop future CKD, and the AKI episode
simply speeds up the development of overt CKD. In this respect, renal outcomes of AKI and CKD are the
same, which is further evidence that they are part of the same pathophysiological pathway.
A key question is whether the ‘I’ in AKI truly stands for injury or actually stands for impairment and/or
injury. Is it underpinned by histopathological damage and, if so, when does this become relevant in terms
of future CKD or CKD progression? Do undetected episodes of AKI in the community lead to CKD?
When patients present with CKD without an obvious cause, is the pathophysiology related to multiple
undetected AKI events in the community?
In an ischaemia–reperfusion injury model of AKI in rats, Basile et al.29 found permanent alterations in renal
structure and function associated with the development of features indicative of CKD. They suggest that
permanent changes in renal blood flow occur following AKI, resulting in tubulointerstitial fibrosis and
altered medullary tonicity (causing impairment of urinary concentrating ability).29 They also suggest a loss
of microvasculature, resulting in a build-up of extracellular matrix, contributing to the development of
interstitial fibrosis,29 which in turn leads to development of CKD. They hypothesise that, as long as there is
adequate functional reserve, the single-nephron GFR of surviving nephrons increases to maintain a
constant total GFR.29 This suggests that, even in patients in whom creatinine levels and GFR return
to baseline, there may be underlying permanent damage masked by compensatory mechanisms.
These patients may subsequently have an increased risk of CKD and AKI, owing to underlying
‘subclinical’ damage.
These results are borne out further by studies of renal transplant patients, which demonstrate that delayed
graft function (most commonly ATN31) is an independent risk factor for graft survival.31–33 The kidney has
the ability to restore structure and function following AKI, but there are some changes and damage which
are permanent. This may lead to development of CKD (or progression of existing CKD) if there is not
sufficient functional reserve to compensate. In cases where compensation maintains baseline GFR, there
may then be increased risk of future development of CKD. This ‘subclinical’ damage will be important in
the management of these patients following AKI, for preventing progression or development of CKD.
Are AKI and CKD biologically part of the same pathway, with eventual glomerulosclerosis and interstitial
fibrosis? The discrete episode of AKI leads to fibrosis by setting up the cycle of inflammation and
cell repair.
Incidence
How many people does AKI affect? It is estimated that in the USA 17 million admissions per year are
complicated by AKI.34 In developing countries AKI is a disease of the young35–37 and children;38,39 in
developed countries it is a disease of the elderly.40,41 With overall decreases in birth rate and mortality,
life expectancy is increasing and is now longer than 80 years in most developed countries. This ageing
population, with age-related changes in the kidney, systemic vasculature and immunological system, along
with the burden of comorbidity and exposure to iatrogenic insults such as medications, radiocontrast
agents and surgery, will lead to a continued rise in the incidence of AKI. It has been suggested that
incidence will nearly double in the next decade.40,42
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The incidence of AKI has been reported as 486–630 per million people per year in data from the past
10 years.43–45 In 2003, Ali et al.,46 from a population of 523,390 in the Grampian region of Scotland,
conducted a population-based study of AKI, reporting an incidence of 1811 cases of AKI and 336
of acute-on-chronic kidney failure per million people. This study reported a much higher incidence than
previous work and may be closer to the true incidence of AKI.
Outcomes of acute kidney injury
What are the outcomes for patients with AKI? There is clear evidence that outcomes for AKI are poor.
According to local data, only 56% of patients who experienced severe AKI in hospital survived to
discharge; only 28% survived to 3 years post discharge.43 Most studies of AKI in the intensive care unit
(ICU) report a mortality exceeding 50%. It is clear that ICU and in-hospital mortality increases alongside
severity of AKI.1,4,46–56 Despite the trend of lower mortality in recent years, AKI still remains an important
negative prognostic factor, particularly in critically ill patients. Even small isolated increases in serum
creatinine levels have an associated increase in short-term morbidity and mortality and in longer-term
outcomes, including 1-year mortality;38,48,57–62 this is even more the case when RRT is required.5,6,13,34,63
A study from the Medicare Sample Beneficiary Analytical File from 1992 to 2001 found that patients with
AKI who required RRT had an in-hospital mortality rate of 32.9%, compared with 27.5% in patients
with AKI not requiring RRT, and 4.6% in patients without AKI. Importantly, it found that the mortality rate
was 32.6% in patients with AKI coded as a secondary diagnosis, and 15.2% in patients with AKI coded
as a primary diagnosis.40 This confirms what is already known: that isolated AKI without other organ
involvement has a better prognosis than AKI in the context of multiple organ failure.
Chronic kidney disease is an independent predictor of morbidity and mortality.64,65 Hence we would
assume that AKI in CKD has a summative effect on outcome, giving rise to the question whether or not
the outcome of AKI differs with the presence of background CKD. Studies actually demonstrate lower
in-hospital mortality rates in patients with AKI with a background of CKD than in patients without a
background of CKD.41,53,57,66–69 This would seem counterintuitive. One explanation might be that patients
with CKD require less of an insult to manifest clinically apparent AKI, and thus the severity of the AKI
episode is less in these patients, resulting in better outcomes. In addition, patients experiencing ‘silent and
discrete’ AKI, which remains unrecognised and does not lead to admission, will not be captured by
epidemiological studies. Only the more seriously ill patients with clinically apparent and recognised AKI will
be included, leading to a bias in mortality statistics. Conversely, those with CKD may have more resilience
to acute insults secondary to conditioning or priming, and tolerate AKI better. It is also possible that
those with CKD receive better/different care from their non-CKD counterparts when AKI is identified,
thus impacting outcomes. Finally, it been suggested that results may be confounded by malnutrition
(lower serum creatinine values from low muscle mass).57
Even small isolated increases in serum creatinine levels have an associated increase in short-term morbidity
and mortality and in longer-term outcomes, including 1-year mortality.1,2,4,47,58,59,70,71 ‘Silent and discrete’
episodes of AKI in the community, therefore, require further research directed at recognition and early
indentification, as intervention in this group may have a significant effect on outcomes.
Another outcome of paramount interest is renal recovery. According to the annual report of the US Renal
Disease Survey 2006,60 approximately 6% of patients with AKI progressed to ESRD within 2 years, and
two-thirds of hospitalised patients who had AKI and progressed to ESRD had background CKD. CKD or
comorbid conditions leading to CKD are risk factors that predict dialysis dependence following AKI.61,62
Wald et al.72 looked at outcomes of chronic dialysis and death in AKI patients requiring in-hospital dialysis
who survived free of dialysis for at least 30 days after discharge, from a 10-year cohort of all adult patients in
Ontario, Canada. Patients with AKI were three times more likely than those without AKI to require chronic
dialysis.72 Individuals with pre-existing CKD who had AKI requiring dialysis had a twofold higher risk of chronic
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dialysis than patients with CKD without AKI requiring dialysis. Patients with AKI requiring dialysis without
pre-existing CKD had a 15-fold higher risk of chronic dialysis than patients with CKD without AKI.72
Other observational and database studies demonstrate that AKI, with a background of CKD, leads to ESRD
at a higher frequency than does AKI alone.12,40,46 Ishani et al.12 assessed, based on Medicare claims, a random
cohort of 233,803 hospitalised patients aged ≥ 67 years on discharge and without previous ESRD or AKI.
Patients with concomitant AKI and CKD were far more likely to develop ESRD, indicating a strong multiplicative
effect of the interaction on ESRD development.12 A population-based study by Ali et al.46 compared patients
with ACKD and those with AKI alone. Patients with ACKD were older, with less chance of renal recovery.
Importantly, these studies all depend on the definitions of both CKD and AKI, which may not be accurate
or comparable. For example, the definition of CKD is based on diagnostic coding or pre-operative GFR
taken as a baseline function. These can introduce bias in AKI and CKD detection. Singh et al.73 suggested
that differences could also reflect greater specificity of administrative codes for AKI among patients
without CKD. This underlines the need for consensus on the definition of baseline function. The debate
surrounding definition will be discussed in more detail later.
There is mounting evidence that AKI contributes significantly to CKD and CKD progression, leading to
ESRD. Okusa et al.30 (pathophysiological concepts from Sutton et al.28) suggest that, following AKI, there
are four possible outcomes: (1) full recovery; (2) incomplete recovery resulting in CKD; (3) exacerbation of
pre-existing CKD accelerating progression to ESRD; and (4) non-recovery of function leading to ESRD.
We suggest a fifth outcome: AKI does not necessarily have to be associated with progressive CKD; instead,
incomplete recovery may occur, leading to step-down in GFR, which subsequently remains stable.
There is no doubt that mortality from AKI is high. In those who survive, there may be decline in function,
in some cases leading to ESRD, either at the time of AKI or in the future.51,74–77 Even in patients with
complete recovery there is still reduced survival and increased incidence of CKD in the years following
AKI.12,78 Patients experiencing AKI are likely to also have risk factors for CKD. It may be that patients
without known background CKD who develop AKI already have unrecognised renal disease and reduced
functional reserve, not yet manifested as CKD. These patients are programmed to develop future CKD,
and the AKI episode simply speeds up the development of overt CKD. Ishani et al.,12 based on Medicare
claims, reported that of patients with AKI and no background of CKD, 72.1% had CKD documented
within 2 years of AKI. Triverio et al.79 demonstrated that AKI progressed to CKD within 3 years in 50% of
patients without background CKD. Hsu et al.80 suggested that the growth of ESRD incidence (in the USA)
could not be accounted for solely by the rise in CKD incidence. Growth in ESRD incidence may partly be
attributable to AKI.
There are further studies suggesting that development of CKD and dialysis dependency follow AKI.1,2,7,9,67,81
Amdur et al.82 tested the hypothesis that AKI, and specifically ATN, causes CKD. A total of 5404 out of
113,272 patients (US Department of Veterans Affairs database, 1999–2005) had diagnostic codes
indicating AKI or ATN without background CKD. A diagnosis of ATN without background CKD was
associated with a similar time to development of stage 4 CKD to that of a patient with early CKD. Twenty
per cent of survivors of ATN rapidly progressed to CKD stage 4. Diagnostic codes of AKI and ATN were
associated with a significant decline in function over time after hospital discharge. Survivors of AKI were
more likely than controls to progress to late-stage CKD. The authors concluded that AKI might be an
important cause of CKD.82
If AKI is a cause of CKD, it seems logical that AKI may exacerbate pre-existing CKD. There are, however,
difficulties in testing this hypothesis. A large number of risk factors for AKI are the same as those for CKD.
AKI also occurs more frequently in an older population with greater burden of comorbidity, in which
there may be greater risk of CKD progression anyway. Many studies looking at outcome following AKI
concentrate on survival and subsequent ESRD development; however, resultant CKD and CKD progression
are less well reported. These studies again depend on the definitions used.
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Could minor episodes of AKI in the community, which are not acknowledged to have occurred because renal
function is either not tested or not properly assimilated, be contributing to development and/or progression
of CKD? The effect of ‘silent and discrete’ episodes of AKI in the community on CKD progression is
presently unknown. There is growing evidence that ‘multiple hits’ may well contribute to progression in
susceptible individuals.
Following an episode of AKI, Kidney Disease: Improving Global Outcomes (KDIGO) guidelines83 suggest
that we should evaluate patients within 3 months for resolution of AKI, and at 3 months or after for new
onset or worsening of pre-existing CKD. They also suggest that if patients do not have CKD they should be
considered at increased risk, on the assumption that one AKI episode demonstrates ‘susceptibility’ and
qualifies a high-risk population. Further research is warranted to inform the optimal follow-up period and
to facilitate better understanding of the clinical consequences of AKI in patients with and without
underlying CKD.83
Why is acute kidney injury under the spotlight?
The concept of AKI, or, as it was previously, acute renal failure, is not new. There was renewed interest
in acute renal failure dating from the now classical description of tubular degeneration and tubular
pigmented casts, together with intact glomeruli, in patients crushed by fallen masonry during the London
Blitz.84 However, in the past 5–10 years there has been a growing impetus and focus on AKI both within
the academic community and politically within government and the NHS. Within the Department of
Health, NHS Kidney Care has brought together experts in AKI from across the country to form the AKI
Delivery Group. They have increased awareness of AKI and actively promoted better clinical management.
We also have the development of guidelines, for example the KDIGO AKI guidelines,83 the recent National
Institute for Health and Care Excellence (NICE) guidance on AKI85 and the updated Renal Association
Guidelines.86 AKI has also now been incorporated as a clinical pathway in the Enhancing Quality Initiative.
So, why is AKI, which is not a new entity, now under the spotlight?
Definition
The first debate surrounding AKI concerned the definition. Over the years, one inherent problem in both
diagnosing AKI clinically and reviewing and comparing studies published in the literature has been the
numerous definitions used for AKI.87 The use of these differing definitions in different locations with
different populations has only worsened the problem. This also precluded the appreciation of the true
problem of AKI in terms of incidence and outcomes.
Risk, Injury, Failure, Loss of function, and End-stage renal failure
In 2003, the Acute Dialysis Quality Initiative group published guidelines to define AKI as a 1.5-fold increase in
serum creatinine levels, a decrease in estimated glomerular filtration rate (eGFR) of > 25% or a reduction
in urine output to < 0.5ml/kg/hour over 6 hours.58 They developed the RIFLE (Risk, Injury, Failure, Loss, and
End-stage renal failure) classification to define patients by changes in serum creatinine level or urine output
criteria.58 Risk was defined as a 1.5- to 2.0-fold increase, injury as a 2.0- to 3.0-fold increase and failure
as a > 3.0-fold increase in serum creatinine level.58 Loss was defined as a complete loss of kidney function
requiring RRT for > 4 weeks and end-stage renal failure as complete loss of kidney function for > 3 months.58
The Acute Kidney Injury Network
In 2007, the Acute Kidney Injury Network (AKIN) modified the RIFLE criteria, defining three stages of AKI
(Table 1): AKI stage 1, equating to the ‘R’ of the RIFLE criteria, with the inclusion of a 1.5-fold or 26.4 µmol/l
(0.3mg/dl) rise in serum creatinine levels; AKI stage 2, representing the ‘I’ of the RIFLE criteria; and AKI stage 3
representing the ‘F’ of the RIFLE criteria.88 The ‘L’ and ‘E’ (end-stage renal failure) were redefined as outcomes.
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The addition of a rise in 26.4 µmol/l to define AKI stage 1 was based on two large studies which
demonstrated an independent association between an increase in serum creatinine of 26.4 µmol/l and
in-hospital mortality.34,63 The RIFLE and AKIN are consensus definitions that have now been validated
and correlate well with patient outcomes.89,90
Kidney Disease: Improving Global Outcomes
In the recent KDIGO AKI guideline, AKI is defined as a syndrome, including direct injury to the kidney as
well as acute impairment of function.83
The guideline defines AKI as:
l increase in serum creatinine level of > 0.3 mg/dl within 48 hours, or
l increase in serum creatinine level of > 1.5-fold above the baseline which is known or presumed to have
occurred within 7 days, or
l urine volume < 0.5ml/kg/hour for 6 hours.
The importance of staging AKI (see Table 1) is stressed, as adverse outcomes worsen with
increasing stage.46–49,83,91–93
The definitions of both AKI and CKD are time dependent. For AKI there must be an increase in serum
creatinine levels over a period of 2 (AKIN) to 7 (RIFLE) days. For CKD, GFR must be reduced for at least
3 months. These definitions may not capture all cases of AKI and CKD. Certain causes of AKI and CKD
may lead to changes in serum creatinine levels and GFR over a time period outside those currently
specified, precluding definition. These cases should not be neglected, as intervention may be required.
For this reason, the KDIGO AKI Work Group proposed an operational definition for AKD to provide an
integrated clinical approach to patients with abnormalities of kidney function and structure, and provide a
diagnostic algorithm for defining AKD, AKI and CKD (Table 2).83
TABLE 1 The staging of AKI by serum creatinine and urine output criteria
Stage Serum creatinine levels Urine output
1 ≥ 1.5–1.9 times baseline
OR
0.3 mg/dl (26.4 µmol/l) increase
< 0.5 ml/kg/hour for 6–12 hours
2 ≥ 2.0–2.9 times baseline < 0.5 ml/kg/hour for ≥ 12 hours
3 ≥ 3.0 times baseline
OR
Increase in creatinine to ≥ 4 mg/dl (354 µmol/l)
OR
RRT
OR
In patients aged < 18 years, a decrease of eGFR
to < 35ml/minute/1.73m2
< 0.3 ml/kg/hour for ≥ 24 hours
OR
Anuria for ≥ 12 hours
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Baseline
Although we now have an internationally agreed on and validated definition of AKI, the time constraints
of these definitions raise the big question and primary focus of the present debate in AKI, which concerns
how we define the baseline kidney function of a patient. The absolute and relative rises in serum
creatinine levels to define AKI are now used widely in clinical practice and research studies, allowing better
comparison of data sets. However, what baseline kidney function are these rises from? The AKIN criteria
suggest a rise in serum creatinine levels over a period of 2 days, whereas the RIFLE criteria suggest a rise
over a period of 7 days. However, a large number of patients presenting acutely to hospital will not have
had blood tests in the preceding 2, or in fact 7, days. The question and debate is then twofold: how far
back do we look for a baseline kidney function and what value over this time period do we take?
A retrospective cohort study by Lafrance and Miller94 assessed 1,126,636 veterans (US Department of
Veterans Affairs healthcare system) who were hospitalised at least once between 2000 and 2005. The
highest serum creatinine level during hospitalisation was compared with the lowest using four different
baseline periods (in-hospital only, 3, 6 or 12 months before admission). AKI was defined as a rise in serum
creatinine level ≥ 1.5 times or an increase of 0.3–0.5 mg/dl over the baseline.94 The cumulative incidence
of AKI ranged from 12.5% (in-hospital baseline) to 18.3% (baseline up to 12 months before admission).
By extending the baseline period to at least 3 months, the authors found that the discriminative power
increased slightly (the c-statistic increased from 0.846 to 0.855; p= 0.001). They suggested the need for
consensus regarding how baseline serum creatinine levels should be determined in database studies.
TABLE 2 The definitions of AKI, CKD, AKD and NKD
Type of disease Functional criteria Structural criteria
AKI Increase in serum creatinine level by 50% within 7 days
OR
Increase in serum creatinine level by 0.3mg/dl within 2 days
OR
Oliguria
No criteria
CKD GFR < 60ml/minute/1.73m2 for > 3 months Damage for > 3 months
AKD AKI
OR
GFR < 60ml/minute/1.73m2 for < 3 months
OR
Decrease in GFR by ≥ 35% or increase in serum creatinine
level by > 50% for < 3 months
Kidney damage for < 3 months
NKD GFR ≥ 60ml/minute/1.73m2
Stable serum creatinine
No damage
NKD, no known kidney disease.
GFR is assessed from measured or estimated GFR. Estimated GFR does not reflect measured GFR in AKI as accurately as
in CKD.
Kidney damage is assessed by pathology, urine or blood markers, imaging and, for CKD, presence of a kidney transplant.
NKD indicates no functional or structural criteria according to the definitions for AKI, AKD or CKD.83
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A clinician’s definition of the baseline kidney function is often achieved through the visualisation of serum
creatinine level results graphically represented (Figure 2). The problem with using the lowest serum
creatinine levels in the preceding 12 months (which is done to allow a computer algorithm to define AKI
from creatinine level results in a structured database) is that a spuriously low result recorded on the
pathology database, either from an error or, more often, from an event such as fluid loading (and hence
dilution) during a previous hospital admission, will be taken as the baseline kidney function (see Figure 2a).
This could, in fact, be significantly lower than the patient’s true baseline kidney function, leading to an
incorrect trigger of a diagnosis of AKI on a new blood test.
There is also the possibility that a patient with progressive CKD may trigger a diagnosis of AKI based on a
baseline defined as the lowest serum creatinine level in the preceding 12 months, when actually the
kidney function has slowly deteriorated over the 12-month period, but comparison of the present
creatinine level with that of 12 months prior triggers a diagnosis of AKI (see Figure 2c). In the same way,
within a 12-month period a patient may have a stepwise reduction in kidney function (probably owing to
an AKI) and hence an increase in creatinine that then remains stable. However, a new serum creatinine
test, although at the same level as the previous number of months, may be higher than the stepwise
increase in creatinine in the past 12 months (see Figure 2b).
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FIGURE 2 Errors in defining acute kidney injury as the lowest creatinine in the 12 months prior to the present test.
(a) Here, the kidney function (creatinine) can be seen to be stable; however, two spuriously low results, which may
be a result of error or more likely fluid loading and dilution may result in an incorrect definition of AKI; (b) here,
there has been a stepwise deterioration in kidney function around 4 months previously (likely to be an AKI at that
point in time), and since then the kidney function has been stable. However, using a 12-month baseline will
continue define this as an acute event; (c) here, a progressive decline in CKD over the course of 12 months. Using
the lowest creatinine in 12 months as the baseline will trigger a definition of AKI. (continued )
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FIGURE 2 Errors in defining acute kidney injury as the lowest creatinine in the 12 months prior to the present test.
(a) Here, the kidney function (creatinine) can be seen to be stable; however, two spuriously low results, which may
be a result of error or more likely fluid loading and dilution may result in an incorrect definition of AKI; (b) here,
there has been a stepwise deterioration in kidney function around 4 months previously (likely to be an AKI at that
point in time), and since then the kidney function has been stable. However, using a 12-month baseline will
continue define this as an acute event; (c) here, a progressive decline in CKD over the course of 12 months. Using
the lowest creatinine in 12 months as the baseline will trigger a definition of AKI.
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In an attempt to tackle some of these issues, other strategies have been suggested: taking the average of
values between 7 and 365 days prior to admission;95 back-calculating reference serum creatinine for
missing values from an assumed modification of diet in renal disease (MDRD) GFR of 75ml/minute/
1.73m2,96 and (most recently) a method employing multiple imputation using known comorbidity
strengthened by factoring in the lowest admission serum creatinine level.97
If there are no serum creatinine results in the preceding 12 months, the KDIGO AKI guideline suggests that
an estimated creatinine level can be used, provided there is no evidence of CKD.83 However, there remain
cases of CKD in the community that have not been previously appreciated; therefore, estimating baseline
creatinine level may lead to diagnosis of AKI in patients with previously unrecognised CKD. These problems
with definition make the assessment of AKI and CKD, and their complex interplay, more problematic.
One other point to note is the fact that serum creatinine is a poor biomarker of kidney injury, requiring
48 hours for levels to rise following insult. This emphasises the need for new biomarkers and point-of-care
devices to facilitate early identification of patients, which would aid early intervention, as well as more
accurate risk assessment to identify patients who may go on to develop AKI.
Although the debate of baseline kidney function in the definition of AKI continues, the now-accepted
staging of AKI leads to the following question: when using these accepted definitions, what are the true
impacts of AKI?
NHS England patient safety alert
NHS England released a patient safety alert, stage three directive on 9 June 2014, to ensure both that
all acute NHS hospital trusts in England are alerting to AKI (by 9 March 2015) and that there is
standardisation in the identification of AKI using a single algorithm (www.england.nhs.uk/aki-algorithm).
Although similar, our study does not use the same algorithm because it was designed and the analysis was
completed before the publication of this directive. In our work following this study we have been using the
NHS England algorithm to validate our models so that when we implement the models in clinical practice
in the next phase of our work we can ensure standardisation and generalisability.
National Confidential Enquiry into Patient Outcome and Death
From what we already know about AKI, it is apparent that early recognition and effective management of
AKI is essential, a concept highlighted in the Renal National Service Framework. However, the 2009
National Confidential Enquiry into Patient Outcome and Death (NCEPOD) in the setting of AKI highlighted
systematic failings in identification and subsequent management.98
The aim of the NCEPOD study was to assess the care of patients who died in hospital with AKI in order to
highlight deficiencies in care and provide recommendations for improving clinical management in the
future. An advisory group, comprising nephrologists, anaesthetists, intensivists and general physicians, was
brought together to review the care of these patients, with a focus on seven main themes:
1. diagnosis and recognition of AKI
2. recognition of risk factors associated with AKI
3. prevention of AKI
4. assessment of patients recognised as having AKI
5. management of established AKI
6. recognition and management of complications of AKI
7. organisational factors relevant to the treatment of AKI.
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All NHS hospitals in England, Wales and Northern Ireland were expected to participate. Hospitals in the
independent sector and public hospitals in the Isle of Man, Guernsey and Jersey also participated.
The inclusion criteria were set as any patient aged 16 years or older who died in hospital between
1 January 2007 and 31 March 2007, inclusive, and who had a coded diagnosis of AKI. Patients were
excluded if they were already receiving renal replacement therapy or if their admission was for palliative
care from the outset. At each hospital, the NCEPOD local reporter, who acted as a liaison between the
NCEPOD and hospital staff, facilitated the identification of these cases within the inclusion criteria, and
then facilitated the dissemination of questionnaires and data collation for these patients. For each patient
identified, a clinical questionnaire was sent to the clinician responsible for the patient’s care at the time of
death and an organisational questionnaire was sent to each hospital. Photocopies of the patient’s case
notes were also made and sent to the NCEPOD. The case notes and questionnaires were anonymised
before the advisory group reviewed each case.
In total, 1518 patients from 215 hospitals met the inclusion criteria. Of these, 473 were subsequently
excluded either for not being indicative of AKI or because the admission was for palliative care at the
outset. In a further 69 cases, the case notes were reported as being lost or the consultant in charge of the
patient at the time of their death had left the trust. This left 976 patients. A clinical questionnaire and/or
case notes were received for 700 patients (72%).
Of the 700 patients, half were from the specialties of general medicine and elderly care medicine. In 14%
of patients, it was the clinician’s opinion that the AKI was avoidable. In an overall assessment of care, only
50% of patients were assessed to have received a ‘good’ standard of care and, importantly, in the majority
of cases in which the care was considered less than good, there was judged to be room for improvement
in the clinical care rather than at an organisational level. This suggests inadequacies in the clinicians’
recognition of AKI and of its subsequent management.
Complications of AKI were missed in 13% of patients and, importantly, in 17% of patients the advisors
concluded that the complications of AKI were avoidable. In 22%, the complications were managed badly.
In relation to the management and assessment of AKI, the advisors found that there was an adequacy of
investigation of AKI in only 67% of patients. The advisors also concluded that in one in six cases there was
a failure to recognise the severity of the illness.
In patients who developed AKI post admission, one-fifth were deemed to have been predictable and
avoidable, and in 43% of cases there was judged to have been an unacceptable delay in recognising AKI.
Although the NCEPOD report does have its limitations, notably the dependency on clinical coding and its
inherent inaccuracies to define AKI, and a patient population in which the outcome in each case was
death, the conclusions are very clear: there are currently significant deficiencies in the recognition and
clinical management of patients with AKI. The NCEPOD report recommends risk assessment for AKI in all
emergency admissions to hospital, and suggests that predictable and avoidable AKI should never occur.98
The NCEPOD report, with its clear conclusions, has been a key factor in the growing impetus of and focus
on AKI and the fact that AKI is now under the spotlight. This also leads to the question of how we can
improve the clinical management of AKI. Although strategies can be put in place to alert clinicians to the
presence of AKI and allow early intervention to improve clinical outcomes, as with any disease process, our
ultimate aim should be prevention.
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Risk prediction
In order to prevent AKI we must have a clear understanding of what factors convey a risk of AKI to the
patient, and in what situations. This also then highlights time points in the clinical pathway at which risk
assessment should be carried out and clinical intervention informed/directed.
As described, the 2009 NCEPOD report,98 in the setting of AKI, highlighted systematic failings in
identification and subsequent management of AKI.98 One of the report’s key recommendations was that
risk assessment for AKI should be carried out for all emergency admissions. Following on from this report,
the 2010 NCEPOD report, ‘An Age Old Problem: a review of the care received by elderly patients
undergoing surgery’,99 suggested that when risk assessing patients prior to surgery the risk factors for
acute kidney injury should also be taken into account and also suggested a need for post graduate
education of physicians, surgeons and anaesthetists to include education of the assessment of risk factors
for the development of AKI in elderly surgical patients’.99
However, a number of patients present to hospital who already have AKI. The risk of AKI in these patients
can be assessed as they enter the emergency department to ensure that patients at high risk have their
kidney function checked, to confirm their underlying AKI. In patients who have established AKI, the risk
assessment should be extended to determine which patients are at high risk of experiencing worsening
AKI and hence are likely to require specialist or critical care intervention.
Once the most important of the large number of factors involved in the development of AKI, or of
worsening AKI, have been identified, these can then be employed in risk models and risk scores to
determine the individual risk of a patient and thereby more accurately guide clinical management.
To date, the development of risk models in AKI has mainly focused on the clinical areas of cardiac surgery
and radiology contrast scans.
In the disease process of AKI there are two points (Figure 3) at which we can intervene. When the patient
experiences an event which carries a risk of AKI we can intervene in order to prevent the development of
AKI, and when the patient already has AKI we can intervene in order to reduce the resultant sequelae of
AKI and prevent worsening AKI. At these points of clinical intervention we can then provide an assessment
of risk factors in order to guide clinical intervention in high-risk patients.
Prevention
Intervention
Early
management
AKI
Patient
event
Harm to
kidneys
Resultant
sequelae
FIGURE 3 Points of clinical intervention in the disease process of AKI.
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The KDIGO clinical practice guidelines for AKI published in March 201283 suggests that risk assessment
should be carried out at four points:
1. before exposure to an insult
2. after exposure to an insult
3. on development of AKI
4. after recovery from AKI.
Before exposure to an insult
In clinical medicine there are certain procedures or treatments that a patient may experience as part of
their clinical management that are essential in their care, but carry an inherent risk of precipitating AKI.
Some insults may not be avoidable and in these cases the patient’s care can be optimised to reduce the
risk of AKI. In some cases, when the risk of AKI is fully appreciated it may outweigh the benefit of the
procedure or treatment. In other cases, although the benefit of a procedure or treatment may outweigh
the risk, modifications in dosing or exposure may reduce the risk of AKI.
Risk assessing the patient in the context of the expected exposure to the insult can allow appropriate
decisions to be made regarding the risk benefit of the procedure or treatment, modifications in dosing and
exposure, and clinical optimisation prior to the procedure.
After exposure to an insult
After a patient is exposed to an insult, whether this is iatrogenic or the presenting disease of the patient,
as it takes up to 48 hours for the creatinine level to rise in AKI, it may not be immediately apparent. In
such cases we can predict which patients are at risk of developing AKI from the insult they have sustained.
In these patients, we can provide clinical intervention in terms of both making management changes
(Box 1) to aid prevention of AKI following the insult and ensuring that repeat kidney function checks are
carried out to monitor for AKI.
BOX 1 Clinical interventions in the management of AKI
Regularly assess fluid status.
Reverse hypovolaemia/hypotension.
Stop and avoid nephrotoxic agents (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers,
non-steroidal anti-inflammatory drugs).
Assess drug dosages with respect to level of kidney function.
Look for and treat infection early.
Recognise and treat hypoxia.
Check for acidosis.
Urinalysis.
Renal tract ultrasound.
Daily kidney function.
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On development of acute kidney injury
When we know a patient has AKI, as shown by blood testing, this is not the end of the story. At this point
we have the opportunity to intervene to make management changes [often the same as prior to the
development of AKI (see Box 1)] to effectively manage the AKI and prevent both the worsening of AKI and
the development of sequelae including morbidity and mortality. By risk assessing patients at this point
and identifying patients at high risk of worsening AKI or resultant morbidity and mortality, we can focus
clinical and specialist care on these patients.
After recovery from acute kidney injury
Following an episode of AKI, a patient may have complete recovery of their kidney function; however,
as described Outcomes of acute kidney injury, in some patients this recovery may not be complete,
resulting in new CKD or the progression of pre-existing CKD. Patients who have experienced an episode of
AKI may also be at increased risk of morbidity, including cardiovascular disease, and mortality in the future.
In this case, risk modelling may be important to highlight patients who require follow-up to diagnose or
manage resultant CKD, and other resultant morbidity, following an episode of AKI.
Defining risk in clinical practice
If each patient’s risk of AKI, or worsening AKI if already present, can be defined, then clinicians can be
alerted to these patients and management changes and interventions can be put in place in order to
prevent, or at least reduce, the risk of the patient developing AKI or worsening AKI.
In any disease process the ultimate treatment is prevention. In the disease process of AKI, risk factors
include pre-existing comorbid disease, the presenting illness and also the treatment given for this illness.
From these risk factors we can attempt to define a patient’s risk.
In the literature, the majority of the reports focus on the need for RRT after cardiac surgery. One of the
first of these was by Chertow et al.,100 who produced a risk model for predicting AKI after cardiac surgery
based on a population of 40,000 patients who underwent cardiac bypass or valvular surgery in 43
Veterans Administration Hospitals in Virginia, USA. A risk stratification algorithm was formulated on the
basis of interactions between potential risk factors. There were inherent flaws in the study cohort,
specifically a lack of femaled and African American patients. Thakar et al.101 produced a clinical risk score
to predict post-cardiac surgery AKI requiring RRT, based on 33,217 patients who underwent cardiac
surgery at the Cleveland Clinic between 1993 and 2002. The scoring system was derived based on 13
preoperative factors, which were weighted; the sum of the scores, ranging from 0 to 17, allowed for
stratification of postoperative risk of AKI from low to high. The lowest-risk group (score of 0–2) had a risk
for AKI requiring RRT of 0.4%, in contrast to those in the high-risk stratum (score of 9–13), who had a RRT
risk of 21.5%. Table 3 demonstrates the risk factors.
There is, however, a paucity in the literature of studies regarding the risk and risk prediction of AKI in
unselected emergency admissions to a district general hospital. Finlay et al.102 published a recent study of
risk factors (Table 4) associated with AKI in patients admitted to acute medical units in a study conducted
over two separate 24-hour periods in a total of 10 acute medical units. Forni et al.103 developed a model
for predicting AKI in a subset of medical patients admitted to a UK hospital, which included some
physiological markers. Alongside this there have been reports in the literature of the development of AKI
alert systems, but none presently demonstrate significant clinical benefit.104,105
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TABLE 4 Risk factors from Finlay et al.102
Risk factor Description/explanation
Age > 75 years
Hypotension SBP < 100mmHg or decrease of ≥ 40mmHg from usual baseline
Sepsis Two or more criteria for SIRS owing to suspected infection
Hypovolaemia Suggested by history or on clinical examination
CKD Stage 3–5 (eGFR < 60ml/minute/1.73m2)
Vascular disease History of atherosclerotic vascular disease
Congestive cardiac failure History of congestive cardiac failure or current presentation consistent
with acute cardiac failure
Diabetes mellitus
Jaundice Clinical or biochemical jaundice
Nephrotoxic medication Nephrotoxic medication used in the week prior to admission
SIRS, systemic inflammatory response syndrome.
Republished with permission of The Royal College of Physicians from Identification of risk factors associated with acute
kidney injury in patients admitted to acute medical units, Finlay S, Bray B, Lewington AJ, Hunter-Rowe CT, Banerjee A,
Atkinson JM, et al., volume 13, issue 3, 2013.
TABLE 3 Risk factors for AKI and weightings (from Thakar et al.101)
Risk factor Points
Female gender 1
Congestive heart failure 1
Left ventricular ejection fraction < 35% 1
Preoperative use of IABP 2
COPD 1
Insulin-requiring diabetes 1
Previous cardiac surgery 1
Emergency surgery 2
Valve surgery only (reference to CABG) 1
CABG and valve (reference to CABG) 2
Other cardiac surgeries 2
Preoperative creatinine level 1.2 to < 2.1 mg/dl (reference to 1.2)a 2
Preoperative creatinine level ≥ 2.1 (reference to 1.2) 5
CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump.
a 1mg/dl equivalent to 88.4 µmol/l.
Minimum score= 0, maximum score= 17.
Republished with permission of the American Society of Nephrology from A clinical score to predict acute renal failure after
cardiac surgery, Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP, volume 16, issue 1, 2005.
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Aims
The aims of this study were as follows:
1. Identification of AKI – accurately identify and report patients with AKI.
2. Predictive model – based on factors identified in primary and secondary care records and the admission
characteristics of each patient, develop a predictive model to stratify the risk of (1) AKI on arrival in
hospital, (2) developing AKI during the admission and (3) worsening AKI if it is already present.
3. Clinical algorithm – use the predictive model to develop an algorithm for all patients admitted to
hospital to stratify them according to risk of developing AKI.
4. Integration into clinical practice – define the most effective way to incorporate the risk model into a
clinical decision support system (CDSS) that can be integrated into everyday clinical practice. This will
inform the follow-on study from this project.
The objectives were to define risk of AKI at three time points (Figure 4):
1. the point of admission to hospital – to predict patients who are already likely to have AKI and hence
should have kidney function testing
2. following initial admission blood tests in the first 24 hours – to predict patients who will develop AKI,
or worsening AKI if already present, within the first 72 hours of admission
3. at 72 hours – to predict patients who will develop AKI, or worsening AKI if already present, during the
rest of the hospital admission.
Hospital admission
AKI on 
admission
After 
24 hours
After 
72 hours
Point of
admission
Data set = point of
admission analysis
Data set = after 
24 hours’ analysis
Data set = after 72 hours’ analysis
AKI by 
72 hours
AKI during
rest of the 
admission
FIGURE 4 Acute kidney injury points of risk modelling.
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Chapter 2 Methods
Quantitative methods
Design and theoretical/conceptual framework
This project involved both quantitative and qualitative methodology. Quantitative methodology was used
to (1) formulate the predictive risk model and (2) validate the risk model in the East Kent population, and
a second population and a NHS trust (Medway NHS Foundation Trust). Qualitative methodology was
employed to plan the CDSS development and facilitate effective integration of the CDSS into everyday
clinical care.
Setting/context
For risk model development and validation in the first population the study population comprised all
patients presenting to the three acute hospitals of East Kent Hospitals University NHS Foundation Trust
(EKHUFT; Kent and Canterbury Hospital in Canterbury, William Harvey Hospital in Ashford, and Queen
Elizabeth the Queen Mother Hospital in Margate) in the calendar year of 2011, excluding maternity
admissions and elective admissions. The renal tertiary referral centre is based at Kent and Canterbury
Hospital. The secondary validation population included all patients presenting to Medway NHS Foundation
Trust over the same time period and with the same exclusions.
Research governance
Ethics
The project received full ethical approval from the Kent Research Ethics Committee (reference number
10/H1101/89) on 20 December 2010. This approval is for patients in East Kent. We subsequently
submitted a substantial amendment on 16 June 2011 to the Research Ethics Committee to include
validation of the risk model in the Medway (Medway NHS Foundation Trust) population, and this was
formally approved on 13 July 2011. The project was also reviewed and had agreement of methods from
the National Information Governance Board. The ethical considerations in this project were:
l Consent – the risk model development involved retrospective assessment of patient data of all
admissions to hospital over a 12-month period. For a retrospective analysis of this type, it would not
have been appropriate or practical to seek consent from all patients previously admitted to hospital.
We had the support and endorsement of our medical director and chief executive of the trust/primary
care trust and our Patient Safety Board to run this study.
l Confidentiality – patient information was extracted and stored anonymously under a unique
identification number on a secure server. We had confirmation from our Caldicott Guardian that the
project satisfied the information governance issues of confidentiality and data security.
There were no potential risks or burdens for research participants as the risk model development used
retrospective data.
Public and patient involvement
We had public and patient involvement in the study design process; however, as this study was a
mathematical analysis of retrospective data there was no public and patient involvement during the study.
Data collection
Prior to study commencement and funding applications, an assessment had been made of the data set
available for the study in terms of database access and variables available. Following commencement of the
study, interfaces were developed with the following clinical systems/databases to enable data extraction.
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Hospital episode data
The hospital data warehouse holds data from coded episodes of care on all admissions and outpatient
activity in East Kent. From these data, the Hospital Episode Statistics and the Secondary Uses Service data
that were collected nationally were derived. A modified Charlson Comorbidity Index score was calculated
using a modified version of the Charlson score developed by Dr Foster Intelligence™.106 The variables
available from this database are demonstrated in Appendix 1.
Pathology
The pathology database holds records of blood tests in East Kent requested in primary and secondary care
in both the outpatient and inpatient setting. All NHS blood-testing results in East Kent are recorded on this
database. The variables available, and thought to be of clinical importance, from this database are
demonstrated in Appendix 1.
Electronic discharge notification
At EKHUFT all discharges from hospital are recorded on an electronic discharge notification, which includes
a summary of the admission and the medications the patient is taking on discharge. This summary is sent
to the general practitioner in primary care at discharge. The variables available from this database are
demonstrated in Appendix 1.
Operation data
Every operation performed in theatres at EKHUFT is recorded in an electronic operation database. The
system records the date and time of procedure, duration of procedure, duration of anaesthetic, surgeon
and anaesthetist, name of procedure, International Classification of Diseases, Tenth Edition (ICD-10) and
Read code for the procedure and American Society of Anaesthesiologists physical status classification
score (see Appendix 1). Each operation was coded with a severity score ranging from 1 (least severe) to
5 (most severe) (see Appendix 1).
Data analysis
The main aim of this study was the development of predictive models for identifying and stratifying the
risk of AKI at the point of, and during, hospital admission. These models included a large set of potential
risk factors identified from secondary care records, as well as admission characteristics of each patient.
Both traditional and Bayesian modelling techniques were assessed in order to develop these models.
We will describe these methods separately.
Traditional methods
Traditional methods were employed using Stata (version 12.1; StataCorp LP, College Station, TX, USA) to
develop the following models:
l risk model 1 – the point of admission to hospital
l risk model 2 – predicting new AKI at 72 hours
l risk model 3 – predicting worsening AKI at 72 hours.
Traditional model development
Risk model 1: the point of admission to hospital
The data analysis considered emergency admissions for patients without pre-admission AKI. Patients with
pre-admission AKI were omitted from the analysis. However, patients whose pre-admission AKI status
was unknown were kept in the data analysis. Non-emergency admissions were also omitted, as were
admissions associated with childbirth and pregnancy. Patients with no information on AKI at admission
were also omitted from the analysis.
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After omissions, the full data set was split into a ‘development’ data set for constructing the risk model
and a ‘validation’ data set on which to evaluate the performance of the model. To allow a larger number
of data on which to construct the model, a 3 : 1 ratio was employed, with the development data set being
the larger of the two. Selection of admissions to one of the two data sets was done at random.
The outcome variable was AKI stage, which was considered as an ordinal measure, the categories being:
l no AKI
l AKI stage 1
l AKI stage 2
l AKI stage 3.
To allow for the ordinal nature of the outcome, all analysis was performed using ordinal logistic regression.
There were multiple admissions for some patients; to allow for this in the data analysis, robust standard
errors were used.
Initially, the individual association between each factor and AKI stage was examined individually in a series
of univariable analyses (see Chapter 3, Risk model 1: the point of admission to hospital).
There were no missing data for the key demographics (e.g. age, sex). In some cases the primary diagnosis
was missing, and these patients would have been excluded from the final model. For the blood test
variables missingness was deemed to be informative (i.e. data missing not at random) and hence missing
values were given their own category.
Subsequently, the joint association between the factors and AKI stage was examined in a multivariable
analysis. Variance inflation factors were used to assess collinearity between the predictor variables. Where
collinearity was found, action was taken to allow for this. This included either excluding variables from this
stage of the analysis or combining variables together. A backwards selection procedure was used to retain
only the statistically significant variables in the final model.
Risk model 2: predicting new acute kidney injury at 72 hours
A specific patient group was selected for risk model 2, to predict AKI at 72 hours based on data available
up to the end of the first 24 hours after hospital admission. The following patients were excluded from the
data set:
l non-emergency admissions
l patients with pre-admission AKI
l patients with AKI at admission
l childbirth/pregnancy admissions
l patients with no information on AKI at 72 hours.
After omissions, the full data set was split into a ‘development’ data set for constructing the risk model
and a ‘validation’ data set on which to evaluate the performance of the model. To allow a larger number
of data on which to construct the model, a 3 : 1 ratio was employed, with the development data set being
the larger of the two. Selection of admissions to one of the two data sets was done at random using
pseudo-random numbers.
The outcome variable was AKI stage at 72 hours, which was considered as an ordinal measure, the
categories being:
l no AKI
l AKI stage 1
l AKI stage 2
l AKI stage 3.
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To allow for the ordinal nature of the outcome, all analysis was performed using ordinal logistic regression.
There were multiple admissions for some patients; to allow for this in the data analysis, robust standard
errors were used.
Initially, the individual association between each factor and AKI stage was examined individually in a series
of univariable analyses.
Subsequently, the joint association between the factors and AKI stage was examined in a multivariable
analysis. Variance inflation factors were used to assess collinearity between the predictor variables. Where
collinearity was found, action was taken to allow for this. This included either excluding variables from this
stage of the analysis or combining variables together. A backwards selection procedure was used to retain
only the statistically significant variables in the final model.
Risk model 3: predicting worsening acute kidney injury at 72 hours
The third risk model is designed to predict worsening AKI by 72 hours in patients with AKI stage 1 or AKI
stage 2 at admission. Note that AKI stage 3 patients could not get any worse and so were not included in
the analysis.
A specific patient group was selected for the 72-hour increase in AKI risk model. The following patients
were excluded from the data set:
l non-emergency admissions
l patients with pre-admission AKI
l patients with no AKI at admission
l patients with AKI stage 3 at admission
l childbirth/pregnancy admissions
l patients with no information on AKI at 72 hours.
After omissions, the full data set was split into a ‘development’ data set for constructing the risk model
and a ‘validation’ data set on which to evaluate the performance of the model. To allow more data on
which to construct the model, a 3:1 ratio was employed, with the development data set being the
larger of the two. Selection of admissions to one of the two data sets was done at random using
pseudo-random numbers.
The outcome was defined as a worsening in AKI, considered as a binary variable. A worsening in this case
was regarded as a higher AKI stage. In other words, worsening was defined as a change to AKI stage 2
or AKI stage 3 for patients with AKI stage 1 on admission, and a change to AKI stage 3 for patients with
AKI stage 2 on admission.
As there were repeated admissions for some patients, the analysis was performed using multilevel
statistical methods. Two-level models were used, with admissions nested within patients. To allow for the
binary nature of the outcome, all analysis was performed using multilevel logistic regression.
Initially, the individual association between each factor and AKI stage was examined individually in a series
of univariable analyses. Subsequently, the joint association between the factors and AKI stage was
examined in a multivariable analysis. Variance inflation factors were used to assess collinearity between the
predictor variables.
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Traditional model validation
Validation in this population
The risk models for AKI were developed using three-quarters of the original patient group meeting the
eligibility criteria. The model was, therefore, validated on the remaining one-quarter of the data.
The validation concentrated on two aspects of the model, the ability to discriminate between the cases
with a high and low risk of AKI, and the calibration of the model, whether or not the risk of AKI from the
fitted model matches that in the observed data.
The model was fitted considering AKI on a 4-point scale: no AKI, AKI stage 1, AKI stage 2 and AKI
stage 3. Thus, the model can be used to obtain predicted probabilities of being in each of the four AKI
categories. Although this is useful, it is harder to validate the model with a 4-point outcome scale.
Thus, for the purposes of validation, two different cut-off points were used. First, the probabilities were
combined to give the probability of AKI (AKI stage 1, 2 or 3), which was compared with the occurrence of
AKI in the data. A second set of analyses split the data into no AKI and AKI stage 1 versus AKI stage 2 and
AKI stage 3, and compared this with the occurrence of AKI stage 2 and AKI stage 3 in the data.
The first approach used was to split the validation data set into risk groups based on the predicted
probabilities. For each analysis, four different risk categories were considered. Within each risk category,
the actual occurrence of AKI was assessed and compared with the predictions; this assesses both the
discrimination and the calibration of the model.
Second, the discrimination between high- and low-risk cases was assessed by calculating the area under
the receiver operating characteristic (ROC) curve. The area under the ROC (AUROC) curve was calculated
and interpreted. One suggested interpretation of the area under the curve (AUC) values is:
l 0.5–0.6: no discrimination
l 0.6–0.7: poor discrimination
l 0.7–0.8: fair discrimination
l 0.8–0.9: good discrimination
l 0.9–1.0: excellent discrimination.
Note that the AUROC value is equivalent to the c-statistic, sometimes used for model assessment.
A final set of analyses examined the difference between the observed outcome and that predicted by the
model using the Hosmer–Lemeshow test. This divided the admissions into the same four categories
described earlier and compares the observed number and the predicted number in each category.
A non-significant result would imply little difference between observed and expected numbers, and thus
a good fit of the model to the data.
Validation in a second population
The population demographic in East Kent is older and has fewer members of ethnic minorities than the
general population of England. It was, therefore, important that we validated our models in a second
population in order to assess the generalisability of the models across the NHS. For our second population
we chose Medway NHS Foundation Trust, which constitutes both a different demographic population and
a different NHS trust from which to extract data.
The method of validation is equivalent to that used in the East Kent data set. The model assessed differs
slightly from that detailed in the East Kent data set, as it excludes the number of drugs given, which was
not measured in this data set.
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Bayesian methods
Bayesian methods were employed, using MATLAB 2014 (MathWorks, Cambridge, UK) statistical software,
to develop the following risk models:
l risk model 1 – the point of admission to hospital
l risk model 2 – predicting new AKI at 72 hours.
The response variable in the case of risk model 1 was AKI on admission, and for risk model 2 it was AKI at
72 hours. AKI was treated as a binary variable. All of the models considered were logistic regression
models. The usual assumptions applied, and these included:
l The link function of the true conditional probabilities and the independent variables was the
logit function.
l All predictors that were considered important were included.
l Collinear variables were avoided.
l There were no errors in the measurement of all possible predictors.
l The episodes included in the database were independent.
l All possible predictors are not linear combinations of each other.
Bayesian model development
As the primary variable consisted of a nominal variable with 19 categories, it was transformed into 19
dummy variables, one for each category/type of primary diagnosis. This allowed us to independently access
the effect of each diagnosis on the response variable.
We followed the usual process of all other Bayesian analyses; that is, we worked out the likelihood
function of the data, placed a prior distribution over all of the unknown parameters and used the Bayes
theorem to calculate the posterior distribution over all parameters. The Bayesian framework should more
naturally allow for modelling biases and systematic errors, and does not suffer from the large sample
constraint (i.e. we do not need to worry about how large our sample should be in order to be able to carry
out inference on the parameters). The results of a Bayesian analysis are direct statements about the
quantities of interest: in our case, the probability of developing AKI.
The likelihood used here matches that of the classical approach; therefore, the likelihood contribution from
the fifth episode is:
eboþb1Xi1þ⋯þbpXip
1+ eboþb1Xi1þ⋯þbpXip
 yi
1−
eboþb1Xi1þ⋯þbpXip
1+ eboþb1Xi1þ⋯þbpXip
 1−yi
, (1)
where Y is the binary response variable, X1, X2, . . . Xp are the predictor variables, and b0, b1, . . ., bp are
the unknown predictor coefficients (the unknown parameters). As the episodes are assumed to be
independent of each other, the likelihood function over the whole data set will then be the nth product of
the above equation.
At the inception of the project we wanted to place an informative prior on the unknown coefficients.
However, the study of predicting AKI is in its infancy, particularly with respect to Bayesian methods, and a
strong opinion as to what characteristics the prior distribution should have could not be agreed; the
approach for variable selection problems is to employ a normal prior. We therefore selected a normal
distribution prior for the unknown coefficients and within that incorporated the stochastic search variable
selection (SSVS) approach described in George and McCullogh.107 The SVSS approach specifies a
hierarchical mixture prior that in turn is informed by the data to assign a larger posterior probability to the
subset of predictors that are more likely to have an effect on the response. The most promising subsets of
predictors can be identified as those with higher posterior probability. The Gibbs sampler was then used to
indirectly sample from this posterior distribution on the set of possible subset choices. The most promising
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predictors can be identified by their more frequent appearance in the Gibbs sample. This means that the
major advantage of SSVS is the fact that it allows for model averaging while avoiding the problem of
calculating probabilities for all 2p subsets (p is the number of predictors). The complete set-up of our
Bayesian logistic regression SSVS approach is as follows:
Yi  Bernoulli(pi),
pi = ehi
1þ ehi,
hi = aþ åkj
= 1 bjXi, j,
bj  N(0, s2) if gj = 1, bj = 0 if gj = 0,
p(gj = 1) = p, p(gj = 0) = 1 p,
a  N(0, h).
(2)
The latent variable is gj and defines if the jth variable is included in the model. A criticism of this approach
is that it is necessary to choose the value of s2. If s2 is too large then we are faced with the danger of
overfitting. As we have standardised the continuous variables, we chose s2= 1. We have assumed a priori
that five variables should be in the model, adhering to the beliefs of the clinical team. This then implied
that p= 5. We feel that this is a reasonable choice as we want to avoid hj being too large.
Bayesian model validation
To assess the predictive accuracy of the models, we randomly divided the data sets in half: half was
used for in-sample estimation/development and the other half used for out-of-sample prediction. The
out-of-sample prediction was made in terms of sensitivity and specificity; that is, we calculated the
probability that the model accurately predicts episodes with AKI and the probability that the model
accurately predicts episodes without AKI.
Although there seem to be large numbers of missing data in the analysis, this appears to be attributable to
failure to conduct a specific test rather than to data being missing in the usual respect. In order to explore
the impact of these data and the fact that they were not missing at random, we created dummy variables
indicating the absence or presence of a particular test result and explored the impact of this on the
outcomes as a sensitivity analysis.
Qualitative methods
The exploratory arm of the study employed both focus group and individual interview designs. The purpose
of this was to inform and plan the follow-up study, adopting a user involvement approach. The aim of the
qualitative methodology was to identify perceptions of the AKI alert system presently in place at the
EKHUFT and explore the best communication and information pathways that would permit an alert system
to both alert and provide actionable recommendations to clinicians for decision-making. This will allow
accurate planning of the new alerting system, which will include AKI and AKI risk alerting following this
study, to ensure effective integration into everyday clinical practice.
Sample
The sample consisted of six renal consultants for the individual interviews and six outreach nurses who
attended the focus group. All of the consultants worked across the three hospitals within the trust, and
there was representation from all hospitals from the outreach nurses; however, the nurses did not work
across all three sites. The consultants used the alert system to identify patients with the more serious AKI
stage 3 and alert medical teams to offer advice and review if required, and the outreach nurses identified
AKI stage 2 patients and provided clinical review of the patients, whose condition was more amenable to
preventative action, on the ward.
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In terms of the accessibility of the consultant and nurse groups, it was established early on that different
qualitative approaches would need to be used on account of their individual availability and potential to
meet together. The consultants had to cover three sites and group meetings were difficult to convene;
therefore, interviews were the method of choice. Conversely, the outreach nurses were difficult to capture
individually but attended a training session as a group once per month, which provided an opportunity
for a focus group. Tuning different methods to the requirements of the population group, in order to
maximise attendance and enrich data, is considered to be good practice.108
Instrumentation and data collection
For the focus group, a schedule was developed that explored perceptions of the impact on clinical practice,
aiming to identify the best methods for delivering the alerts and recommendations. This covered aspects
such as accessibility of information, hardware, whom the recipient should be (junior doctor or consultant),
what form the alert should take (additional e-mail or text), how to avoid alert fatigue and alerts being
ignored. The focus group lasted 1 hour and was facilitated by an experienced researcher from a university
external to the clinical team. Interviews took place at a convenient time and location, and were carried out
by the same experienced researcher.
The template and coding framework for both the focus group and the interviews has been included in
Appendix 3.
Data analysis
Data consisted of six 30-minute interviews and a 1-hour focus group. The data were transcribed verbatim
and subjected to a thematic analysis using a predetermined theme, derived from the interview schedule,
as an initial template for analysis. Clinical team members were not involved at all in the data collection or
analysis of the data; this was undertaken by a researcher from a university external to the clinical team.
Regarding the interview and focus group schedules, sections 1, 2 and 4 are identical. Section 3 has been
altered to account for the differing clinical roles in the project and communication experiences (i.e. with
different people at different times) regarding exposure to the project. There are, however, similarities, as
both sections focus on communication with teams, changes to clinical practice and impacts. Although it is
accepted that data obtained from focus groups are influenced by group dynamics and consensus, data
sources from different qualitative methodological approaches can be blended and contrasted, provided
that they are at first analysed thematically in a separate manner. An overarching, thematic pattern
matching can be used to determine an explanation of the data, which is the method used here.109
The analytical approach taken was Flick’s content analysis,110 whereby themes and subthemes were
categorised within a pre-existing template (within the instrumentation). With this approach, however, care
must be taken not to artificially represent data within the template but to introduce new themes when
identified. This approach required peer review to ensure analytical trustworthiness, which was conducted
within the research team. The analysis from the focus group concentrated on the identification of best
methods for delivering the alerts and recommendations in order to inform the AKI and AKI risk alert
system development and implementation in the follow-up study.
We would aim to have two further focus group waves in our next clinical intervention study to deliver AKI
and AKI-risk alerting to clinicians at the point of care. The qualitative analysis described here is, therefore,
part of a larger longitudinal qualitative research design. Longitudinal qualitative research involves repeat
interviews or observations of, ideally, the same research subjects over time.111 In recent years, longitudinal
qualitative research has been used in a number of health-related areas to generate rich data and a deeper
understanding of people’s perspectives and experiences and how and why these may change over time in
order to improve practice.112–115 Rather than comparing findings at a number of distinct moments,
longitudinal qualitative research is concerned with the comparison of different, continuous processes
of change.
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The benefits of the longitudinal design will be that it will permit the same participants to be involved in
identifying practice challenges and solutions, in developing methods for how alerts and recommendations
can be best delivered for action, and for examining and reflecting on the effects with regard to practice
change as well as system evaluation and improvement. The qualitative aspect of both this and the
follow-on study will strengthen the production of potentially transferable practice guidelines and system
accessibility across the NHS.
The focus group method is a favoured approach in the health-care setting not only for expanding ideas,
but also for gaining consensus on views and promoting good practice.108 This particular research study
promotes new and innovative ideas that may benefit from being explored within a group, particularly with
a longitudinal approach. Variations in perception and experience will encourage deeper discussion and
illuminate impacts, as well as reveal the nature and cause of practice changes in relation to the intervention.
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Chapter 3 Quantitative results
Clinical practice algorithm development
Points of decision-making
The study was designed to develop and validate risk models to define risk of AKI or of worsening AKI
during hospital admission. We determined three time points during the period of admission when
significant clinical decision-making takes place at which the use of risk models would have the greatest
impact on clinical care and patient management. These time points are described below.
The point of admission to hospital
The model applied in this case (referred to as risk model 1) uses all electronic data up until the point of
admission (and the reason for admission to hospital) to determine risk of patients already having AKI
on admission. In this way, the model is guiding the testing of kidney function to ensure that patients who
are likely to have AKI have their kidney function tested to unmask the condition and allow efficient
appropriate clinical intervention to treat the AKI.
After 24 hours of admission
These models use all electronic data both prior to admission and up to 24 hours after admission to
determine the risk of developing AKI (model 2) or of worsening AKI (model 3) in the first 72 hours after
admission. At the 24-hour point, patients will be admitted to the ward and are likely to then be reviewed
by the admitting clinical team on the post-take ward round, or by the ward team on their ward round of
new patients. The models guides clinical management at this point to define patients at risk of AKI
who require:
l Management changes to include the stopping of nephrotoxic medication, fluid assessment and
ensuring fluid replete, monitoring of blood pressure and ensuring adequate blood pressure and
appropriate use of antihypertensive drugs.
l Daily renal function testing to observe for development of AKI. If there is consideration at this point of
discharge from hospital, the models at this point may inform the discharge decision or, if discharge is
still intended, guide follow-up in primary care to observe for AKI (and also management of medications
that may have been stopped temporarily while the risk of AKI exists).
After 72 hours of admission
The purpose of this model was to predict patients who will develop AKI, or worsening AKI if already
present, during the rest of the hospital admission. During the progression of this study, the clinical experts
on the board (informed by the results of the risk modelling) determined that this point of risk assessment
would not add clinical benefit for a number of reasons:
l The risk models at this point were not sufficiently accurate to determine risk and guide clinical
management, which are also related to and a consequence of the other reasons.
l Most patients remain in hospital for < 3 days (72 hours). For those who do stay in hospital over
72 hours, the period of admission may range from 3 days up to as high as 90–365 days. It is very
difficult to determine risk of developing AKI in a widely varying time period, most importantly because
these patients will develop new conditions and changes in blood results (variables in the risk models)
after 72 hours, which change their risk and cannot be accounted for.
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Clinical alerting
The purpose of the risk models is to guide clinical management. This will be achieved through alerting
clinicians at the point of care. These systems have been developed as part of this project, but are awaiting
formal assessment in a trial setting. The clinical alerting system will not solely alert to risk of AKI; it will also
alert to patients with established AKI and provide clinical guidance for improving the management of
these patients and reducing both the progression of AKI and the development of resultant sequelae.
It is therefore important that both alerting to AKI and alerting to AKI risk are brought together in a clinical
practice algorithm to guide both the alerting and the clinical management pathway following the alert.
Alerting at the point of admission
Initial risk model development for the point of admission included pre-admission AKI as a variable in the
models. As would be expected, if a patient has AKI just prior to admission then there is a high risk that
they will still have AKI at the point of admission. The initial models developed confirmed that the variable
‘pre-admission AKI’ was by far the strongest predictor of AKI on admission and diluted other variables in
the model. As part of the clinical practice algorithm, the decision was made by the clinical experts on
the project team that all patients with pre-admission AKI should be alerted by the alerting system as
‘pre-admission AKI’, irrespective of risk assessment. In the cases of these patients, renal function testing
should always occur on admission and the management changes above should be implemented. Patients
with pre-admission AKI were, therefore, removed from the admission models for predicting AKI, and
hence the population of assessment for the point of admission models included only patients without
pre-admission AKI or patients who did not have pre-admission AKI status determined because they did
not undergo renal function testing pre admission.
Alerting after 24 hours of admission
For patients who have AKI on admission, the clinical alerting system will suggest appropriate management
interventions as above listed (see Points of decision-making), including daily renal function testing. Again,
as part of the clinical practice algorithm, patients with AKI on admission were removed from the risk
models at 24 hours to predict AKI at 72 hours, as these patients have already been highlighted by the
system. Moreover, including AKI on admission as a variable in a model to predict AKI at 72 hours would
be highly predictive, dilute the other variables and reduce the clinical utility of the system, especially as
these patients will already be flagged up by the system anyway.
This led to the development of the clinical practice algorithm (Figure 5) to guide:
l AKI alerting
l patients to be assessed by the risk models at the point of admission and at 24 hours after admission
l appropriate renal function testing
l appropriate management interventions.
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FIGURE 5 Acute kidney injury clinical practice algorithm. A&E, accident and emergency.
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Relationships
The first stage of the risk modelling work was to determine relationships between risk factors and AKI.
This was carried out following the definition and extraction of appropriate variables for the model. Of key
importance was assessing the relationship between pathology results and AKI. Once we had established a
normal range, variables were converted from continuous to categorical. Rather than simply using the
laboratory normal range, the point at which each variable became associated with AKI was used; in the
majority of cases this assessment agreed with laboratory normal ranges. For each of the pathology blood
tests we performed a univariate analysis to create a plot of blood-test value on the x-axis and risk of AKI
on the y-axis. The clinical experts in the project group then assessed this in order to define the normal
ranges for the tests.
In the risk models, the options for a given pathology variable were therefore:
l not tested
l normal
l abnormal.
The assessment of the pathology tests in this way is reported in Appendix 2.
Traditional risk modelling analysis
The purpose of the first risk model is to both guide renal function testing and highlight patients most likely
to benefit from detailed review with respect to AKI at the point of admission. This model uses electronic
data from prior to admission, as well as the reason for hospital admission, to predict AKI already being
present at the point of admission. In line with the clinical practice algorithm already discussed, patients
who have confirmed AKI pre admission (in the 2 weeks prior to admission to hospital) will automatically be
highlighted by the AKI alert and CDSS as having pre-admission AKI and the need for urgent retesting and
clinical review. Therefore, the population assessed by this first risk model at the point of admission
excludes patients with pre-admission AKI, but includes patients with no testing of renal function
pre admission.
The variables used in this first model are included in Appendix 3, Table 32. We used both traditional and
Bayesian methods of risk model development to determine the most effective method of providing risk
assessment in this setting. We will present the results of these models separately.
Risk model 1: the point of admission to hospital
Development
After exclusions from the full database (as described in Chapter 2), three-quarters of the data set was
randomly selected for the development database. This consisted of 27,532 admissions with available
AKI-on-admission data. These admissions occurred in 20,330 different patients.
A series of separate univariable ordinal logistic regression analyses were performed to examine factors
associated with AKI on admission. A summary of the analysis results is given in Appendix 3, Table 32.
The sizes of effects are reported in the form of odds ratios. The odds ratio is calculated as the exponential
of the parameter estimates (beta). For categorical variables, these give the odds of being in the next
highest outcome category (e.g. AKI stage 1 rather than no AKI, AKI stage 3 rather than AKI stage 2) for
each category relative to a baseline category. For the continuous predictor variables, the odds ratios
represent the relative change in the odds of being in the next highest category for a given increase in that
predictor. The p-value indicating the overall significance of each variable is also reported.
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The results in Appendix 3, Table 32, are interpretable for the categorical predictor variables. The results for
the continuous variables are less interpretable, and the results for these variables are best showed graphically.
The graph in Figure 6 shows the relationship between age and the probability of AKI. For graphical
purposes, the occurrence of any AKI is plotted.
A similar graph for baseline eGFR is shown in Figure 7.
The next stage in the analyses examined the joint association between the variables and AKI stage in a
multivariable analysis.
The collinearity between the different predictors was examined. The examinations suggested collinearity
between platelet count (PLT), white blood cell count (WBC) and haemoglobin (Hb) levels. Additionally,
collinearity was found between potassium (K) and sodium (Na). The nature of the collinearity was that
these tests were performed on the same patients, and so the ‘not measured’ category was almost
equivalent where collinearity was found.
Before the main multivariable analysis was performed, an additional analysis was performed, examining
the association between PLT, WBC and Hb levels on AKI stage on the subgroup of patients with all tests
performed. The analyses suggested that only Hb was statistically significant, with WBC and platelets
not significant after adjusting for Hb. As a result, only Hb was considered for the multivariable analysis.
A similar analysis was performed for K and Na in the subgroup where these variables were measured.
This analysis suggested that both were independently associated with AKI stage. As a result, a combined
variable was derived, consisting of the following categories: one/both tests not measured, both tests
normal, Na only abnormal, K only abnormal and both tests abnormal.
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FIGURE 6 Risk model 1: relationship between age and probability of AKI in the univariable analysis.
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A backwards selection procedure was used to retain the statistically significant variables in the final model.
This procedure omitted the following variables (in order of removal):
l wound swab/fluid aspirate
l combined Na/K
l calcium
l gender
l faeces
l sputum
l number of outpatient appointments.
The final model is summarised in Table 5.
The results suggested that most factors had a smaller effect after adjustment for the other factors in the
model. This is to be expected, as there will be correlations between many of the risk factors. However,
the results for the majority of predictors showed a similar effect to the results from the univariable analyses.
The exception was for an admission in the last 30 days. In the univariable analyses patients with an
admission in this time period had a higher AKI stage; however, after adjustments for the other factors
these patients had a lower status.
The results for the continuous variables (age and baseline GFR) are again difficult to visualise from the odds
ratios alone. The adjusted predicted probabilities for age are shown in Figure 8 (assuming ‘average’
values for all other variables). This graph shows a broadly similar relationship for age to that seen in the
univariable analyses, although the increased risk peaks around the age of 75 years.
The adjusted relationship for eGFR is shown in Figure 9. After adjusting for the other variables, it seems
that those with the highest values have a lower risk, around the same risk as those with the lowest eGFR
values. The peak risk is around 100.
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FIGURE 7 Risk model 1: relationship between baseline eGFR and probability of AKI in the univariable analysis.
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TABLE 5 Risk model 1: results of the multivariable ordinal logistic regression analysis to examine factors associated
with AKI on admission
Variable Category/term Odds ratio (95% CI) p-value
Agea Linear term 3.35 (1.82 to 6.16) < 0.001
Quadratic term 0.89 (0.81 to 0.98)
Cubic term 1.003 (0.998 to 1.009)
Admissions (last 30 days) No 1 < 0.001
Yes 0.82 (0.74 to 0.91)
Admissions (last 2–12 months) 0 1 < 0.001
1–2 1.28 (1.16 to 1.42)
3–5 1.54 (1.36 to 1.75)
6+ 2.01 (1.70 to 3.80)
6+ 1.67 (1.52 to 1.84)
Primary diagnosis Neoplasms 1 < 0.001
Infectious diseases 1.37 (1.05 to 1.80)
Blood diseases 0.50 (0.35 to 0.72)
Circulatory system 0.66 (0.55 to 0.80)
Digestive system 0.83 (0.68 to 1.02)
Diseases of head/neck 0.30 (0.15 to 0.63)
Genitourinary system 1.76 (1.43 to 2.15)
Musculoskeletal 0.39 (0.30 to 0.49)
Nervous system 0.53 (0.39 to 0.72)
Respiratory system 0.90 (0.75 to 1.09)
Skin 0.87 (0.68 to 1.16)
Endocrine/metabolic 1.64 (1.26 to 2.13)
Injury/poisoning 0.55 (0.45 to 0.67)
Mental disorders 0.79 (0.55 to 1.12)
Symptoms/signs 0.53 (0.44 to 0.64)
Other 0.36 (0.16 to 0.79)
CRP Not measured 1 0.009
Normal (≤ 10mg/l) 0.99 (0.86 to 1.14)
Abnormal 1.19 (1.04 to 1.35)
Hb Not measured 1 < 0.001
Normal
(female: 11–15 g/dl)b
0.79 (0.70 to 0.89)
Abnormal 1.10 (0.98 to 1.24)
HbA1c (12-month average) Not measured 1 0.008
Normal (≤ 7.5%) 1.06 (0.96 to 1.17)
Abnormal 1.24 (1.08 to 1.43)
continued
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TABLE 5 Risk model 1: results of the multivariable ordinal logistic regression analysis to examine factors associated
with AKI on admission (continued )
Variable Category/term Odds ratio (95% CI) p-value
Troponin 0 1 < 0.001
1 1.27 (1.11 to 1.45)
2+ 1.46 (1.15 to 1.85)
Blood culture Not taken 1 < 0.001
Not significant 1.49 (1.29 to 1.73)
Significant 3.12 (2.36 to 4.12)
Charlson score ≤ 0 1 < 0.001
1–10 1.08 (0.97 to 1.21)
11+ 1.37 (1.23 to 1.53)
Not recorded 1.11 (0.96 to 1.29)
Baseline eGFRc Linear term 0.93 (0.60 to 1.43) < 0.001
Quadratic term 0.83 (0.74 to 0.93)
Cubic term 1.03 (1.02 to 1.04)
Drugs takend 0 1 < 0.001
1 1.15 (1.04 to 1.27)
2 or 3 1.38 (1.20 to 1.58)
Not recorded 0.86 (0.77 to 0.95)
MSU or CSU Not taken 1 < 0.001
Not significant 1.05 (0.80 to 1.36)
Significant 1.37 (1.19 to 1.59)
Proteinuria (worst result) Not done 1 < 0.001
1 1.07 (0.96 to 1.19)
2 or 3 1.38 (1.23 to 1.54)
CI, confidence interval; CRP, C-reactive protein; CSU, catheter specimen urine; HbA1c, glycated haemoglobin;
MSU, mid-stream specimen urine.
a Odds ratio given for a 10-unit increase in age.
b Normal range 13–18 g/dl for males.
c Odds ratio given for a 20-unit increase in baseline GFR.
d Number of the following drugs taken: angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs
and diuretics.
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FIGURE 8 Risk model 1: relationship between age and probability of AKI in the multivariable analysis.
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FIGURE 9 Risk model 1: relationship between baseline eGFR and probability of AKI in the multivariable analysis.
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Validation
After exclusions from the full database (as described earlier), one-quarter of the data were randomly
selected for the validation database. This consisted of 9177 admissions. However, owing to a small
number of missing values, predicted probabilities were obtained for 9157 admissions.
First, the development and validation data sets were compared, with the finding that the two data sets
were very matched in terms of the model variables. This was not surprising given the selection of the two
data sets at random.
The first set of analyses split the patients into risk groups based on the predicted probability of AKI. The
‘expected’ risk of AKI in each category based on the predicted probabilities was calculated, along with
the observed occurrence of AKI in each category. Analyses were performed based on the probability of
any AKI, and then again based on the predicted probability of either AKI stage 2 or AKI stage 3. The
results are summarised in Table 6.
The results suggested reasonably good discrimination between the risk groups for both categorisations.
For both models the observed results increased with increased risk, with the categories correctly ordered.
The calibration of the models was also good, with the observed percentages falling within the risk
boundaries for both categorisations. In addition, there was a fairly good agreement between the predicted
percentages and those observed by the data. The slight exception was for the highest risk subjects for the
AKI stage 2/3 categorisation, in whom the observed percentage of AKI stage 2/3 cases was lower than
that predicted by the model.
The next set of analyses further examined the discrimination of the two categorisations using ROC curves
based on the predicted probabilities. A summary of the AUROC values is given in Table 7.
The ROC curve analyses suggested that the model had some discriminatory power, although the AUC
values were only ‘fair’.
The ROC curve for any AKI is shown in Figure 10.
Figure 11 shows the ROC curve for the prediction of AKI stages 2 and 3.
The final analyses compared the observed numbers of patients with AKI in each AKI group and the
numbers predicted by the model using the Hosmer–Lemeshow test. A summary of the results is given
in Table 8.
TABLE 6 Risk model 1: a comparison of the expected with the observed probabilities of AKI in the different risk
groups for AKI on admission
Categorisation Risk category (%) n Mean expected (%) Observed (%)
Any AKI ≤ 10 3325 6.2 5.0
> 10–20 3057 14.3 14.8
> 20–40 2178 27.5 28.4
> 40 597 51.7 51.6
AKI stage 2/3 ≤ 2 3962 1.2 0.8
> 2–5 3358 3.2 3.8
> 5–10 1294 6.9 7.2
> 10 543 15.8 11.4
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TABLE 7 The ROC analyses for the validation of risk model 1
Categorisation AUROC (95% CI) Interpretation
Any AKI 0.75 (0.74 to 0.77) Fair
AKI stage 2/3 0.75 (0.73 to 0.78) Fair
CI, confidence interval.
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FIGURE 10 Risk model 1: ROC curve for the prediction of any AKI.
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FIGURE 11 Risk model 1: ROC curve for the prediction of AKI stages 2 and 3.
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The results suggested that for both models there was a significant difference between the observed
numbers and those expected by the model. This suggests some lack of fit of the model to the data. The fit
of the model for any AKI is slightly better than that for AKI stage 2/3.
For any AKI, the model overpredicts the number of cases of AKI in the lowest-risk group, but provides a
good prediction in the upper risk group. For the AKI stage 2/3 predictions, the model overpredicts the
number of AKI stages 2 and 3 cases in the upper risk group, as seen in Table 6.
Despite the test suggesting a lack of fit to the data, this test is known to be fairly sensitive to slight
deviations between observed and expected frequencies, and so a statistically significant difference
often occurs.
Validation in a second population
The same exclusions were applied to the Medway data set as to those applied to the East Kent data for
the admission AKI model (risk model 1). After excluding certain episodes, the data set consisted of 4726
admissions. Predicted probabilities of AKI were obtained for all admissions.
Initially, the East Kent data set (the development data set only) and Medway data sets were compared for
the admissions suitable for inclusion in the admission model. This revealed some differences between the
two sets of data, as AKI was more common in the Medway data set, occurring in approximately 23% of
patients, compared with 17% in East Kent. There were also differences in a number of the patient
characteristics that were included in the model.
The first set of analyses looked at the occurrence of AKI in each category. Analyses were performed on
patients split into risk groups based on the predicted probability of AKI. The ‘expected’ risk of AKI in each
category was calculated based on the predicted probabilities, along with the observed probability of any
AKI, and then again based on the predicted probability of either AKI stage 2 or AKI stage 3. The results are
summarised in Table 9.
The results suggested reasonably good discrimination between the risk groups for both categorisations.
For both models the observed results increased with increased risk, with the categories correctly ordered.
TABLE 8 A comparison of the observed numbers of patients with AKI in each AKI group and the numbers
predicted by the model using the Hosmer–Lemeshow test for the validation of risk model 1
Categorisation Risk category (%)
No AKIa (n) AKIa (n)
χ
2b p-valueObserved (expected) Observed (expected)
Any AKI ≤ 10 3158 (3119) 167 (206) 9.4 0.009
> 10–20 2606 (2619) 451 (438)
> 20–40 1559 (1580) 619 (598)
> 40 289 (289) 308 (308)
AKI stage 2/3 ≤ 2 3931 (3916) 31 (46) 16.4 0.0003
2–5 3232 (3250) 126 (108)
5–10 1201 (1205) 93 (89)
> 10 481 (457) 62 (86)
a Or AKI stage 2/3 for second categorisation.
b With 2 degrees of freedom.
QUANTITATIVE RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
The calibration of the models was less good, with the observed outcomes in each category higher
than those ‘expected’ by the model. In some instances the observed percentage in each category was
outside the range of the risk category. For example, for all AKI, in those patients with a predicted risk
of 10–20% the observed percentage with AKI was 23.0%, which was higher than the upper boundary of
the prediction.
The next set of analyses further examined the discrimination of the two categorisations using ROC curves
based on the predicted probabilities. A summary of the AUROC values is given in Table 10.
The ROC curve analyses suggested that the model had some discriminatory power, although the AUC
values were only ‘fair’. These values compare with values of 0.75 (for both categorisations) that were
obtained from the internal validation with the East Kent data.
The ROC curve for any AKI is shown in Figure 12.
Figure 13 shows the ROC curve for the prediction of AKI stages 2 and 3.
The final analyses compared the observed numbers of patients with AKI in each AKI group and the
numbers predicted by the model using the Hosmer–Lemeshow test. A summary of the results is given
in Table 11.
The results suggested that for both analyses there was a strong overall lack of fit for the models to the
validation data set. In both instances the number of cases of AKI and AKI stage 2/3 was higher than that
which might be expected by the model. This mirrors the results observed earlier.
TABLE 9 Risk model 1: a comparison of the expected with the observed probabilities of AKI in the different risk
groups for AKI on admission in the second population
Categorisation Risk category (%) n Mean expected (%) Observed (%)
Any AKI ≤ 10 1961 6.1 10.7
> 10–20 1597 14.1 23.0
> 20–40 960 27.1 39.8
> 40 208 51.1 63.0
AKI stage 2/3 ≤ 2 2329 1.1 2.1
> 2–5 1657 3.2 5.9
> 5–10 552 6.8 9.6
> 10 188 15.3 18.6
TABLE 10 The ROC analyses in the second population for the validation of risk model 1
Categorisation AUROC (95% CI) Interpretation
Any AKI 0.72 (0.71 to 0.74) Fair
AKI stage 2/3 0.71 (0.68 to 0.75) Fair
CI, confidence interval.
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FIGURE 12 Risk model 1: ROC curve for the prediction of any AKI in the second population.
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FIGURE 13 Risk model 1: ROC curve for the prediction of AKI stages 2 and 3 in the second population.
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Summary
The results suggest that the model is fairly well calibrated, with the predictions of AKI in quite close
agreement with the observed occurrence of AKI. This is perhaps unsurprising, as the characteristics of the
development data set and the occurrence of AKI were very similar to those of the validation data set.
The model was found to have some predictive powers, and generally was found to be able to distinguish
between low- and high-risk cases. However, the model was by no means perfect in terms of producing
correct predictions for all patients.
The results of the validation in the second population indicate that, using the Medway data, the East Kent
risk model underpredicts the risk both of any AKI and of the occurrence of AKI stage 2/3. This could
potentially be partly attributable to the higher occurrence of both of these outcomes in the Medway data
than in the East Kent data.
However, the discrimination of the model is still reasonable on this external data set, suggesting that it is
able to separate out the high-risk from the low-risk cases. In terms of AUROC curve, the result was only
slightly worse than that obtained when performing the internal validation.
Risk model 2: predicting new acute kidney injury at 72 hours
Development
After exclusions from the full database (as described in Chapter 2), the data consisted of 10,075
admissions. Of these, three-quarters were randomly selected for the development database, resulting in
7556 admissions for the development of the model. These admissions occurred in 6626 different patients.
A series of separate univariable ordinal logistic regression analyses were performed to examine factors
associated with AKI at 72 hours. A summary of the analysis results is given in Appendix 3, Table 33. The
size of effects is reported in the form of odds ratios. For categorical variables, these give the odds of being
in the next highest outcome category (e.g. AKI stage 1 rather than no AKI, AKI stage 3 rather than AKI
stage 2) for each category relative to a baseline category. For the continuous predictor variables, the odds
ratios represent the relative change in the odds of being in the next highest category for a given increase
in that predictor. The p-value indicating the overall significance of each variable is also reported.
TABLE 11 A comparison of the observed numbers of patients with AKI in each AKI group and the numbers predicted
by the model in the second population using the Hosmer–Lemeshow test for the validation of risk model 1
Categorisation Risk category (%)
No AKIa (n) AKIa (n)
χ
2b p-valueObserved (expected) Observed (expected)
Any AKI ≤ 10 1752 (1842) 209 (119) 269.6 < 0.0001
> 10–20 1229 (1372) 368 (225)
> 20–40 578 (700) 382 (260)
> 40 77 (119) 131 (106)
AKI stage 2/3 ≤ 2 2280 (2302) 49 (27) 66.9 < 0.0001
> 2–5 1560 (1604) 97 (52)
> 5–10 499 (515) 53 (37)
> 10 153 (159) 35 (29)
a Or AKIN2/3 for second categorisation.
b With 2 degrees of freedom.
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The results in the above table are interpretable for the categorical predictor variables.
A linear term only was found to be sufficient for age. A 10-year increase in age was associated with a
28% increase in the odds of AKI being in the next highest category. This result is also shown in Figure 14,
which plots age and the probability of AKI. For graphical purposes the occurrence of any AKI is plotted.
A quadratic (squared) term was necessary for baseline eGFR, and thus the odds ratios are difficult to
interpret and the relationship is best viewed graphically. A graph, similar to that for age, is shown in
Figure 15 for baseline eGFR.
The next stage in the analyses examined the joint association between the variables and AKI stage in a
multivariable analysis.
The collinearity between the different predictors was examined. The examinations indicated no strong
evidence of collinearity between any of the predictors; therefore, all predictors were considered for the
multivariable analyses.
The univariable analyses suggested that patients with normal and abnormal glycated haemoglobin (HbA1c)
(from the 12-month average) had almost equivalent risks of AKI. As a result, for this second stage in the
analysis, this variable was recategorised as ‘not measured’ and ‘measured’.
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FIGURE 14 Risk model 2: relationship between age and probability of AKI in the univariable analysis.
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A backwards selection procedure was used to retain the statistically significant variables in the final model.
This procedure omitted the following variables (in order of removal):
l calcium
l gender
l B-type natriuretic peptide (BNP) (12-month average)
l creatinine kinase (CK)
l number of outpatients’ appointments in 12 months
l sputum pre admission
l number of contrast radiology scans
l wound swab/fluid aspirate pre admission
l wound swab/fluid aspirate at admission
l Na
l alanine transaminase (ALT)
l mid-stream specimen urine (MSU) or catheter specimen urine (CSU) pre admission
l faeces at admission
l Hb
l sputum at admission
l MSU or CSU at admission
l faeces pre admission
l operation score at 12 hours
l PLT
l admissions within 30 days of current admission
l blood culture
l number of drugs
l amylase (AMY).
The final model is summarised in Table 12.
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FIGURE 15 Risk model 2: relationship between baseline eGFR and probability of AKI in the univariable analysis.
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TABLE 12 Risk model 2: results of the multivariable ordinal logistic regression analysis to examine factors
associated with new AKI at 72 hours
Variable Category/term Odds ratio (95% CI) p-value
Agea Linear term 1.78 (1.22 to 2.60) < 0.001
Quadratic term 0.97 (0.95 to 1.00)
Admissions (last 2–12 months) 0 1 < 0.001
1–2 1.41 (1.14 to 1.75)
3–5 1.58 (1.20 to 2.09)
6+ 2.24 (1.57 to 3.19)
Primary diagnosis Neoplasms 1 < 0.001
Infectious diseases 1.53 (0.90 to 2.61)
Blood diseases 0.58 (0.25 to 1.36)
Circulatory system 0.77 (0.50 to 1.20)
Digestive system 0.84 (0.55 to 1.30)
Genitourinary system 1.52 (0.95 to 2.43)
Musculoskeletal 0.79 (0.39 to 1.58)
Nervous system 0.57 (0.23 to 1.38)
Respiratory system 0.59 (0.38 to 0.91)
Skin 0.88 (0.46 to 1.72)
Endocrine/metabolic 0.71 (0.34 to 1.46)
Injury/poisoning 1.04 (0.67 to 1.60)
Mental disorders 0.18 (0.02 to 1.32)
Symptoms/signs 0.78 (0.49 to 1.26)
Other 1.33 (0.36 to 4.85)
CRP Not measured 1 0.05
Normal (≤ 10mg/l) 0.89 (0.65 to 1.22)
Abnormal 1.15 (0.85 to 1.55)
HbA1c (12-month average) Not measured 1 0.03
Measured 1.26 (1.03 to 1.56)
K Not measured 1 0.02
Normal (3.5–5.3mmol/l) 0.69 (0.50 to 0.94)
Abnormal 0.86 (0.58 to 1.26)
Magnesium Not measured 1 0.02
Normal (0.7–1.0mmol/l) 0.88 (0.65 to 1.17)
Abnormal 1.69 (1.14 to 2.50)
Troponin 0 1 < 0.001
1 1.42 (1.15 to 1.77)
2+ 2.19 (1.67 to 2.87)
WBC Not measured/normal 1 0.03
Abnormal 1.18 (1.00 to 1.40)
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The final model suggested that a combination of 12 variables could help to predict AKI. A number of these
variables [C-reactive protein (CRP) and Charlson score] were only of borderline statistical significance, but
were retained in the final model.
The univariable results suggested that only a linear term for age was required. However, after adjusting
for the other factors, a quadratic term was found to improve the fit of the model and was, therefore,
included. As a result of the inclusion of this term, the results for age are difficult to visualise from the odds
ratios alone. The adjusted predicted probabilities for age are shown in Figure 16 (assuming ‘average’
values for all other variables). This graph shows a broadly similar relationship for age to that seen in the
univariable analyses, although the increased risk with age tails off for subjects over 80 years.
TABLE 12 Risk model 2: results of the multivariable ordinal logistic regression analysis to examine factors
associated with new AKI at 72 hours (continued )
Variable Category/term Odds ratio (95% CI) p-value
Charlson score ≤ 0 1 0.05
1–10 1.14 (0.87 to 1.49)
11+ 1.35 (1.05 to 1.75)
Not recorded 1.41 (1.02 to 1.95)
Baseline eGFRb Linear term 0.40 (0.28 to 0.57) < 0.001
Quadratic term 1.11 (1.06 to 1.16)
Proteinuria (worst result) Not done 1 0.001
1 0.95 (0.73 to 1.22)
2 or 3 1.52 (1.19 to 1.95)
CI, confidence interval; CRP, C-reactive protein.
a Odds ratio given for a 10-unit increase in age.
b Odds ratio given for a 20-unit increase in baseline GFR.
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FIGURE 16 Risk model 2: relationship between age and probability of AKI in the multivariable analysis.
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The adjusted relationship for eGFR is also best viewed graphically, and this relationship is shown in
Figure 17. After adjusting for the other variables, the graph suggests that patients with a baseline eGFR of
around 90ml/minute/1.73m2 have the lowest risk, with a slight rise in risk for those with higher baseline
eGFR values.
Validation
After exclusions from the full database (as described in Chapter 2), one-quarter of the data were randomly
selected for the validation database. These consisted of 2519 admissions. However, owing to a small
number of missing values, predicted probabilities were obtained for 2514 admissions.
Initially, the development and validation data sets were compared, with the finding that the two data sets
were very matched in terms of the model variables. This is not surprising given that the selection of the
two data sets was at random.
The first set of analyses split the patients into risk groups based on the predicted probability of AKI.
The ‘expected’ risk of AKI in each category based on the predicted probabilities was calculated, along
with the observed occurrence of AKI in each category. Analyses were performed based on the probability
of any AKI, and then again based on the predicted probability of either AKI stage 2 or 3. The results are
summarised in Table 13.
The results suggested reasonably good discrimination between the risk groups for any AKI. For the
prediction of this outcome, the observed results increased with increased risk, with the categories
correctly ordered.
The discrimination for the prediction of AKI stage 2 or AKI stage 3 was less impressive. AKI stage 2/3 was
less common in the lowest-risk group. However, there was a similar occurrence of AKI stage 2/3 in the
three higher-risk groups, with this outcome occurring slightly more frequently in the second highest-risk
group than in the highest-risk group. However, it should be noted that AKI stage 2/3 was relatively rare in
this patient group and the group sizes were relatively small for the higher-risk groups.
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FIGURE 17 Risk model 2: relationship between baseline eGFR and probability of AKI in the multivariable analysis.
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The calibration of the model for the prediction of AKI was good, with the observed percentages falling
within the risk boundaries. In addition, there was a fairly good agreement between the predicted
percentages and those observed by the data.
The calibration for the prediction of AKI stage 2/3 was less good, with an observed occurrence of AKI
stage 2/3 in the 1–2% and 2–3% categories above the risk category boundary. Additionally, the observed
occurrence of AKI stage 2/3 for the > 3% category was below the category boundary; however, it is noted
that the risk boundaries were relatively tight for the prediction of this outcome.
The next set of analyses further examined the discrimination of the two categorisations using ROC curves
based on the predicted probabilities. A summary of the AUROC values is given in Table 14.
The ROC curve analyses suggested that the model had there was some discriminatory power, with the
lower bounds for the confidence intervals (CIs) higher than 0.5 for both categorisations. Despite the model
having some predictive ability, the AUC values were classed as ‘poor’ (although approaching ‘fair’).
The ROC curve for any AKI is shown in Figure 18.
Figure 19 shows the ROC curve for the prediction of AKI stages 2 and 3.
The final analyses compared the observed numbers of patients with AKI in each AKI group and the
numbers predicted by the model using the Hosmer–Lemeshow test. A summary of the results is given
in Table 15.
The results indicate that for both models there was a significant difference between the observed numbers
and those expected by the model. This suggests some lack of fit of the model to the data. The fit of the
model for any AKI was better than that for AKI stage 2/3, with the lack of fit only just statistically significant.
TABLE 13 Risk model 2: a comparison of the expected with the observed probabilities of AKI in the different risk
groups for new AKI at 72 hours
Categorisation Risk category (%) n Mean expected (%) Observed (%)
Any AKI ≤ 5 709 3.3 4.5
> 5–10 1023 7.3 7.7
> 10–20 633 13.7 15.3
> 20 149 26.9 22.1
AKI stage 2/3 ≤ 1 1441 0.6 0.8
> 1–2 737 1.4 2.6
> 2–3 210 2.4 3.3
> 3 126 4.3 2.4
TABLE 14 The ROC analyses for the validation of risk model 2
Categorisation AUROC (95% CI) Interpretation
Any AKI 0.67 (0.64 to 0.71) Poor
AKI stage 2/3 0.68 (0.61 to 0.76) Poor
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FIGURE 18 Risk model 2: ROC curve for the prediction of any AKI.
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FIGURE 19 Risk model 2: ROC curve for the prediction of AKI stages 2 and 3.
QUANTITATIVE RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
For any AKI, the model underpredicts the number of cases of AKI in the three lowest-risk groups, but
overpredicts in the upper risk group. The results for the AKI stage 2/3 predictions are similar.
Despite the test suggesting a lack of fit to the data, this test is known to be fairly sensitive to slight
deviations between observed and expected frequencies, and so a statistically significant difference
often occurred.
Validation in a second population
The same exclusions were applied to the Medway data set as those applied to the East Kent data for the
72-hour AKI model (as described in Risk model 2: predicting new acute kidney injury at 72 hours). After
excluding certain episodes, the data set consisted of 1585 admissions. Predicted probabilities of AKI were
obtained for all admissions.
Initially, the East Kent data set (the development data set only) and Medway data sets were compared for
the admissions suitable for inclusion in the 72-hour model.
This suggests some differences between the two sets of data. However, results for AKI by 72 hours were
relatively similar in the two data sets. Any AKI occurred in 8.9% of the East Kent patients, compared with
7.6% of the Medway patients. AKI stage 2/3 was rare in both data sets, but the occurrence was similar in
the two groups.
The first set of analyses looked at the occurrence of AKI in each category. Analyses were performed on
patients split into risk groups based on the predicted probability of AKI. The ‘expected’ risk of AKI in each
category based on the predicted probabilities was calculated, along with the observed probability of any
AKI, and then again based on the predicted probability of either AKI stage 2 or AKI stage 3. The results are
summarised in Table 16.
The results suggested reasonably good discrimination between the risk groups for any AKI. For this
categorisation the observed results increased with increased risk, with the categories correctly ordered.
The discrimination was less good for the prediction of AKI stage 2/3. The first three categories are correctly
ordered, although there is little difference in the observed occurrence of AKI stage 2/3 in the lowest two
groups. The highest-risk group actually has the lowest occurrence of AKI stage 2/3 (no observed cases);
however, it is noted that the group is small in number.
TABLE 15 A comparison of the observed numbers of patients with AKI in each AKI group and the numbers
predicted by the model using the Hosmer–Lemeshow test for the validation of risk model 2
Categorisation Risk category (%)
No AKIa (n) AKIa (n)
χ
2b p-valueObserved (expected) Observed (expected)
Any AKI ≤ 5 677 (685) 32 (24) 6.4 0.04
> 5–10 944 (949) 79 (74)
> 10–20 536 (546) 97 (87)
> 20 116 (109) 33 (40)
AKI stage 2/3 ≤ 1 1430 (1432) 11 (9) 10.4 0.005
> 1–2 718 (727) 19 (10)
> 2–3 203 (205) 7 (5)
> 3% 123 (120) 3 (5)
a Or AKIN2/3 for second categorisation.
b With 2 degrees of freedom.
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The calibration of the models was good for any AKI. The observed outcomes in each category are broadly
similar to those ‘expected’ by the model. For the first three risk categories the model underpredicted
slightly. In all instances, the observed percentage in each category was within the range of the risk
category. The calibration of the AKI stage 2/3 model was less good, with the model overpredicting the
occurrence of AKI stage 2/3 in all risk categories.
The next set of analyses further examined the discrimination of the two categorisations using ROC curves
based on the predicted probabilities. A summary of the AUROC values is given in Table 17.
The ROC curve analyses suggested that there was some discriminatory power for the prediction of any
AKI, although the AUC values were only ‘fair’. This is comparable with the value of 0.68 obtained from the
internal validation with the East Kent data; therefore, this is a slightly better performance than that of
the internal data.
The AUROC was poorer for the prediction of AKI stage 2/3, with a value of 0.63, which is a fairly poor
value. This is a lower value than that obtained from the East Kent internal validation.
The ROC curve for any AKI is shown in Figure 20. Figure 21 shows the ROC curve for the prediction of
AKI stages 2 and 3.
The final analyses compared the observed numbers of patients with AKI in each AKI group and the
numbers predicted by the model using the Hosmer–Lemeshow test. A summary of the results is given
in Table 18.
The results suggested that for both models there was no statistically significant difference between the
observed numbers and those expected by the model. This typically suggests a fairly good fit of the model
to the data.
TABLE 16 Risk model 2: a comparison of the expected with the observed probabilities of AKI in the different risk
groups for new AKI at 72 hours in the second population
Categorisation Risk category (%) n Mean expected (%) Observed (%)
Any AKI ≤ 5 760 3.0 3.7
> 5–10 563 6.8 8.5
> 10–20 214 13.4 15.0
> 20 48 26.5 25.0
AKI stage 2/3 ≤ 1 1218 0.5 0.7
> 1–2 262 1.4 0.8
> 2–3 69 2.4 1.4
> 3 36 4.3 0.0
TABLE 17 The ROC analyses in the second population for the validation of risk model 2
Categorisation AUROC (95% CI) Interpretation
Any AKI 0.71 (0.67 to 0.76) Fair
AKI stage 2/3 0.63 (0.52 to 0.75) Poor
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FIGURE 20 Risk model 2: ROC curve for the prediction of any AKI in the second population.
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FIGURE 21 Risk model 2: ROC curve for the prediction of AKI stages 2 and 3 in the second population.
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Summary
The results suggest that the model performs better for the prediction of any AKI than for the prediction of
AKI stage 2/3. However, it is noted that AKI stage 2/3 is relatively rare in this cohort of patients. The model
for the prediction of AKI is relatively well calibrated, although its discriminatory ability is poorer than for
the model predicting AKI on hospital admission.
The results of validation in a second population indicate that, using the Medway data, the East Kent risk
model has a fairly good calibration for the prediction of any AKI. The discrimination of the model is as
good as, if not slightly better than, observed when validating on the East Kent data.
Both the calibration and the discrimination of the prediction of AKI stage 2/3 were poorer when tested on
this Medway data set. The performance of the model for the prediction of this outcome is probably not
sufficiently good for use in practice. However, it is noted that AKI stages 2/3 in this patient group is rare,
making it more difficult to predict the outcome.
Risk model 3: predicting worsening acute kidney injury at 72 hours
Development
After exclusions from the full database (as described in Chapter 2), the data consisted of 3111 admissions.
Of these, three-quarters were randomly selected for the development database, resulting in 2333
admissions for the development of the model. These admissions occurred in 2159 different patients.
A series of separate univariable logistic regression analyses were performed to examine factors associated
with worsening AKI at 72 hours. A summary of the analysis results is given in Appendix 3, Table 34.
The sizes of effects are reported in the form of odds ratios. For categorical variables, these give the odds
of worsening AKI for each category relative to a baseline category. For the continuous predictor variables,
the odds ratios represent the relative change in the odds of worsening AKI for a given increase in that
predictor. The p-value indicating the overall significance of each variable is also reported.
TABLE 18 A comparison of the observed numbers of patients with AKI in each AKI group and the numbers
predicted by the model in the second population using the Hosmer–Lemeshow test for the validation of risk
model 2
Categorisation Risk category (%)
No AKIa AKIa
χ
2b p-valueObserved (expected) Observed (expected)
Any AKI ≤ 5 732 (737) 28 (23) 4.3 0.12
> 5–10 515 (525) 48 (38)
> 10–20 182 (185) 32 (29)
> 20 36 (35) 12 (13)
AKI stage 2/3 ≤ 1 1209 (1211) 9 (6.2) 4.0 0.14
> 1–2 260 (258) 2 (3.6)
> 2–3 68 (67) 1 (1.7)
> 3 36 (34) 0 (1.6)
a Or AKIN2/3 for second categorisation.
b With 2 degrees of freedom.
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The next stage in the analyses examined the joint association between the variables and AKI stage in a
multivariable analysis.
The collinearity between the different predictors was examined. The examinations indicated no strong
evidence of collinearity between any of the predictors. Therefore, all predictors were considered for the
multivariable analyses.
A backwards selection procedure was used to retain the statistically significant variables in the final model.
This procedure omitted the following variables (in order of removal):
l admissions within the last 12 months
l faeces at admission
l troponin
l number of radiology scans
l K
l HbA1c
l gender
l AMY
l BNP
l MSU or CSU pre admission
l wound swab/fluid aspirate pre admission
l Na
l admissions within 30 days
l calcium
l outpatient appointments within the last 12 months
l sputum pre admission
l WBC
l faeces on admission
l MSU or CSU on admission
l blood culture
l sputum on admission
l Charlson Comorbidity Index score
l number of drugs
l age
l proteinuria
l CRP
l ALT.
The final model is summarised in Table 19.
The final model suggested that a combination of seven variables could help to predict worsening in AKI.
Of these variables, one (PLT) was only of borderline statistical significance but was retained in the
final model.
Validation
After exclusions from the full database (as described above), one-quarter of the data were randomly
selected for the validation database. These consisted of 778 admissions. However, owing to a small
number of missing values, predicted probabilities were obtained for 775 admissions.
First, the development and validation data sets were compared. This suggested that the two data sets
were closely matched in terms of the model variables. This is not surprising given that the selection of the
two data sets was at random.
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The first set of analyses split the patients into risk groups based on the predicted probability of worsening
AKI. Three risk categories were used (as opposed to four in previous risk models) because of the smaller
sample size for this data set and the low occurrence of worsening AKI.
The ‘expected’ risk of worsening AKI in each category based on the predicted probabilities was calculated,
along with the observed occurrence of worsening AKI in each category. The results are summarised in
Table 20.
TABLE 19 Risk model 3: results of the multivariable ordinal logistic regression analysis to examine factors
associated with worsening AKI at 72 hours
Variable Category/term Odds ratio (95% CI) p-value
Primary diagnosis Neoplasms 1 0.01
Infectious diseases 7.91 (2.06 to 30.3)
Circulatory system 2.20 (0.67 to 7.23)
Digestive system 1.30 (0.38 to 4.44)
Genitourinary system 3.54 (1.04 to 12.0)
Musculoskeletal 1.48 (0.20 to 10.8)
Nervous system 0.81 (0.07 to 9.45)
Respiratory system 1.92 (0.58 to 6.38)
Skin 1.27 (0.27 to 6.12)
Endocrine/metabolic 1.03 (0.25 to 4.32)
Injury/poisoning 2.64 (0.74 to 9.43)
Symptoms/signs 1.18 (0.31 to 4.55)
Other 0.41 (0.04 to 4.37)
Magnesium Not measured 1 0.03
Normal (0.7–1.0 mmol/l) 1.10 (0.64 to 1.90)
Abnormal 2.25 (1.23 to 4.13)
PLT Not measured/normal 1 0.06
Abnormal 1.48 (0.99 to 2.12)
CK Not measured 1 0.01
Normal (≤ 1000U/l) 1.54 (0.70 to 3.39)
Abnormal 5.44 (1.72 to 17.2)
Baseline eGFRa Linear term 1.19 (1.04 to 1.37) 0.01
Operation score at 12 hours 0 1 0.003
Score 1–2 1.16 (0.44 to 3.03)
Score 3–4 4.68 (1.91 to 11.5)
Wound swab/fluid aspirate Not taken 1 0.001
Admission Taken 2.63 (1.49 to 4.64)
a Odds ratio given for a 20-unit increase in baseline GFR.
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The results indicated fairly poor discrimination between the risk groups for worsening AKI. The first two
risk categories had little difference in the observed percentage of patients with worsening AKI, with the
occurrence in the highest-risk category being not significantly higher.
The calibration of the model was also not particularly good. There was an overprediction of the risk of
worsening AKI for the lowest-risk category.
The next set of analyses further examined the discrimination of the model using ROC curves based on the
predicted probabilities of worsening AKI. The AUC value was found to be 0.53 (95% CI 0.45 to 0.61).
This suggests that the model has little or no discriminatory ability. The ROC curve is shown in Figure 22.
The final analyses compared the observed numbers of patients with worsening AKI in each AKI group
against the numbers predicted (expected) by the model using the Hosmer–Lemeshow test. A summary of
the results is given in Table 21.
The results indicated that there was a highly significant difference between the observed numbers and
those expected by the model. This suggests a lack of fit of the model to the data.
The model overpredicts the number of cases of worsening AKI in the lowest-risk group, but underpredicts
the number in the upper risk group.
TABLE 20 Risk model 3: a comparison of the expected with the observed probabilities of AKI in the different risk
groups for worsening AKI at 72 hours in the second population
Risk category (%) n Mean expected (%) Observed (%)
≤ 4 445 2.6 7.4
> 4–10 244 5.9 7.0
> 10 86 19.7 11.6
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FIGURE 22 Risk model 3: ROC curve for the prediction of worsening AKI.
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Summary
The results suggest a poor performance of the model in all validation assessments. As a result, this model
is unlikely to be useful in clinical practice in predicting which patients are more likely to have worsening
AKI. The poor performance of the model may be because there are considerably fewer patients in this
group, because key variables have not been included in the model (e.g. physiological variables) or, finally,
because development of AKI in this setting is subject to a random effect.
Bayesian risk modelling analysis
Risk model 1: the point of admission to hospital
Development
After exclusions from the full database (as described in Chapter 2), half of the data were randomly selected
for the development database. Table 22 displays the variables that were selected via the SSVS method for
the Bayesian logistic regression model.
TABLE 21 A comparison of the observed numbers of patients with worsening AKI in each AKI group and the
numbers predicted by the model in the second population using the Hosmer–Lemeshow test for the validation
of risk model 3
Risk category (%)
No worsening (n) Worsening (n)
χ
2a p-valueObserved (expected) Observed (expected)
≤ 4 412 (433) 33 (40) 44.8 < 0.001
> 4–10 227 (229) 17 (15)
> 10 76 (69) 10 (17)
a With 1 degree of freedom.
TABLE 22 Variables selected for the Bayesian logistic regression model: admission
Variable Median 95% credible interval Mean
Intercept –1.1835 –1.2318 to –1.1375 –1.1839
Variables with probability of inclusion > 0.5
Episode 0.1352 0.0800 to 0.1920 0.1353
Primary diagnosis: diseases of the genitourinary system 0.0988 0.0530 to 0.1398 0.0980
Charlson Comorbidity Index score 0.1480 0.0966 to 0.1975 0.1478
Baseline eGFR –0.2255 –0.2812 to –0.1693 –0.2255
Proteinuria 12-month test count 0.0683 0 to 0.2045 0.0047
HbA1c recent result provided –0.0839 –0.3052 to 0 –0.0760
Variables with probability of inclusion > 0.25
Primary diagnosis: diseases of the respiratory system 0.0009 0 to 0.1069 0.0290
MSU or CSU in previous 2 weeks 0.0007 0 to 0.1045 0.0335
Platelet result available –0.0005 –0.1364 to 0 –0.0246
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This model considers only the main effects. SSVS calculates the probability of inclusion of variables in the
model. A high inclusion probability implies that the variable is important. A good cut-off point for this
probability is 0.5. Based on this, the model should include six variables: spell type, primary diagnosis –
diseases of the genitourinary system, Charlson Comorbidity Index score, baseline eGFR, proteinuria
12-month test count and whether or not the HbA1c recent result has been provided. Based on this model
we can make the following statements, which are illustrated in Figure 23:
1. The odds of developing AKI are 1.15 times greater for non-elective admission than for elective.
2. The odds of developing AKI are 1.1 times greater for an episode with primary diagnosis= 12; that is,
a diagnosis of a disease of the genitourinary system.
3. The odds of developing AKI are 1.16 times greater for an episode with Charlson Comorbidity Index
score= 10 than for an episode with Charlson Comorbidity Index score= 9.
4. The odds of developing AKI decrease by a factor of 0.80 when the baseline eGFR increases by 1 unit.
5. The odds of developing AKI increase by a factor of 1.07 when the proteinuria 12-month test count
increases by 1 unit.
6. The odds of developing AKI decrease by a factor of 0.92 when the recent HbA1c blood result is provided.
The effects of a diagnosis of a disease of the respiratory system, of MSU or CSU taken 2 weeks earlier and
of the provision of recent PLT are very small, which means that the odds are very close to 1, suggesting
that the risk of AKI is the same.
Validation
Validation of the developed Bayesian model was performed as described in the methods. Half of the data
set had been randomly selected for use in model development, and half had been selected for
model validation.
For this Bayesian model, the in-sample sensitivity was 35% and specificity was 98%, and out-of sample
sensitivity was 32% and specificity was 97%.
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FIGURE 23 Graphical representation of variables indicating the probability of their inclusion in the final model.
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The specificity, which is the probability that the model accurately predicts the episodes when AKI will not
develop or, better, who will not develop AKI, is high. The sensitivity is poor.
Summary
The results of the Bayesian modelling demonstrate excellent specificity and hence this model is good at
defining patients at very low risk of having AKI; however, the sensitivity is poor and so the model cannot
accurately determine which patients are at high risk. This model would, therefore, be good for defining
the population of patients who do not need renal function testing to assess for AKI; by inference it can,
therefore, determine the population for testing. However, a large number of the population for testing will
be false positives.
Risk model 2: predicting new acute kidney injury at 72 hours
Development
After exclusions from the full database (as described in Chapter 2), half of the data were randomly selected
for the development database. Table 23 displays the variables that were selected via the SSVS method for
the Bayesian logistic regression model.
This model considers only the main effects. SSVS calculates the probability of inclusion of variables in the
model. A high inclusion probability implies that the variable is important. A good cut-off point for this
probability is 0.5. Based on this cut-off the model should include only one variable, the Charlson
Comorbidity Index score. Based on a cut-off of 0.25 only one other variable is included, the outpatient
attendances in the last 12 months. The second and third columns of Table 23 display the median effect
and 95% credible interval (for the effect) of the selected variables. Based on this model we can make the
following statements, which are illustrated in Figure 24:
1. The odds of developing AKI are 1.20 times greater for an episode with Charlson Comorbidity Index
score= 10 than for an episode with Charlson Comorbidity Index score= 9.
2. The odds of developing AKI decrease by a factor of 1 when the outpatient attendance in the last
12 months increases by one additional attendance. This suggests that this variable has a very
insignificant impact on the risk of developing AKI.
TABLE 23 Variables selected for the Bayesian logistic regression model: 72 hours
Variable Median 95% credible interval
Intercept –1.3377 –1.5866 to –1.2238
Variables with probability of inclusion > 0.5
Charlson Comorbidity Index score 0.1744 0 to 0.2714
Variables with probability of inclusion > 0.25
Outpatient attendances in the last 12 months 0.0010 –1.6156 to 0
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Validation
Validation of the developed Bayesian model was performed as described in the methods. Half of the data set
had been randomly selected for use in model development and half had been selected for model validation.
For this Bayesian model the in-sample sensitivity was 33% and specificity was 98%, and out-of sample
sensitivity was 32% and specificity was 97%.
The specificity, which is the probability that the model predicts accurately the episodes without AKI or,
better, who not develop AKI, is high. The sensitivity is poor.
Summary
The results of the Bayesian modelling demonstrate an excellent specificity and hence this model is good at
defining patients at very low risk of having AKI; however, the sensitivity is poor and so cannot accurately
determine those patients at high risk. This model would, therefore, be good for defining the population of
patients who do not need renal function testing to assess for AKI; by inference it can, therefore, determine
the population for testing. However, a large number of the population for testing will be false positives.
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FIGURE 24 Overall plot of variables indicating the probability of their inclusion in the final model.
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Chapter 4 Qualitative analysis
Analysis of qualitative data
This chapter reports on the findings of the individual interviews with renal consultants and the focus group
with outreach nurses from critical care conducted approximately 18 months following the introduction of
the alert system. The purpose of this part of the study was to gather information on perceptions of the
system, levels of interaction with the technology, communication with medical teams, impacts on patients
and clinical practice, and recommendations for improvements.
Table 24 lists the main themes and subthemes emanating from the data. Quotes from the respondents are
used in the analysis to justify interpretation, with ‘C’ referring to a consultant response and ‘ON’ referring
to an outreach nurse response. Further numerical coding refers to the interviewee code for the
respondents and the page number of the transcript from which the quote was derived. For example,
C3:4= consultant 3, transcript page 4.
At the time it was assessed, the AKI alert system at EKHUFT was delivered through QlikView, a
browser-based reporting tool; references to ‘QlikView’ in quotes are, therefore, referring to the AKI
alert system.
Each section of the analysis is followed by a short summary highlighting the main points raised.
TABLE 24 Analytical themes and subthemes
Themes Subthemes
1 Introducing the alert system 1.1 Getting to know the alert system
1.2 First reactions to the system
2 Using the technology 2.1 General comments
2.2 Issues with user friendliness
2.3 Timing and workload
2.4 Accessing data and making decisions
3 Interacting with medical teams 3.1 Finding the right doctor
3.2 Discussing the cases
3.3 Awareness of the alert system
4 Monitoring cases 4.1 To follow up or not to follow up?
4.2 Acting on advice
5 Impacts on patient care and clinical practice 5.1 Making a difference to patient care
5.2 Impacts on clinical practice
5.3 Perceptions of cost-effectiveness
6 Recommendations for improvements 6.1 Improving trust-wide knowledge of the alert system
6.2 Improving the technology
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Introducing the alert system
This first theme focuses on how respondents first heard of the alert system and were instructed how to
use it, and their initial reactions to becoming part of the system.
Getting to know the alert system
Some respondents had already used a similar system and so found the transition to using it for the
research straightforward:
I’ve used QlikView already so I’m familiar with it . . . [researchers] took me through the system and I
basically got on with it.
C6:1
. . . I’d used QlikView previously, some of the trust data’s on QlikView itself . . . I think [researcher]
probably discussed it at one of our senior doctor meetings and then it was introduced, and we’d had
a chat about using it . . . that the on-call consultant would use it every day to identify patients.
C4:1
I basically was using it in a previous job role . . . to access A&E [accident and emergency] data so we
was [verbatim] kind of familiar with it from there. And then . . . I’ve just adapted the bits of it that I’m
using really.
ON2:1
The nature of the first introduction appeared to be informal and brief; some participants had difficulty
remembering it:
I think it was at a meeting that [researcher] briefly mentioned but it wasn’t a formal you know,
unveiling of the system . . .
C1:2
I don’t think there was any formal training that I remember, just opened it and started using it.
C3:1
I can’t remember actually . . . I suppose [researchers] must have shown us, shown me how to use it but
I honestly can’t remember.
C2:1
The outreach nurses appeared to have had more formal training, which they rated highly in terms of
meeting their needs, and they particularly valued the accessibility of the researcher:
. . . when [researcher] trained us, I certainly felt that it was very adequate. We had several sessions
with him. And I feel very much that if I needed anything I could always get what I wanted from
[researcher] so it wasn’t . . . it wasn’t just an informal thing for us.
ON1:4
I mean [researcher] is very adaptable and approachable in terms of giving us what we need, I think,
as a whole team across the sites in terms of education and updates and stuff.
ON3:4
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Some of the consultants had been involved in the project’s conception so they were already
knowledgeable about it, as explained here:
I was aware of its development and you know [researcher] would talk about it whilst it was being
developed and ask for ideas and suchlike . . .
C5:2
Most respondents felt that the system was relatively straightforward and that they were able to learn
experientially, without the need for more formal training:
. . . a lot of it was sort of learning as you tried to use the system, you try . . . and you learned how to
access this bit of it or that bit of it . . .
C1:1
. . . it’s not very complicated, but yes we were given passwords for access to QlikView and the AKI
system and then I think [researcher] took a quick whizz through and that was it.
C5:1
. . . you learn the tricks as you go, so I think expectations of how you’re taught how a system works
are probably too high . . . the practicalities of doing it – actually that experience is quite a useful tool.
C4:3
First reactions to the system
All respondents appeared to be keen to support colleagues and welcomed the alert system. There was
also an acknowledgement of its importance and potential contribution to innovation and change in
renal medicine:
. . . well I thought it was a good idea because we I mean we have been doing this with chronic kidney
disease and advising GP [general practitioner] practices so I thought with acute kidney injury . . . it was
quite a good idea and I was keen to continue with it and help out the research process.
C1:1
I think it’s great that there’s a system in place to pick people up.
ON4:26
It’s important work, not only for the trust but it fits with the recommendations of the NCEPOD report
for AKI . . . and the general Department of Health Research and Innovation Agenda . . . yeah, so good
for patients and practice.
C6:1
In addition to recognising how the system could improve patient care and impact on practice, other
respondents discussed the proactive nature of the alert system in bringing this about:
. . . people can be going ‘off’ without anybody realising, so having an alert system that actually picked
it up and prompted the doctors looking after them to actually have a think about what might be
going on with this patient seemed like a very good idea.
C5:1
. . . it’s our only means of identifying some of the sick patients . . . and quite often some of these
groups of patients we will only pick up on because they’ve been identified through the alert system
. . . Had we not had that access to that we probably would never even know they’re in hospital.
ON2:5
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. . . well I think it’s a very good idea . . . I think is very important and using the benefits of the expertise
that we have in the trust for building these platforms I think makes a lot of sense, I’m enthusiastic.
C2:1
One respondent, however, did feel a sense of imposition, suggesting that there was little choice in terms
of participation:
. . . we were told that we had to start using it, we were told that it was part of a research and that
they were trying to sort of incorporate it into our normal daily activities and practice.
C1:1
The outreach nurses also had some collective reservations about the added workload and goodness of fit
with their role, an aspect elaborated on later:
I’m not sure we were totally warm to it because it was just something else to add to our job . . . And
we’ve got one of those umbrella jobs where we . . . ‘Outreach will do it anyway’ . . . And then it was
like oh. But . . . it is quite appropriate to see the patients very often because they’re sick and they have
renal failure . . . But we weren’t exactly, ‘Yay!’
ON1:4/5
I . . . I sort of personally queried why this wasn’t being taken up by the renal satellite unit . . . and I did
feel a little bit well I’m not quite sure that that’s appropriate for us.
ON3:5
Summary
Initial responses to the alert system appeared to be encouraging. There was strength of opinion regarding
the desire to support colleagues and the research endeavour, and an understanding of its potential
contribution to renal medicine. Given that the alert system has been in operation for nearly 2 years, the
sentiments expressed by most respondents appeared to be enduring, evidenced by their use of the present
tense when describing their views. Alongside this, however, there was a tendency for the outreach nurses
to greet the system with a degree of uncertainty regarding their roles. Outreach nurses had more formal
training, which they appreciated, and, although seemingly brief and informal for the consultants, the
induction process appeared to be sufficient for engaging colleagues given that the technology was
not complex.
Using the technology
The second theme explores opinions and use of the system technology and includes a general overview of
accessibility and functionality, followed by a deeper analysis of issues concerning user friendliness, timing
and workload, and factors relating to accessing data and making decisions.
General comments
General comments about the technology are summarised by the quotes below and include opinions about
accessibility of information and the population group:
I think the accessibility is good, the fact that it’s web based so you don’t have to have software
installed on a specific computer and the fact that I can access it from my iPad® [Apple Inc., Cupertino,
CA, USA] at home . . . I don’t have a problem with it, it’s quite intuitive, visual impact you know that’s
fine again.
C2:3
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I use it really just to identify the patients with AKI 3 and those who have not had intervention . . .
I only deal with the ones who have not had any comments, so the new ones.
C4:5
With respect to its overall functionality, a frequent comment related to how respondents restricted their
use to certain features deemed most relevant:
. . . there are a lot of buttons at the top but I never use most of them . . . most of the information is,
the important things, that they’ve got AKI 3, where they are and what team they’re under . . .
C4:8
I appreciate that there are a lot of tabs along the top that I just haven’t explored really through lack of
time more than anything else but in terms of the core functionality it’s very easy to use.
C2:1
To be honest I only access the first page and then I go into other systems because they provide for
more information.
C5:4
Issues with user friendliness
More detailed exploration with respondents highlighted a number of issues regarding the ease or difficulty
of navigating the system and accessing data. The following quotes describe the main difficulties
experienced. First, the speed and responsiveness of the system appeared problematic:
. . . sometimes the pages wouldn’t load and if you were trying to filter out things it wouldn’t, it would
take a while to . . . get to the filter page which you wanted to look at so sometimes a lot of clicking
and logging out of the system and logging back onto it . . .
C1:2
The system is very variable in terms of it does seem to not want to upload or refresh and stuff
quite regularly.
ON2:20
. . . there’s a way you can add comments so that your colleagues for the following day know that
you’ve already sort of dealt with that patient and that can be a little bit sluggish to upload . . .
C6:4
One respondent also commented on the ‘modernity’ of the system:
. . . it’s not very pretty . . . because actually we’re used to doing most stuff on webpages then you go
to Amazon or whatever else you know that’s what we’re used to, and it’s a very different system and
I don’t think it’s knowledge user friendly.
C4:9
Issue were also raised about the mechanisms through which identifiable patient data could be retrieved
and information added:
. . . sometimes just when you start, when you log in you have to clear all the selections and then start
again otherwise you don’t get all the patients quite right . . . you might miss patients.
C4:4
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. . . if you were reporting on a certain patient you have to manually enter sort of details, for example
the NHS number or whatever and that was a bit time-consuming . . .
C1:2
. . . it’s been hard to be able to print . . . off the lists and then when I’ve gone back at the end of the
day to try and put something in I get locked out again or not being able to log in.
ON4:20
if you’re documenting in notes, on a handover sheet . . . then try and do it on the QlikView as well
and you think . . . It’s an endless process.
ON2:20
Given that the system was in development, the research team appeared responsive to some of the
difficulties respondents were experiencing:
Things that [researcher] has changed which I like is that now it actually updates more quickly when
you actually fill in a form and that information goes in there much more quickly now.
C5:2
Timing and workload issues
Although, overall, respondents appeared keen to participate, a further theme that came to light concerned
the amount of time it took to use the alert system. The following quotes, from a consultant and an
outreach nurse, respectively, summarise the different patterns of system use and associated activity:
. . . an average month about three times, and then when you’re on the wards, which is 1 month every
fourth month you’re on the ward, then actually on top of that three you’ll do two weekends so you’ll
access it another six times that month.
C5:6
. . . [we access it] Every day. And then we look at the people that are scoring twos and maybe threes.
We, you know, we don’t exclude the threes because they might not have been enquired about at the
point that we go.
ON3:7
Consultants were particularly keen to highlight the relationship with work plans. Each time they are on
call, they encounter between one and eight new cases of AKI stage 3. This respondent appeared
reconciled to accommodating the work:
You just incorporate it into your work plan . . . yes, other things get pushed down the list but it’s
swings and roundabouts.
C6:4
However, most respondents found the integration of this additional work troublesome in that it was not
officially incorporated into their work plans:
. . . there’s been no time put in my job plan to do it . . . it depends on the day but often it’s quite
a burden . . .
C5:7
. . . you need a good one and a half to two hours of just you and the computer and the phone . . .
I think that it needs to be accounted for . . . I think because it’s a big chunk of work that we have
to do . . .
C1:5
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A further issue that came to light concerned difficulties prioritising the work, particularly as there was a
significant time commitment; reasons for this are explored more fully in a later section (see Interacting with
medical teams):
. . . trying to fit it in there was very difficult and it didn’t always happen to be perfectly honest and I
used to slightly resent it then but there you go, just one of those things.
C2:4
. . . a lot of time is wasted especially when you’re on call and you have to have other things you know,
if you have got a ward round that day, clinic that day, so it takes time.
C3:3
. . . we’ve all got lots of other things going on and OK it’s only once every 10 days so it’s not that
often but it’s just a bit irritating having to do it . . .
C4:8
Accessing data and making decisions
An issue of concern related to the fact that the data on the alert system provided information that was up
to 24 hours old; this posed problems for locating patients and created uncertainty about their medical
condition and concerns about wasted time:
. . . sometimes the ward has changed . . . you have to go on some other system to find where exactly
the patient is and sometimes you have to, when we ring a ward they say, well, they’ve moved to the
other one.
C3:4
. . . a lot of the time the results will be from A&E and they’ll flag up on QlikView from A&E so you
think I’ll go into the computer system and track a patient. Oh where are they now on the site you
know. You’ll trawl all the way over there to find out they‘ve just had their bloods done and their
result’s better so you’ve wasted like half an hour.
ON2:18
. . . you are in a way acting on yesterday’s data so you’re coming in up to 24 hours later when a lot
more things would have happened to that patient in the time period, which is a small problem I think.
C1:3
There was a view among some respondents that this time lag had its advantages:
I’m not sure true real time would be a necessary advantage actually . . . because I think that 24 hours
of hindsight allows certain things to sort themselves out . . . the patient that’s admitted clearly dying
. . . and me phoning up the team looking after them and saying this patient’s got acute kidney injury
. . . would probably not serve any useful benefit to either the patient or the team.
C2:3
So there’s somebody who’s flagged up as [AKI stage] three, but the team have already started treating
and if you can wait till the results are back you might see that their results are already improving,
so . . . it’s sort of a good thing . . .
C4:4
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Respondents described in more detail how patients with AKI were identified and how decisions were made
to formalise the alert and contact relevant teams. Given the time lag, it was clear that other data sets were
needed to support the decision-making process, as the alert system provided a first-level identification of
patients that only included such details as NHS number, AKI stage and the ward:
. . . you would have to log on to other systems . . . the iSOFT system, to sometimes look at the past
clinical history from clinic letters and you’d also have to log onto the X-ray system to look at the
current images and the historical images.
C1:3
. . . I use all the other trust IT systems . . . so PAS [patient administration system (iSOER)] to identify
where they are . . . and you can get in and use the blood results system either on that or DART
[pathology database] to see what the latest result is and also the new VitalPAC system I’ll look up their
observations and things . . . you know you have to go and find it, yeah you have to open it up . . .
there’s no link directly onto QlikView.
C4:5
. . . we can also look on the clinical functions at previous documents where they might have been to
clinics so you can get a bit of a background but not all patients have those updated.
ON3:22
For some this was frustrating, and one outreach nurse summed up the general feeling among the nurses:
None of these systems interact with each other and it’s just a nightmare really.
ON3:20
It was considered preferable to have all the data in one system; however, the absence of this was not
perceived to be too much of an imposition:
I suspect it would be quite complicated to put interfaces with other systems so I think it, the other
information is easily accessible on the net so it’s not too complicated to access it . . . I would say it
probably takes me 5 or 10 minutes to look at all the systems and formulate an opinion as to what
might be going on with the patient before I try to ring them . . .
C5:5/7
. . . the system identifies the patients, that’s the crucial bit yeah I can access the other information, oh
it’s on another, I have to click another box and put in another password or whatever, but yes it’s not
the end of the world . . .
C6:6
Summary
Most respondents restricted their use of the technology to the few alert system functions that were
necessary for identifying the AKI patients and initiating the alert to medical teams. Observations were
made about lack of user friendliness with regard to the sluggishness of navigating the system and inability
to access data, and consultants raised the issue of increased workloads that were not built into work plans.
Although some felt able to assimilate this extra work, a number found this to be quite onerous. Much
discussion focused on the need to access data from other sources to facilitate decision-making about
whether or not to alert the medical team, and the pros and cons of having a system that provided data
that were 24 hours out of date.
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Interacting with medical teams
A prominent issue for all respondents was accessing and interacting with medical teams to action the alert.
This third theme describes how respondents tracked down the appropriate doctor, the differing
experiences with communicating and discussing the cases, and the extent to which respondents felt that
medical teams were aware of the alert system.
Finding the right doctor
Consultants in particular described this as a ‘chasing game’ that was frustrating, took up valuable time and
tried their patience. The following quotes elaborate on typical communication attempts in detail, focusing
on difficulties tracking junior doctors and the ‘tyranny’ of bleep identification:
. . . the main problem . . . is mapping junior doctor or junior doctor team to an individual patient and I
think that work wasn’t sufficiently developed before the system was rolled out . . . a patient is flagged
up as having AKI you then have to . . . go through switchboard to identify which junior doctor is
looking after the patient, you may phone the ward where . . . you get given one bleep number, it
turns out not to be the right bleep number . . . and then that person doesn’t answer that bleep and so
you try a different member of the team and you know it can take half an hour to get hold of the right
junior doctor and that’s not an exaggeration . . . that actually gets very tedious when you’ve got lots of
other stuff to do to be bleeping about five different people before you get a response and I think
that’s a fairly common issue with it.
C2:2
And we have this daft system in this trust where the [junior doctors] look after the wards at a
weekend but because they’re not actually on call . . . the switchboards don’t carry their bleep number
. . . they haven’t got any number for them so you have to ring up the on-call team to actually ask
them which [junior doctor] is on for the weekend and what bleep are they carrying.
C5:11
. . . it’s teams, and it’s partly because teams are so unstable because the registrar’s on holiday, the
SHO [senior house officer]’s just done nights so it’s only the house officer and actually they’re in the
middle of a ward round for a different team . . . that is the big problem.
C4:12
For all respondents, the frustration of trying to find the team responsible for the patient was clear, and the
alert system did not appear to help in this regard:
I mean you can’t get hold of the right person, the person you eventually get hold of does not know
the patient . . . you know the conversation doesn’t take very long, it’s just getting hold of people and
whether they know about it or not.
C3:3
You deal with it generally out of hours by contacting a doctor who’s not really responsible for that
speciality of patient who is already generally busy and probably overworked so it’s not an ideal system.
ON2:12
. . . that’s the real downside of this, I don’t actually mind any of the other bits but I get so frustrated
about trying to actually pin down somebody who actually knows something about this person who’s
willing to take responsibility and take it forward . . .
C5:8
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Very difficult. Very difficult. I think there was a thing, a page where you could look at the contact
details of the teams and sometimes I cannot access that information from the actual
QlikView dashboards.
C1:5
There were added difficulties when the patient was admitted through accident and emergency (A&E) and
when trying to contact certain specialties:
. . . trying to identify which team you’re meant to be talking to when it’s an A&E patient, so somebody
comes in with AKI 3 into A&E, it’ll flag up as A&E and then you have to track them down which is,
I mean it’s possible using the other IT systems but it’s just a bit frustrating . . .
C4:5/6
. . . surgery – particularly orthopaedics they, you can ring around quite a number of F2s [junior doctors]
before you actually find someone who’ll take responsibility or go and see the patient.
C5:7
. . . what you need to do is get the best person that’s going to give the best treatment to that patient
and generally unfortunately that’s not always the orthopaedic doctor.
ON2:13
One respondent felt that the European directive on working time contributed towards these difficulties:
. . . what I’ve noticed is, you know, numbers of junior teams who don’t know their patients because
they weren’t on call or they weren’t, you know, or they were on a different ward round . . . it’s
European working time that’s mucked the whole thing up.
C4:6/7
One respondent felt that more trust-wide communication at the beginning of the project would have
been better:
I think it probably wasn’t fully sorted out and like anything you introduce a system and actually you
have to anticipate there’s going to be problems and there will be a grumpy clinician somewhere who
gets a bit silly about it all . . .
C4:2
Respondents had adapted to these difficulties by developing a range of strategies to improve their chances
of accessing the right doctors:
. . . usually I get hold of the right person straight away by actually phoning the ward . . . I guess then
that reflects the fact that the nurses just have the local knowledge on the ground on the day.
C2:2
I’m not sure how reliable those bleep numbers are but . . . I don’t even look at them now I still go
back to ringing switchboard and trying to find out.
C3:6
. . . it’s very difficult to locate an orthopaedic doctor so I guess that our first port of call isn’t actually
the orthopaedic team, it would be the on-call medical team or ITU [intensive therapy unit].
ON3:12
. . . we’re just communicating. We just talk to people a lot of the time.
ON3:19
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Discussing the cases
Once the appropriate doctors had been located to formally alert them to an AKI patient in their care, there
were differences between consultants’ and nurses’ experiences because of the differing intervention
pathways; however, there were also similarities. First, these respondents provide a general overview of
their approaches. A consultant describes their general intervention pathway:
I phone them up and I give them advice and make sure that they are repeating the bloods and doing
all the appropriate things I think they need to do and it may be a case of just saying ‘are you aware’
and they say ‘yes’ and I say ‘fine you’re doing all the right things’ or it may be much more detailed
advice depending on the situation . . .
C2:5
For outreach nurses, there were some pathway differences between the sites because of the professional
judgements and discretion of the outreach team members. This did have the potential, however, to cause
confusion among doctors who worked across three sites:
. . . we look to see where the patients are . . . and then we go out to the wards to see the patients and
speak to the teams so we’ll put a sticker in the notes alerting the team to the patient . . . and we’ll
find out . . . what’s happening with the patient . . . then we’ll speak directly with the teams about that.
And then if we feel that they need continued monitoring then we’ll retain them on our list. If not,
that will be our only contact with them.
ON3:7
Other people on that initial visit, even if it’s basic, might still go on to do a complete full assessment
. . . And I think that’s when then you get a differing expectation maybe from the medical teams.
ON2:10
However, respondents found that in most cases action had already been taken:
. . . by and large I think that by the time I get round to speaking to the team they’re usually aware that
the patient has AKI. I cannot really recall any instance, maybe one or two instances in the last year or
however long since we rolled it out, that I phoned a team and they were genuinely unaware.
C2:9
. . . the doctors that I’ve spoken to will say ‘oh yes we know about the patient, we’ve done A, B and C
and we’re awaiting X, Y and Z’, so most of the times they are already on the case and our advice
isn’t needed.
C1:5
Although nurses had similar experiences, they felt that the stickers were instrumental in bringing
about awareness:
Quite honestly, I think the stickers have been quite successful – generally [the teams have] already
identified that they’ve got acute kidney injury, they’ve already started all the processes on the advice
sticker and we stick the sticker on the notes anyway, even though it’s all happening.
ON3:7
When it came to reactions from doctors to these interventions, respondents had mixed experiences.
This respondent, for example, felt that consultant colleagues were supportive overall:
I have spoken to other consultants, medical consultants in other hospitals and they say it’s a good
thing that someone else is keeping an eye and providing that extra layer of advice to their teams.
C1:4
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For outreach nurses, despite the sticker often being applied after the event, these respondents were keen
to point out that this did not seem to interfere with interpersonal relationships within the teams:
. . . but they’ve identified it, they’ve done it all and then we’ve come along with our sticker! But I think
there is sort of quite a . . . a good rapport with them . . . And we just go, ‘Ha, ha, ha. I’m afraid it’s got
to go in there,’ because it’s like an audit trail, isn’t it? . . . but I’ve never felt anybody was really cross
about it . . .
ON1:9
Not ever had a negative response from anybody.
ON2:14
. . . we’re quite good at . . . at rapport . . . There’s sometimes a bit of a competitive spirit as well.
They go, ‘I’ve done it already!’
ON3:15
For other respondents, the general experience of doctors’ reactions varied, with some respondents
perceiving some indifference because action had already been taken:
. . . it’s a mixture of positive and indifferent but not negative. I’ve not had anyone getting irritated,
cross, abusive or obviously lacking in gratitude. Indifferences maybe one-third and people actually sort
of sounding quite positive’s probably two-thirds and that is irrespective of the sort of level if you like,
of the person I’m speaking to . . .
C2:5
. . . they’ve got you know other priorities they are busy . . . they just give you the information and if
you say something to them they will just note it down but I don’t think they’re hugely interested.
C3:5
Another respondent highlighted that there could sometimes be an issue with understanding the urgency
of the situation for the patient:
. . . sometimes you’ll get a registrar who’ll say ‘well I’m in clinic I’ll deal with it later’ and you say
‘no you can’t’ . . . and yeah, so occasionally perhaps there’s a perception issue as to the significance
of the problem, it’s how you handle that . . .
C4:10
As intimated previously, some of the respondents did notice a difference between the teams in the trust in
terms of how the patients were dealt with:
. . . medical teams usually have it under control, it’s the surgical teams that have the challenges . . .
C6:5
. . . often I find that the ward manager knows far more about what’s going on with Mrs Bloggs than
the surgical junior doctors . . .
C5:10
. . . you are dependent . . . on one on-call doctor at a junior level who specialises in people with broken
or damaged bones who then have – this is a slightly sweeping statement that I’m going to make, –
the inability to do anything about anything that’s not to do with an injured bone! It’s just like,
‘That’s not my job.’
ON3:12
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This respondent had a sympathetic opinion regarding these differences:
. . . I am aware that in many instances . . . the surgeons are less aware but they’re surgeons . . .
physicians should be looking after these patients . . . surgeons should get on with the job they’re best
at . . . they’re not particularly concerned with post-op . . .
C6:3
It was of interest, though, that many of the consultants recognised the potentially intrusive nature of the
alert system and were empathetic about how the telephone calls could be received:
I feel very guilty about troubling them . . . the post-take ward round is probably the most stressful
point in the week when your workload is at its highest. And to then have somebody bugging you
about a patient you already know has got AKI to tell you they’ve got AKI, I feel slightly guilty about to
be perfectly honest . . . they are remarkably restrained I think.
C2:7
If I had a patient coming in under my care and a doctor phoned me up asking me basic questions, I
would probably get a bit upset but that’s me, every doctor is different.
C1:6
. . . it’s sort of stepping on professional toes a little bit . . . there is perhaps sometimes a worry that we
almost take a bit of a holier-than-thou attitude . . . you know, somebody coming in and, not even
invited . . . and saying ‘well you’ve got this wrong and this needs to happen’, it could be perceived as
you know a little bit arrogant or a bit rude. Not the intention at all.
C4:2
Awareness of the alert system
One of the factors that influenced the response by the teams was the extent to which they were aware of
the alert system. Some felt that this was an enduring problem caused by working patterns, especially
among junior doctors:
The juniors . . . haven’t had a clue about them at all but once you get to registrar level and above
they’re very receptive to it . . .
ON4:14
. . . even now I think a lot of them are basically not certain why we’re ringing them . . . it happens,
because there are so many clinicians all over and surgeons, and physicians and nurses, junior doctors.
I don’t think everybody knows about it.
C3:2
. . . teams are changing all the time. Junior doctors change every year . . . you just get one group used
to the system then a new group arrives with no knowledge, no training in dealing with patients with
AKI . . . so it’s a challenge.
C6:11
This respondent highlighted the importance of communication skills:
Sometimes they’ll go ‘ugh, no!’ and don’t know about the system . . . they’re not fully aware that they
might get a phone call, so how you introduce yourself in the first instance I think sets a tone of the
rest of your discussion . . .
C4:10
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For others, there had been more problems at the beginning of the project:
I think in the early days people were surprised that someone else was aware of that clinical issue . . .
sometimes if you rang you’d end up speaking to the ward . . . and then they would say ‘sorry, who are
you? And what system is this?’ . . . So it’s almost like sometimes I felt I was a bogus caller . . . then
eventually, eventually now it’s old hat they generally are aware.
C1:4
Well, we did some work early on in getting round to tell people about the system . . . getting
buy-in . . .
C6:3
Summary
There were similarities between how consultants and nurses approached ‘alerting’ and discussing cases
with the relevant medical teams; however, for outreach nurses, the extent of professional involvement
in this varied between the hospital sites, which could cause confusion among doctors. The difficulties
respondents had in tracking down the appropriate junior doctor manifested themselves as a major
problem, and it was clearly frustrating and costly in time. Respondents highlighted the many intricate
instances of how communication can fail to connect them to the right person in a timely manner. This
included failures with how bleeps are managed, the complexity of junior doctors’ working patterns, how
their responsibilities are organised, the instability of medical teams, and how the movement of patients is
monitored. All respondents had developed strategies to cope with this frustration, which mainly entailed
telephoning the nursing staff on the wards, who they felt had more immediate knowledge of who to
contact, and maintaining good channels of communication.
In the face of these difficulties with contact, the general experience of the respondents was that once the
appropriate doctor was located and cases were discussed, most found that teams were already aware
and were dealing with the situation. Outreach nurses noted the success of the stickers in bringing about
awareness. Some respondents felt a degree of discomfort with ringing colleagues uninvited for little
justification, noting that responses sometimes implied disinterest. On the whole, however, responses were
not negative and there was recognition of the importance of interpersonal communication skills. It
appeared that there were differences between specialties; not only did some respondents seem to have
greater difficulties accessing surgical and orthopaedic teams than physicians, but surgical teams were,
by and large, less aware of their AKI patient and how to action the alert.
When it came to colleagues’ awareness of the alert system, respondents were mixed in their responses.
Some felt uncertain about whether or not there was full understanding of why they were being contacted.
The shifting nature of junior doctors’ employment explained some of this. Others felt that there were
problems at the outset but that there was now generally a good understanding.
Monitoring cases
Although the function of the alert system is to ensure that AKI patients are identified, that accountable
clinicians are informed and that appropriate interventions have been or will be actioned, respondents were
asked whether they undertook any monitoring or follow-up of cases. The two sections here focus on
differing views of whether or not respondents felt that they should follow up, and the extent to which
they felt that advice was acted on.
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To follow up or not to follow up?
The responses were varied; these quotes from consultants, for example, describe experiences in which
respondents were particularly concerned about inappropriate management and took action:
. . . we had one last week where I felt very strongly that the patient had been inappropriately managed
. . . my colleague went and saw the patient, you know, absolutely agreed that this was an avoidable
situation, that really they should have been more aware of the risks and the fact that the patient
already was developing AKI . . .
C2:6/7
. . . there are a couple of cases where I’ve been really, really worried about somebody . . . then I will
actually follow it up and look at it the next day and the next day to make sure that actually they’re
getting better . . .
C5:10
. . . probably once every 6 or 9 months then you know I feel actually this hasn’t been appropriately
managed and there needs to be a bit of follow-through for this.
C2:6
As intimated in earlier sections, outreach nurses’ involvement varied across sites according to the condition
of the patient and professional judgement:
. . . in my workload . . . they either get a sticker and we’d never ever promise to do anything more than
one visit, or they are a documented outreach patient, so they’ll have a full assessment.
ON1:10
. . . if they have already identified AKI then . . . then that’s it and we don’t really necessarily go back.
ON3:11
. . . you’ll find people that are more complex, that have got a lot of other ongoing problems, that have
got maybe multiple potential causes of their AKI that are very sick . . . you keep on the outreach list
because they’re sick, not necessarily just because they’ve got an AKI.
ON2:9/10
These consultants, however, felt that the teams should be accountable following the alert communication:
I really don’t see the need for further monitoring, once it’s handed over then it’s the responsibility of
that team . . .
C6:5
I think really the ball should be in their court, whose patient it is, that they should be just chasing up
and let us know if there is progress or lack or it rather than, you know, we chasing them all the time
which is happening at the moment . . .
C3:5
Whether or not they followed up cases, all respondents made efforts to ensure that a communication was
recorded to alert the teams to their involvement, or that a mechanism was in place should more advice
be needed:
. . . following up, no . . . I try to remember . . . put that as a final comment you know, registrar or SHO
[senior house officer] informed, discussed blah blah blah, team aware to contact renal if they have any
further concerns or issues.
C4:8
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. . . if I was going to carry on monitoring or seeing a patient from a trigger . . . I would write something
at the end of the notes along the lines of ‘we will continue to monitor this patient’s progress’ and
something along those lines.
ON2:10
. . . obviously the team can contact you but sometimes the team will contact the on-call doctor as well
or would have already done that so there is a way of, for the team to follow up those cases.
C1:3
Many of the patients eventually came under the care of the renal team:
. . . a lot of them do end up on dialysis and they eventually come to our ward anyway so there is that
follow-up. I think out of all the cases I’ve done there was one that I was particularly interested in and
kept contacting the team and . . . then eventually they came over to our ward . . .
C1:3
Acting on advice
There were distinct differences between the consultants and the outreach nurses on this subject. For
consultants, the extent to which advice was acted on was not generally known because of work patterns.
One respondent stated:
. . . you generally aren’t really aware of whether it’s been carried out or not – your recommendation –
because the next day you’re not on call again . . . On one occasion I did ring to speak to the doctors
and I advised them to call me back, and they never did. And for whatever reason they probably felt
that they’d finished the case effectively and they didn’t need my advice, I’m assuming.
C1:4
A further concern related to this was the failure of teams to make a written note of the discussions with
respondents, which impacted on the audit trail and clinical decision-making process. This respondent
summarises consultant experiences:
What I hadn’t done until recently was actually ask them to document the discussion that had been
had with them . . . There’s no documentation of these discussions happening, and I suspect that’s
because often the discussions happen when the doctor’s not in front of the notes because we’re
ringing them and . . . catching them wherever they are.
C5:8
The outreach nurses found that there were clear comparisons between different medical teams, and
significant concerns were raised again regarding the lack of appropriate trauma and orthopaedic team
responses and accountability. The following responses highlight the extremes to which the nurses feel they
need to go to ensure that patients are appropriately managed:
. . . the medics are really very good at dealing with the acute kidney injury. The area that we have a
huge problem with . . . is the trauma and orthopaedic areas . . . you know, they . . . they will watch
their patient’s renal function deteriorate and then the nurses will call the outreach team to say,
‘This patient’s got a really big problem,’ and then we’ll tip up and start the whole ball rolling really . . .
in extreme cases they’ve already contacted the renal team and they completely ignore the advice.
And that’s really an area that needs a lot of work . . .
ON3:11
We’ve started using words like ‘life-threatening’ ‘this patient will die’ and then . . . and then the next
thing we do is we say, ‘Shall we phone [the renal team] for you? Here you are; they’re on the phone’.
ON2:15
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. . . we’ve highlighted it, shown the doctors the stickers in the notes and said to them, ‘This is actually
quite serious now and this patient looks like they have a potential to deteriorate. We feel that you
need to take this further,’ and the doctors have walked past us and carried on talking to other nurses
and . . . and we’ve had to wait and wait our turn to then come back to them and say, ‘Did you quite
understand that this is serious? Can you please listen to us?’
ON4:15
Summary
There were differences in consultants’ and outreach nurses’ experiences regarding monitoring patients and
acting on advice given. For consultants, monitoring or follow-up of cases was conducted on few occasions
and only when patients gave cause for concern and confidence in managing the patient was not high.
Some felt quite strongly that their involvement should end following the alert, as teams should take over
responsibility. Ongoing monitoring by outreach nurses varied between the three sites and was dependent
on professional judgement and the condition of the patient.
Most consultants were not aware whether or not advice had been acted on, and there were some
concerns regarding the documenting of the advice given. However, all respondents, including nurses,
agreed that they would ensure the availability of a contact for further advice if needed. Outreach nurses
focused on challenges with trauma and orthopaedic teams and highlighted the difficulties with passing on
the management responsibility of AKI patients to them.
Impacts on patients and clinical practice
The final theme is concerned with establishing the extent to which respondents felt that their involvement
in the alert system had any effects, beneficial or otherwise, on patient care and clinical practice, as well
as cost-effectiveness.
Making a difference to patient care
Some respondents could point to circumstances in which they might have had some positive impact on
patient outcomes, and outreach nurses tended to have a firm conviction that they were essentially
contributing to patient benefit:
. . . for the patients. I know . . . I mean I don’t know how many we’ve seen . . . but I know that there
are some that we’ve changed things for.
ON1:24
. . . how can it not be a benefit? It has to be, doesn’t it? It has to be.
ON2:25
. . . most AKI is . . . secondary to sepsis or dehydration, or excess diuresis, you know, so actually if you
can alert the teams to it and get them to intervene early, then actually you will significantly
improve outcomes.
C5:12
I think sometimes . . . when we pitch up a lot of the relatives and the patients are, ‘Oh thank goodness
somebody’s going to come and do something,’ because they’ve got . . . they’ve noticed that there’s
something wrong and it looks as if somebody’s coming to sort it out so that’s a patient benefit, isn’t it,
from their perception.
ON3:26
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But consultants were largely sceptical about the benefits. This was mostly because of the observation that
either teams were already aware or full-scale intervention was not clinically appropriate:
I question whether phoning a junior doctor team or consultant . . . about a patient admitted the day
before with acute kidney injury and who, they must be aware if they’ve looked at the blood results,
has AKI, I wonder whether that actually provides any added value at all.
C2:7
. . . I’d say three-quarters of the patients you ring up . . . they’re either dying and there is nothing you
can do or the team’s got it in hand and they know exactly what they’re doing and they’re doing fine.
So you know it does feel sometimes like quite a lot of work for very little benefit.
C5:11
One respondent indicated that the lack of perceived benefits stemmed from advice not being followed:
I think that generally speaking it doesn’t improve patient care . . . there was one case only where I did
give advice which was the correct advice and then we subsequently found that the advice wasn’t
followed and that patient was eventually transferred here for dialysis therapy so I feel that it doesn’t
really add to patient management . . .
C1:5
Comments were also made that suggested a need for proper comparative research and larger samples to
better estimate benefits:
. . . once you’ve, you know, given the information and instructions, what happens it’s not really
followed up and whether it would have made any difference you would have to compare it with
somebody who has not had that, you know, data so you have to compare it with something to know
whether there is a difference or not.
C3:5
I think there are too few numbers of patients to really point to whether it has a benefit or not, but it’s
brought AKI to people’s attention . . . we just need to have the means to track patients . . .
C6:10
The following respondent indicated that more benefits could potentially be achieved through the outreach
team, who focus on patients with the earlier stages of AKI:
I think the outreach team have been looking at going out to see people with acute kidney injury
stage 2 and they’ve actually physically seen patients and put information in the notes . . . I suspect that
probably the biggest benefits will have come from that intervention, getting in there a little bit earlier
and actually steering people in the right direction.
C5:12
Impacts on clinical practice
Most respondents saw both positive and negative impacts on clinical practice. The following statements
refer to cases in which intervention can be positive and serve an educational purpose:
I think that there are certain groups in the hospital that are very poor at managing the sick patients
and particularly patients with AKI . . . so I think that actually, I think that’s where I see that we have
the benefit . . . when I ring up some, one of the surgeons to say did you realise your patient has
deteriorating renal function . . . they usually haven’t got a clue . . . so it does prompt them to go and
actually look and get their medical review.
C5:9/10
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. . . sometimes it’s not direct intervention, it’s almost preventing intervention . . . you know, facilitating
the team making a clinical judgement on what is or isn’t appropriate for the demented ninety seven
year old with multiple other illnesses . . . So some of them are sort of much more soft interventions
about sort of management strategy rather than medical treatment . . . some of it’s educational as well.
C4:13
The outreach nurses specifically identified the positive and proactive contribution of the stickers, as well as
the ability of their involvement to reduce unnecessary work:
And they’re actually now approaching us when we go onto the unit and say, ‘Can we have a sticker?’
and they will have people that haven’t even been identified on the database as acute kidney
injury and they want stickers for those notes.
ON3:7
. . . whoever’s on the nightshift will go round in the early hours of the morning, we’d go into
QlikView, get the list out, go and identify these patients and their notes so that when they’re being
post-take in the morning it’s identified to the teams . . . Which is . . . certainly cutting out one ward
round and potentially 1 day’s worth of medical input.
ON2:17
In addition, outreach nurses in particular saw the educational opportunities for themselves:
I think for me it’s been positive because I’ve . . . it’s done a lot for my knowledge and maybe . . .
maybe I see patients in a different way now. Sharing skills which is part of our job, people show
interest in the stickers and you’re able to tell them what you’re looking for and why so they might
pick things up about the drugs that you’re looking at and so on.
ON1:24
The following comment from a consultant indicates the benefits of an AKI database, again in terms of
enhancing educational opportunities in the trust:
. . . the system does mean that we’ve now got a very good database of actually what sort of AKI we
have in the trust and where it is . . . which groupings is it happening under and maybe an idea as to
you know, who’s doing well and who’s not doing so well and to allow us to focus some education on
those areas that aren’t doing well.
C5:11
Conversely, other comments related to the negative personal impact on practice brought about by the
alert system:
. . . I think it adds to my busy day already when I’ve put you know, I can actually do other things . . .
C1:6
. . . I’m not sure it’s the best use of my time to be perfectly honest . . . a lot of it’s an administrative
task which is pretty tedious.
C2:9
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However, all respondents highlighted concerns regarding clinical responsibility for the patient and the
impact of the alert system. This comment describes what this means in practice for consultants:
I have quite a lot of concerns about ownership of the patients. So for example if a patient was
admitted on my take, I would assume a hundred per cent responsibility for . . . acting and looking into
each problem and dealing with it. And when you include a system like this I feel that number one
ownership could be eroded and doctors . . . could become more nonchalant and lethargic and say ‘oh
there is this computer system that could pick this patient up and because they have renal failure it’s
not my problem any more’ and I feel strongly about that.
C1:6
As has been noted, outreach nurses had particular concerns about where their involvement began and
ended, and how some doctors interpreted this:
I think ownership of the . . . ownership of the alert system from my feeling is . . . becomes an issue. My
feeling is that once you document in the notes ‘Outreach’, you then become the first point of contact
for anything that ever goes wrong or problems . . . you then become embroiled in the rest of the
unfolding of the events.
ON2:6/7
. . . some doctors will see the sticker and your signature and think that every day you’re going to make
sure their bloods are done and you’re going to check the results. Other teams won’t. Other teams will
just manage what they do but it’s very varied.
ON1:9
Even from the medical teams; ‘Mrs so-and-so – you’ve seen this person?’ ‘I’ve kind of not really; I just
stuck an . . . alert sticker in the notes and signed it.’
ON3:6
This respondent made particular reference to the establishment of a specialist orthogeriatric system that
compounded the problem of patient accountability within certain surgical teams:
. . . part of the problem with trauma and orthopaedics is now that there is this orthogeriatric system in
place, it’s almost exacerbated the problem of them now completely ignoring anything . . . there’s
almost a mentality now that; out of hours – oh that can wait, the orthogeries will be on in
the morning.
ON2:15
There were also concerns that the alert system had generally impacted on their professional roles in a
negative way, reducing it to an unsatisfactory screening process as a result of being provided with
by ‘lists’:
I think the problem for us is that we have so many parts of our role and we’ve . . . we’ve become very
much a list and screening culture, so we . . . we start off every morning with a list from the alert
system, we have a list from the VitalPAC, we have our list of patients and it feels very much as though
we’re trawling around the hospital to keep a lot of lists . . . you obviously have to go through that
process to get to people that you’re going to have effective interactions with but it’s beginning to feel
like we are part of this list culture . . . that’s not very nice really.
ON3:17
QUALITATIVE ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
Continuing with outreach nurse perceptions of professional issues, respondents were aware that there
were numerical differences in patient interactions brought about by the alert system between the three
hospital sites. This was explained by an administrative problem with recording on two of the sites (the
numbers recorded did not in fact reflect activity in reality) and that there were fewer identified patients on
the third site:
. . . we go and see these patients but we don’t always at the end of the day sit down and put them on
the system . . . Now, unless we keep all of that documentation we can’t go back retrospectively and
put it on the system so we . . . we miss that time slot. So there are a lot of interactions we do on this
site that we don’t put on the system.
ON3:19
Probably at [site] our patient numbers are lower . . . And it is doable within our working hours.
ON1:19
Perceptions of cost-effectiveness
It was generally difficult for respondents to express the extent to which they felt that the alert system
saved money, but the following comments demonstrate that it is certainly an aspiration:
Well it costs £150 to dialyse a patient, and that’s around £30,000 per patient per year . . . so it would
be nice to think it was making some impact on that . . .
C6:10
If you’re highlighting early people that have got an acute kidney injury that’s then being treated and
managed it’s got to save money in terms of length of stay and ongoing treatment or higher levels
of treatment.
ON2:26
. . . so do we save money? Don’t know . . . do we improve patient outcomes? One would hope to
think so and actually you could then say well improving outcomes is going to be a cost saving in
terms of if you can prevent somebody needing to go onto dialysis or needing to go up to ITU for
haemofiltration, yes you will save money, you will shorten their patient inpatient stay.
C4:14
This respondent, however, was more sceptical:
. . . if somebody’s already in ITU and being managed and they know about AKI I don’t think that will
save money just to tell them that he has AKI.
C3:7
Other, more comparative views focused on the cost of respondent time:
I don’t know how much QlikView costs, I’m assuming it’s part of the great IT budget of the hospital so
in terms of everything else it’s probably a small cost, but in terms of time at the moment it’s quite
costly on time.
C1:7
. . . well it’s highly cost-effective at the moment because it’s not included within any of our job plans
to my knowledge, so essentially the trust is getting this additional work for – for nothing!
C2:8
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Summary
Despite some respondents, largely outreach nurses, perceiving positive proactive, preventative and
educational benefits for patient outcomes and clinical practice, other respondents were not wholly
convinced of the value of the system in terms of inducing these benefits, nor of being cost-effective. This
scepticism resulted from the observation that most clinical teams already had the situation in hand, or that
intervention was not indicated. In addition, the small number of patients made impacts difficult to assess.
An issue of concern centred on the potential of the alert system to divert perceived clinical responsibility of
the patient away from the clinician who was actually accountable, and outreach nurses in particular felt
that this aspect impacted on their professional roles. It was also revealed that discrepancies in outreach
nurse system activity between the sites were largely caused by an administrative recording issue.
Recommendations for improvement
Improving trust-wide knowledge of the alert system
Knowledge of the alert system could be improved by the following means: inclusion of a user manual;
an initial comprehensive and wide exposure of clinicians and nurses to the new system; an ongoing
programme of updates; a focus on junior doctors’ education; and greater visibility of the stickers.
maybe a user’s guide . . . you know, an idiot’s guide how to quickly get to the reporting page . . .
C1:2
. . . perhaps if they would have maybe sat down with everybody at the beginning and explained how
the system works and what to do and how to go through the system.
C1:1
I think that it would have probably been advisable to have made it more obvious, more visible to other
staff in the trust . . . you’d have to kind of redo that every time you induced a new load of junior
doctors across multiple sites, I’m not sure that would be practical so maybe some, you know some pre
rollout announcements and so on . . .
C2:2
I think [junior doctors] need to be made aware of that but that will have to be a very extensive
education programme, because it’s across three sites and it includes all specialities surgical, medical
and the juniors change as well.
C6:4
I have to say the stickers are good. I do think the stickers need to be a bit more in your face, though,
because I sometimes put them in the notes and think mmmm, do you know what; I’d just like
something a bit more out there.
ON2:23
Improving the technology
Aligning the data systems and technology
The following methods should be employed to improve alignment: improving the accessibility of clinical
data sources within the alert system and its speed; providing up-to-date clinical information; improving
how NHS numbers are accessed; developing a link directly to the clinician responsible; and having an
accessible electronic form to improve reporting.
. . . well it’d be really nice if it was all in one place, that would be amazing, but you know, it’s a new
project and I think . . . you might want the Ferrari but having the Ford Fiesta is a start!
C4:5
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. . . if it’s incorporated into the VitalPAC system where you know you are highlighting patients with
acute kidney injury and you can just with the click of a button look at their observations and then the
historic blood results and then what has been ordered and what is awaited and it’s live data, that
would be . . . helpful.
C1:6
. . . if the system was actually – represented what, you know was real time, then . . . it would save you
quite a lot of time . . .
C5:6
. . . there should be facility to copy and paste for example the NHS number because that’s how it
identifies it on the monitoring form but you can’t do that so you have to write it down first and then
put it in there.
C3:3
. . . in an ideal world there should . . .some sort of link system whereby the alerts can be sent . . .
directly to the teams looking after that patient that says, ‘Your patient, Mr Smith, is an AKI 2. Deal
with it please.’ . . . if we need to be contacted for our input then we’re there, however it’s kind of
cutting out the middle man in a sense.
ON2:17
. . . doctors don’t record the discussion in the notes, so there’s no evidence that it existed or how it
was acted on . . . so it would be good to have an electronic form that could be universally accessed . . .
C6:5
From a reporting point of view, we wanted to know last year how many patients we’d seen on the
system . . . so I guess for us it would be nice if we could have an easy to pull reporting system.
ON3:23
Establishing clinical ownership of the patient and responsiveness
Clinical ownership should involve greater organisational accountability for tracking the whereabouts of
junior doctors; developing a ‘response’ alert; improving pathways to clinical responsibility for patient
management; and creating a clearer understanding of the role of outreach nurses, as well as reassessing
their function in the alert system.
I suspect the nursing staff on the ground probably know amongst themselves who the right person
will be but that knowledge has to be translated up the corporate structure so that actually, the
corporation, the organisation knows exactly how individual patients are mapped onto the
junior teams.
C2:3
. . . to have an alert that links to advice and then to have an escalation system whereby . . . we can see
where alerts hadn’t been responded to . . . I think that would be you know a huge advantage.
C2:9
doctors . . . could become more nonchalant and lethargic and say ‘oh there is this computer system
that could pick this patient up and because they have renal failure it’s not my problem any more’.
C1:6
. . . the difficulties are that we’re . . . we’re acting as screening people . . . I’m not sure that that
couldn’t be screened by somebody else and then we could be alerted to the fact that they need us.
ON3:6
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Chapter 5 Discussion and conclusions
Discussion
The overall aim of this study was to develop risk models for the development of AKI in patients admitted
to hospital and, using qualitative analysis, to provide personal insight into and explanation of the processes
involved in using an alert system through an experiential narrative gleaned via semistructured interviews.
In this study we developed and assessed both Bayesian and traditional methods of providing risk models
for the prediction of new or worsening AKI in patients presenting to hospital. The results of the Bayesian
modelling demonstrated an excellent specificity, indicating that the models were good at defining patients
at very low risk of having AKI; however, as the sensitivity was poor, they would not be able to accurately
determine those patients at high risk. These models would therefore be good at defining the population of
patients who do not need renal function testing to assess for AKI, and could determine a population to
test by inference. However, a large proportion of the population tested would be false positives. It became
apparent during the modelling iterations that the traditional methods were superior to the Bayesian in
terms of providing risk models that could be used in clinical practice to provide clinical benefit. We
therefore progressed the traditional modelling further and will carry this forward in our future work.
We will, however, look into assessing the use of more specific priors that may provide greater benefit in
the future with a more defined data set.
From the traditional risk modelling presented here, we have developed a risk model which is designed to
predict patients who will have AKI at admission to hospital, and to guide renal function testing alongside
the clinical practice algorithm. The ROC curve analyses suggest that the model has discriminatory power
and, with an AUC value of 0.75, it is acceptable for use in clinical practice. This has been validated in a
second population. We have also developed a risk model designed to predict patients who will develop
new AKI in the first 72 hours of admission to hospital. The ROC curve analyses suggest that this second
model has discriminatory power but that it is not as effective as the admission model, with an AUC value
of 0.68. This has again been validated in a second population. The third model for predicting worsening
AKI in the first 72 hours of hospital admission did not prove to have any discriminatory power and would
not provide clinical benefit. This was therefore not validated further. The results suggest that we have not
included key variables in the third model or that the development of AKI in hospital is subject to a random
effect which is not measured. The model for predicting new AKI in the first 72 hours may be refined
further once physiological data becomes more commonly available electronically across the NHS.
The methodology used has its limitations, and further analysis and testing, including continuous modelling,
non-linear modelling and interaction exploration, may refine the model further. This study provides
valuable evidence of the relationships between AKI and key variables available from hospital electronic
records. This work also gives other insights as to which variables may not be associated with AKI,
something that has been lacking in the literature.
Risk models in the setting of acute kidney injury
In the literature, the majority of the reports focus on the need for RRT after cardiac surgery. One of the
first of these was by Chertow et al.,34 who produced a risk model for predicting AKI after cardiac surgery,
based on a population of 40,000 patients who underwent cardiac bypass or valvular surgery in 43
Veterans Administration Hospitals in Virginia, USA. A risk stratification algorithm was formulated on the
basis of interactions between potential risk factors. There were inherent flaws in the study cohort,
specifically a lack of female patients and African-American patients. Thakar et al.101 produced a clinical risk
score to predict post–cardiac surgery AKI requiring RRT, based on 33,217 patients who underwent cardiac
surgery at the Cleveland Clinic between 1993 and 2002. The scoring system was derived based on
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13 preoperative factors which were weighted; the sum of the scores, ranging from 0 to 17, allowed for
stratification of postoperative risk of AKI from low to high. The lowest-risk group (score of 0–2) had a risk
of AKI requiring RRT of 0.4%, in contrast to the high-risk stratum (score of 9–13) who had a RRT risk of
21.5%. However, there is a paucity in the literature of studies about the risk and risk prediction of AKI in
unselected emergency admissions to a district general hospital. Finlay et al.102 published a recent study of
AKI risk factors associated with AKI in patients admitted to acute medical units in a study conducted over
two separate 24-hour periods at a total of 10 acute medical units. Forni et al.103 have developed a model
for predicting AKI in a subset of medical patients admitted to a UK hospital. Their model included some
physiological markers.
NHS England initiatives in acute kidney injury
NHS England has recently made considerable progress in improving patient safety with respect to AKI.
A national algorithm has been developed to standardise the definition of AKI. A patient safety alert was
issued on 9 June 2014 requiring all hospital trusts to embed the algorithm in routine pathology reporting.
Although this will go a long way towards the identification of established AKI, it does not address the
issue of prevention of harm in the first place, hence the requirement for the development of risk
assessment tools. In addition, the reporting of AKI will not require a response by the attending medical
team; in other words, there is currently no requirement for a standardised response to alerts to established
AKI. Although this work goes along way towards highlighting established AKI, it does not address the
issue of assessing the risk of AKI. This work and a future study examining the impact of an automated
alert will inform further national strategy with respect to AKI prevention.
Our study and further studies examining the complexities of implementation of auditable clinical alerts
have informed these work streams and in the future will provide more clarity in a complex area.
Intervention studies
To date there have been no intervention studies in comparable unselected populations that have shown
a reduction in episodes of AKI. A formal health economic analysis of the impact and costs of such
intervention needs to be performed, along with a technology appraisal to maximise the benefit from
electronic alerting.
Generalisability
Quantitative analysis
Using a number of combined hospital databases, we have identified a number of key variables that predict
AKI; this methodology can therefore be used to highlight patients at risk of AKI. We have validated our
findings in second data sets from the same hospitals and then a further data set from a second hospital
trust with very different population characteristics. The key variables used in these models are available in
most UK hospitals and the majority of them are not susceptible to coding bias; however, the potential for
such bias is always a concern. The use of physiological parameters to predict AKI for inpatients may pose a
problem for some hospitals across the NHS because of the lack of electronic recording. Many hospitals are
adopting electronic recording of physiological parameters as part of their patient-safety programmes, so
these data are likely to become more ubiquitous in the future; the application of these models across the
NHS is therefore a feasible proposition. As discussed previously, the model would benefit from further
refinement and analysis.
Qualitative analysis
The aim of the qualitative arm of this project was to provide personal insight into, and explanation of, the
processes involved in using the alert system through an experiential narrative gleaned via semistructured
interviews. A total of 12 members of staff participated and, given this low number, generalisability cannot
be applied to measure rigour nor to infer fittingness of the findings to the wider population; this is not the
intention of qualitative research. Instead, the study has conformed to two leading qualitative principles to
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ensure the collection of rich experiences and to achieve credibility. First, there was a high level of adequacy
regarding representation within the sample; the majority of consultant and outreach nurse users across the
trust participated, thereby ensuring a full complement of views concerning the alert system. Second, the
data collected through the use of semistructured interviews were, on the one hand, rich and diverse, but,
on the other, clearly revealed consensus of opinion through thematic representation. Agreement of the
strengths and weaknesses of the system, alongside contextual issues that helped or hindered, was reached
in a number of core areas; thus it can be implied that data saturation was achieved. The high level of user
representation alongside consensus of opinion suggests that this arm of the project has added a credible
explanatory component to the wider study in terms of taking the system forward to the next stage.
Delivery of alerts
During the course of this project we have explored a number of methods of alert delivery. NHS England
has implemented alerts to the presence of AKI across the NHS; however, there are no plans to alert to risk
of AKI. Desktop alerting systems can easily be made available across the NHS with little adaption of
existing information technology (IT) systems. The use of ‘push notification’ to mobile devices may require
infrastructure changes in some NHS hospitals; however, there has been a significant increase in the
availability of wireless communication and mobile devices in recent years.
Strengths and weaknesses of the study
Weaknesses of this study include the fact that this was a retrospective cohort study using hospital
databases to find predictors of AKI. It was carried out in a small geographical area of England (Kent) and
covered a 1-year period. Neither of the hospitals studied have cardiothoracic services. The combination of
such data sets is labour intensive and, as such, would not provide generalisable results unless an easily
accessible subset of the data was found to contain useful predictors. Our work has provided a list of
candidate variables for the prediction of AKI at admission and 72 hours. Importantly, we have also
provided a comprehensive analysis of variables that do not appear to influence the risk of AKI. We have
been unable to produce a predictive model for worsening AKI during admission. This may be because key
candidate variables have not been included or because of a random effect.
Further analysis and testing, including continuous modelling, non-linear modelling and interaction
exploration, may refine the models further.
Certain groups of patients were excluded from the analysis (e.g. those with established AKI) requiring the
use of a clinical practice algorithm as well as multiple predictive models for use in different scenarios.
Finally, the delivery of alert systems to doctors and allied health professionals at the point of care will
require modification for different hospitals with differing IT infrastructure.
However, this study used a very large unselected data set, which represents the kind of populations
presenting to the majority of UK hospitals. While there was no cardiothoracic surgery performed at either
hospital, AKI in this setting has been extensively studied and represents a very small and unrepresentative
group of people with AKI. The study was carried out using robust methodology and the initial data set
used to develop the models was randomly selected from all hospital admissions over a year on a 3:1 ratio.
The model was validated in the remainder of the population and then subsequently tested in a second
population from a different hospital trust, demonstrating that ethnic and social differences had little effect
on the model, nor did the potential difference in coding practices between organisations. We have
therefore been able to demonstrate that we can transfer our model to one other hospital trust; however,
these models may only provide a platform for further analysis and refinement before they can be
employed more widely.
DOI: 10.3310/hsdr04060 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 6
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
Although the qualitative analysis has provided accurate guidance as to the best approach to further
implementation of this technology to highlight patients at risk of AKI in our hospitals, it was a small-scale
analysis in one centre and, as such, may not be generalisable. Finally, we have tested a number of the
methods of delivery of such alerts and have developed a reliable and user-friendly approach, maximising
the chances of successful implementation and assessment in a wider health-care setting.
What our study adds
Our study adds the following to the literature:
l We have developed clear clinical practice algorithm to guide clinical alerting and risk modelling for AKI
in emergency hospital admissions.
l We have identified the key variables that are associated with the risk of AKI at the point of admission
and during admission to hospital. Importantly, this study used an unselected population, unlike many in
the literature.
l Our study also provides a comprehensive list of variables that do not appear to be associated with the
risk of AKI at the time points discussed.
l Relationships between key variables available from hospital electronic records and AKI were identified,
which will aid other groups in the development and validation of risk models in this and other settings,
for example primary care.
l Risk models were validated in two populations to predict AKI on admission to hospital, and the
development of new AKI in the first 72 hours of admission to hospital.
l Risk models to predict worsening AKI during admission were not successful, suggesting that this
requires further study or that there is a random effect.
l A qualitative analysis provides guidance as to the best approach to the implementation of clinical
alerting designed to highlight patients at risk of AKI in hospitals.
Conclusion
In our studies we have been able to demonstrate that routinely available data can be used to highlight
patients at risk of AKI both at the point of admission to hospital and following admission. However, the
methodology used has its limitations, and further analysis and testing, including continuous modelling,
non-linear modelling and interaction exploration, may refine the model further. This study provides
valuable evidence of the relationships between AKI and key variables available from hospital electronic
records. Some of the models may be refined further once physiological data become more commonly
available across the NHS. This study has also highlighted the complexity of the implementation and delivery
of alerting systems to the clinical front line.
Recommendations for future work
The next stage of this work is to test these risk models in terms of their clinical, logistic and economic
impact in routine clinical practice in a clinical intervention pilot study. Alongside this there should be
further analysis and testing, including continuous modelling, non-linear modelling and interaction
exploration, which may refine the model further. There should also be further work to investigate the
development of clinical risk models in different settings (e.g. elective surgery or radiocontrast
investigations) within clinical practice, as we believe there a number of different risk models that we need
to employ across the different settings within the secondary care environment.
There should also be work to investigate the development of risk models to predict the presence of AKI in
patients presenting to their general practitioner in primary care, to guide testing in this setting.
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The qualitative analysis reported here has provided guidance as to the best approach in terms of delivering
AKI and AKI-risk alerting to the point of care in our hospitals; however, this was a small-scale analysis in
one centre and, as such, may not be generalisable. A further multicentre qualitative analysis is required to
inform delivery across the NHS.
The qualitative analysis has suggested that different methods of delivery of clinical alerting to the point of
care may be beneficial. This requires further investigation in terms of technical appraisal and usability.
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Appendix 1 Variable definitions
TABLE 25 Hospital Episode Statistic database variable definitions
Data entry Calculated variable Variable description
NHS number Not used in analysis Identifier used to link patient data removed following data linkage
Trust unique episode
number
Not used in analysis Identifier used following anonymisation
Gender Gender Gender of the patient. Coded as:
1=male
2= female
Age on admission Age on admission Age of the patient on admission to hospital
Spell type Spell type Type of patient admission. Coded as:
DC= day case
EL= elective
NEL= non-elective
Admission date
and time
Admissions (last 12 months) Using admission date, the number of admissions in the last
12 months for this patient is calculated
Admission date
and time
Admissions (last 30 days) Using admission date, the number of admissions in the last
30 days for this patient is calculated
Length of stay Length of stay Number of days the patient remained in hospital as an inpatient
Died in hospital Died in hospital Whether or not the patient died in this admission to hospital
Admission source Increase in care on discharge By comparison of admission source and discharge destination
an assessment of increase in care (from home to residential or
nursing care) is made
Discharge destination Increase in care on discharge By comparison of admission source and discharge destination
an assessment of increase in care (from home to residential or
nursing care) is made
Primary diagnosis Primary diagnosis group Individual primary diagnosis for this admission coded by
ICD-10 is recoded into ICD-10 group
Secondary diagnoses Individual comorbidity:
l AIDS
l Any malignancy except skin
l Chronic heart failure
l Congestive pulmonary
disease
l Cerebrovascular disease
l Dementia
l Diabetes
l Hemiplegia or paraplegia
l Hypertension
l Myocardial infarction
l Metastatic solid tumour
l Mild liver disease
l Moderate/severe
liver disease
l Peripheral vascular disease
l Peptic ulcer disease
l Renal disease
l Rheumatic disease
Up to 12 secondary diagnoses are coded per hospital episode.
All previous episode (i.e. not this present episode of care)
secondary diagnoses are used to define the Charlson individual
comorbidities using validated coding algorithms
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TABLE 25 Hospital Episode Statistic database variable definitions (continued )
Data entry Calculated variable Variable description
Secondary diagnoses Modified Charlson Comorbidity
Index score
Up to 12 secondary diagnoses are coded per hospital episode.
All previous episode (i.e. not this present episode of care)
secondary diagnoses are used to define the modified Charlson
Comorbidity Index score using a validated algorithm
Outpatient
appointment date
Outpatient attendances
(last 12 months)
Using outpatient appointment date and the outcome field
(coded as ATT= attended) the number of outpatient
attendances in the last 12 months for this patient is calculated
Renal modality Not used in analysis This data variable was linked from the renal system at the
EKHUFT, using NHS number, in order to remove patients on
RRT from the analysis
AIDS, acquired immunodeficiency syndrome.
TABLE 26 Pathology database variable definitions
Data entry Calculated variable Variable description
ALT 12-month average Average of all ALT results in the 12 months prior to hospital admission
Most recent result Most recent ALT result within the last 30 days prior to hospital admission
Admission result Peak ALT result within 12 hours prior to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak ALT result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
AMY 12-month average Average of all AMY results in the 12 months prior to hospital admission
Most recent result Most recent AMY result within the last 30 days prior to hospital admission
Admission result Peak AMY result within 12 hours prior to 12 hours post admission time (taken
from ‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak AMY result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
BNP 12-month average Average of all BNP results in the 12 months prior to hospital admission
Most recent result Most recent BNP result within the last 30 days prior to hospital admission
Ca 12-month average Average of all calcium results in the 12 months prior to hospital admission
Most recent result Most recent calcium result within the last 30 days prior to hospital admission
Admission result Peak calcium result within 12 hours prior to 12 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak calcium result within 12 hours post admission to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
CRP 12-month average Average of all CRP results in the 12 months prior to hospital admission
Most recent result Most recent CRP result within the last 30 days prior to hospital admission
Admission result Peak CRP result within 12 hours prior to 12 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak CRP result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
Hb 12-month average Average of all Hb results in the 12 months prior to hospital admission
Most recent result Most recent Hb result within the last 30 days prior to hospital admission
Admission result Peak Hb result within 12 hours prior to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak Hb result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
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TABLE 26 Pathology database variable definitions (continued )
Data entry Calculated variable Variable description
HbA1c 12-month average Average of all HbA1c results in the 12 months prior to hospital admission
Most recent result Most recent HbA1c result within the last 30 days prior to hospital admission
K 12-month average Average of all K results in the 12 months prior to hospital admission
Most recent result Most recent K result within the last 30 days prior to hospital admission
Admission result Peak K result within 12 hours prior to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak K result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
Mg 12-month average Average of all Mg results in the 12 months prior to hospital admission
Most recent result Most recent Mg result within the last 30 days prior to hospital admission
Admission result Peak Mg result within 12 hours prior to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak Mg result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
Na 12-month average Average of all Na results in the 12 months prior to hospital admission
Most recent result Most recent Na result within the last 30 days prior to hospital admission
Admission result Peak Na result within 12 hours prior to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak Na result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
PLT 12-month average Average of all PLT results in the 12 months prior to hospital admission
Most recent result Most recent PLT result within the last 30 days prior to hospital admission
Admission result Peak PLT result within 12 hours pre to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak PLT result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
WBC 12-month average Average of all WBC results in the 12 months prior to hospital admission
Most recent result Most recent WBC result within the last 30 days prior to hospital admission
Admission result Peak WBC result within 12 hours pre to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak WBC result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
CK Most recent result Most recent CK result within the last 30 days prior to hospital admission
Admission result Peak CK result within 12 hours pre to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
72-hour peak Peak CK result within 12 hours post admission to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
BC Taken within
2 weeks
Binary blood culture taken (Y/N) within the 2 weeks prior to hospital admission
2 weeks significant
growth
Binary blood culture reported with significant growth (Y/N) within the 2 weeks
prior to hospital admission
Taken within
24 hours
Binary blood culture taken (Y/N) within 12 hours pre to 12 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
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TABLE 26 Pathology database variable definitions (continued )
Data entry Calculated variable Variable description
Taken within
72 hours
Binary blood culture taken (Y/N) within 12 hours pre to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
72 hours significant
growth
Binary blood culture reported with significant growth (Y/N) within 12 hours pre to
72 hours post admission time (taken from ‘Admission Date and Time’ data entry
in Table 25)
FAE Taken within
2 weeks
Binary faeces culture taken (Y/N) within the 2 weeks prior to hospital admission
2 weeks significant
growth
Binary faeces culture reported with significant growth (Y/N) within the 2 weeks
prior to hospital admission
Taken within
24 hours
Binary faeces culture taken (Y/N) within 12 hours pre to 12 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 1)
Taken within
72 hours
Binary faeces culture taken (Y/N) within 12 hours pre to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
72 hours significant
growth
Binary faeces culture reported with significant growth (Y/N) within 12 hours pre to
72 hours post admission time (taken from ‘Admission Date and Time’ data entry
in Table 25)
MSU or CSU Taken within
2 weeks
Binary MSU OR CSU taken (Y/N) within the 2 weeks prior to hospital admission
2 weeks significant
growth
Binary MSU OR CSU reported with significant growth (Y/N) within the 2 weeks
prior to hospital admission
Taken within
24 hours
Binary MSU OR CSU taken (Y/N) within 12 hours pre to 12 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
Taken within
72 hours
Binary MSU OR CSU taken (Y/N) within 12 hours pre to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
72 hours significant
growth
Binary MSU OR CSU reported with significant growth (Y/N) within 12 hours pre to
72 hours post admission time (taken from ‘Admission Date and Time’ data entry
in Table 25)
SPU Taken within
2 weeks
Binary sputum culture taken (Y/N) within the 2 weeks prior to hospital admission
2 weeks significant
growth
Binary sputum culture reported with significant growth (Y/N) within the 2 weeks
prior to hospital admission
Taken within
24 hours
Binary sputum culture taken (Y/N) within 12 hours pre to 12 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
Taken within
72 hours
Binary sputum culture taken (Y/N) within 12 hours pre to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
72 hours significant
growth
Binary sputum culture reported with significant growth (Y/N) within 12 hours pre
to 72 hours post admission time (taken from ‘Admission Date and Time’ data
entry in Table 25)
SAP Taken within
2 weeks
Binary SAP taken (Y/N) within the 2 weeks prior to hospital admission
2 weeks significant
growth
Binary SAP reported with significant growth (Y/N) within the 2 weeks prior to
hospital admission
Taken within
24 hours
Binary SAP taken (Y/N) within 12 hours pre to 12 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
Taken within
72 hours
Binary SAP taken (Y/N) within 12 hours pre to 72 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
72 hours significant
growth
Binary SAP reported with significant growth (Y/N) within 12 hours pre to
72 hours post admission time (taken from ‘Admission Date and Time’ data entry
in Table 25)
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TABLE 26 Pathology database variable definitions (continued )
Data entry Calculated variable Variable description
Cr Baseline creatinine
level
Lowest creatinine level in the 12 months prior to hospital admission (not including
the 2 weeks prior to admission)
Baseline eGFR eGFR calculated using the MDRD equation, based on the baseline Cr
Baseline CKD stage CKD stage based on the baseline eGFR
Pre-admission
creatinine level
Peak creatinine level in the 2 weeks prior to hospital admission [from 12 hours pre
admission up to 2 weeks (taken from ‘Admission Date and Time’ data entry in
Table 25)]
Pre-admission AKI
stage
AKI stage based on the pre-admission creatinine level
Admission creatinine
level
Peak creatinine level within 12 hours pre to 12 hours post admission time (taken
from ‘Admission Date and Time’ data entry in Table 25)
Admission AKI stage AKI stage based on the admission creatinine level
72-hour peak
creatinine level
Peak creatinine level within 12 hours post admission to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
72-hour AKI stage AKI stage based on the 72-hour peak creatinine level
Trop 12-month test count Number of troponin tests performed in the 12 months prior to hospital admission
12-month positive
count
Number of troponin tests classed as positive for myocardial infarction in the
12 months prior to hospital admission
Admission result Peak trop result within 12 hours pre to 12 hours post admission time (taken from
‘Admission Date and Time’ data entry in Table 25)
Admission result
tested
Binary troponin tested (Y/N) within 12 hours pre to 12 hours post admission time
(taken from ‘Admission Date and Time’ data entry in Table 25)
Admission result
positive
Binary troponin result positive for myocardial infarction (Y/N) within 12 hours pre
to 12 hours post admission time (taken from ‘Admission Date and Time’ data
entry in Table 25)
72-hour peak Peak troponin result within 12 hours post admission to 72 hours post admission
time (taken from ‘Admission Date and Time’ data entry in Table 25)
72-hour result tested Binary troponin tested (Y/N) within 12 hours post admission to 72 hours post
admission time (taken from ‘Admission Date and Time’ data entry in Table 25)
72-hour peak result
positive
Binary troponin result positive for myocardial infarction (Y/N) within 12 hours post
admission to 72 hours post admission time (taken from ‘Admission Date and
Time’ data entry in Table 25)
ACR and
PCR
Proteinuria – 12-
month test count
Number of proteinuria tests performed in the 12 months prior to hospital
admission (taken from ‘Admission Date and Time’ data entry in Table 25)
Proteinuria – 12-
month worst stage
Worst proteinuria stage [either ACR or PCR, as defined by KDIGO (see Table 29)]
in the 12 months prior to hospital admission (taken from ‘Admission Date and
Time’ data entry in Table 25)
ACR, albumin-to-creatinine ratio; BC, blood culture; Ca, corrected calcium; Cr, creatinine; FAE, faeces culture;
Mg, magnesium; PCR, protein-to-creatinine ratio; SAP, swab, aspirate, pus culture; SPU, sputum culture; trop, troponin;
Y/N, yes/no.
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TABLE 27 Electronic discharge notification database variable definitions
Data entry Calculated variable Variable description
Medication name ACEi/ARB count From medication name field of last discharge summary for that
patient and cross reference with lookup table of medication names
and parent groups, calculation of number of this class of medication
Medication name Non-steroidal anti-inflammatory
count
From medication name field of last discharge summary for that
patient and cross reference with lookup table of medication names
and parent groups, calculation of number of this class of medication
Medication name Diuretic count From medication name field of last discharge summary for that
patient and cross reference with lookup table of medication names
and parent groups, calculation of number of this class of medication
Medication name Total number of medications Total number of entries in the medication name field
ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
TABLE 28 Operation database variable definitions
Data entry Calculated variable Variable description
Operation date
and time
24-hour operation performed Binary (Y/N) operation performed in the first 24 hours of admission
(taken from ‘Admission Date and Time’ data entry in Table 25)
Operation score 24-hour maximum operation
score
[1 (least severe) to 5 (most
severe)]
Maximum operation score in the first 24 hours of admission
(taken from ‘Admission Date and Time’ data entry in Table 25)
Y/N, yes/no.
TABLE 29 Proteinuria classification (KDIGO)83
Measure
Categories
Normal to mildly
increased (1)
Moderately
increased (2)
Severely
increased (3)
AER (mg/24 hours) < 30 30–300 > 300
PER (mg/24 hours) < 150 150–500 > 500
ACR
mg/mmol < 3 3–30 > 30
mg/g < 30 30–300 > 300
PCR
mg/mmol < 15 15–50 > 50
mg/g < 150 150–500 > 500
Protein reagent strip Negative to trace Trace to + + or greater
ACR, albumin-to-creatinine ratio; AER, albumin excretion rate; PCR, protein-to-creatinine ratio; PER, protein excretion rate.
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TABLE 30 Operative Severity Score classification
OPCS subsection code OPCS subsection description
Operative Severity
Score
# Blank or unknown code
A32 Other decompression of cranial nerve 2
A33 Neurostimulation of cranial nerve 1
A36 Other operations on cranial nerve 2
A39 Repair of dura 4
A40 Drainage of extradural space 4
A41 Drainage of subdural space 4
A47 Other destruction of spinal cord 4
A48 Other operations on spinal cord 4
A52 Therapeutic epidural injection 1
A53 Drainage of spinal canal 1
A54 Therapeutic spinal puncture 1
A55 Diagnostic spinal puncture 1
A57 Operations on spinal nerve root 3
A59 Excision of peripheral nerve 1
A60 Destruction of peripheral nerve 1
A61 Extirpation of lesion of peripheral nerve 1
A62 Microsurgical repair of peripheral nerve 1
A64 Other repair of peripheral nerve 1
A65 Release of entrapment of peripheral nerve at wrist 1
A66 Release of entrapment of peripheral nerve at ankle 1
A67 Release of entrapment of peripheral nerve at other site 1
A68 Other release of peripheral nerve 1
A69 Revision of release of peripheral nerve 1
A70 Neurostimulation of peripheral nerve 1
A73 Other operations on peripheral nerve 1
A75 Excision of sympathetic nerve 2
A76 Chemical destruction of sympathetic nerve 1
A77 Cryotherapy to sympathetic nerve 1
A78 Radiofrequency controlled thermal destruction of sympathetic nerve 1
A79 Other destruction of sympathetic nerve 2
A81 Other operations on sympathetic nerve 2
A83 Electroconvulsive therapy 2
A84 Neurophysiological operations 2
B08 Excision of thyroid gland 3
B09 Operations on aberrant thyroid tissue 2
B10 Operations on thyroglossal tissue 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
B12 Other operations on thyroid gland 2
B14 Excision of parathyroid gland 2
B16 Other operations on parathyroid gland 2
B22 Excision of adrenal gland 4
B27 Total excision of breast 3
B28 Other excision of breast 2
B29 Reconstruction of breast 2
B30 Prosthesis for breast 2
B32 Biopsy of breast 1
B33 Incision of breast 1
B34 Operations on duct of breast 1
B35 Operations on nipple 1
B36 Reconstruction of nipple and areola 1
B37 Other operations on breast 2
C01 Excision of eye 3
C02 Extirpation of lesion of orbit 2
C03 Insertion of prosthesis of eye 2
C04 Attention to prosthesis of eye 1
C05 Plastic repair of orbit 2
C06 Incision of orbit 2
C08 Other operations on orbit 2
C09 Replacement of canthal tendon 2
C10 Operations on eyebrow 1
C11 Operations on canthus 1
C12 Extirpation of lesion of eyelid 1
C13 Excision of redundant skin of eyelid 1
C14 Reconstruction of eyelid 1
C15 Correction of deformity of eyelid 1
C16 Other plastic repair of eyelid 1
C17 Other repair of eyelid 1
C18 Correction of ptosis of eyelid 1
C19 Incision of eyelid 1
C20 Protective suture of eyelid 1
C22 Other operations on eyelid 1
C24 Operations on lacrimal gland 1
C25 Connection between lacrimal apparatus and nose 1
C26 Other operations on lacrimal sac 1
C27 Operations on nasolacrimal duct 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
C29 Other operations on lacrimal apparatus 1
C31 Combined operations on muscles of eye 2
C32 Recession of muscle of eye 2
C33 Resection of muscle of eye 2
C35 Other adjustment to muscle of eye 2
C37 Other operations on muscle of eye 2
C39 Extirpation of lesion of conjunctiva 1
C40 Repair of conjunctiva 1
C43 Other operations on conjunctiva 1
C44 Other plastic operations on cornea 1
C45 Extirpation of lesion of cornea 1
C46 Plastic operations on cornea 1
C47 Closure of cornea 1
C48 Removal of foreign body from cornea 1
C49 Incision of cornea 1
C51 Other operations on cornea 2
C53 Extirpation of lesion of sclera 1
C54 Buckling operations for attachment of retina 2
C55 Incision of sclera 2
C57 Other operations on sclera 2
C59 Excision of iris 2
C60 Filtering operations on iris 1
C61 Other operations on trabecular meshwork of eye 1
C62 Incision of iris 1
C64 Other operations on iris 1
C65 Operations following glaucoma surgery 2
C66 Extirpation of ciliary body 2
C69 Other operations on anterior chamber of eye 2
C71 Extracapsular extraction of lens 2
C72 Intracapsular extraction of lens 2
C73 Incision of capsule of lens 2
C74 Other extraction of lens 2
C75 Prosthesis of lens 2
C77 Other operations on lens 2
C79 Operations on vitreous body 2
C80 Operations on retinal membrane 2
C81 Photocoagulation of retina for detachment 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
C82 Destruction of lesion of retina 1
C84 Other operations on retina 2
C85 Fixation of retina 2
C86 Other operations on eye 2
C89 Operations on posterior segment of eye 2
C90 Local anaesthetics for ophthalmology procedures 1
D01 Excision of external ear 1
D02 Extirpation of lesion of external ear 1
D03 Plastic operations on external ear 1
D04 Drainage of external ear 1
D06 Other operations on external ear 1
D07 Clearance of external auditory canal 1
D08 Other operations on external auditory canal 1
D10 Exenteration of mastoid air cells 2
D12 Other operations on mastoid 2
D13 Attachment of bone anchored hearing prosthesis 2
D14 Repair of eardrum 2
D15 Drainage of middle ear 1
D16 Reconstruction of ossicular chain 2
D17 Other operations on ossicle of ear 2
D19 Extirpation of lesion of middle ear 2
D20 Other operations on middle ear 2
D23 Operations on inner ear 2
D26 Operations on vestibular apparatus 2
D28 Other operations on ear 2
E01 Excision of nose 2
E02 Plastic operations on nose 1
E03 Operations on septum of nose 1
E04 Operations on turbinate of nose 1
E05 Surgical arrest of bleeding from internal nose 1
E06 Packing of cavity of nose 1
E07 Other plastic operations on nose 1
E08 Other operations on internal nose 1
E09 Operations on external nose 1
E10 Other operations on nose 1
E12 Operations on maxillary antrum using sublabial approach 3
E13 Other operations on maxillary antrum 2
E14 Operations on frontal sinus 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
E15 Operations on sphenoid sinus 2
E16 Other operations on frontal sinus 2
E17 Operations on unspecified nasal sinus 2
E19 Excision of pharynx 4
E20 Operations on adenoid 2
E21 Repair of pharynx 3
E23 Other open operations on pharynx 3
E24 Therapeutic endoscopic operations on pharynx 2
E25 Diagnostic endoscopic examination of pharynx 1
E27 Other operations on pharynx 3
E28 Operations on cricopharyngeus muscle 2
E29 Excision of larynx 4
E30 Open extirpation of lesion of larynx 3
E31 Reconstruction of larynx 3
E33 Other open operations on larynx 3
E34 Microtherapeutic endoscopic operations on larynx 2
E35 Other therapeutic endoscopic operations on larynx 2
E36 Diagnostic endoscopic examination of larynx 1
E38 Other operations on larynx 3
E39 Partial excision of trachea 3
E40 Plastic operations on trachea 3
E41 Open placement of prosthesis in trachea 3
E42 Exteriorisation of trachea 3
E43 Other open operations on trachea 3
E48 Therapeutic fibre-optic endoscopic operations on lower
respiratory tract
1
E49 Diagnostic fibre-optic endoscopic examination of lower
respiratory tract
1
E50 Therapeutic endoscopic operations on lower respiratory tract using
rigid bronchoscope
1
E51 Diagnostic endoscopic examination of lower respiratory tract using
rigid bronchoscope
1
E52 Other operations on bronchus 4
E59 Other operations on lung 4
E85 Ventilation support 3
E95 Tuberculosis support 1
F01 Partial excision of lip 1
F02 Extirpation of lesion of lip 1
F03 Correction of deformity of lip 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
F04 Other reconstruction of lip 1
F05 Other repair of lip 1
F06 Other operations on lip 1
F08 Implantation of tooth 1
F09 Surgical removal of tooth 2
F10 Simple extraction of tooth 1
F12 Surgery on apex of tooth 1
F13 Restoration of tooth 1
F14 Orthodontic operations 1
F15 Other orthodontic operations 1
F16 Other operations on tooth 1
F17 Operations on teeth using dental crown or bridge 1
F18 Excision of dental lesion of jaw 2
F20 Operations on gingiva 2
F22 Excision of tongue 4
F23 Extirpation of lesion of tongue 2
F24 Incision of tongue 2
F26 Other operations on tongue 3
F28 Extirpation of lesion of palate 2
F29 Correction of deformity of palate 3
F30 Other repair of palate 2
F32 Other operations on palate 2
F34 Excision of tonsil 2
F36 Other operations on tonsil 2
F38 Extirpation of lesion of other part of mouth 2
F39 Reconstruction of other part of mouth 3
F40 Other repair of other part of mouth 3
F42 Other operations on mouth 2
F43 Other examinations of mouth 1
F44 Excision of salivary gland 2
F45 Extirpation of lesion of salivary gland 1
F46 Incision of salivary gland 1
F48 Other operations on salivary gland 1
F51 Open extraction of calculus from salivary duct 1
F53 Other open operations on salivary duct 1
F56 Manipulative removal of calculus from salivary duct 1
F58 Other operations on salivary duct 1
F63 Insertion of dental prosthesis 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
G02 Total excision of oesophagus 4
G07 Repair of oesophagus 4
G09 Incision of oesophagus 3
G10 Open operations on varices of oesophagus 4
G13 Other open operations on oesophagus 4
G14 Fibre-optic endoscopic extirpation of lesion of oesophagus 2
G15 Other therapeutic fibre-optic endoscopic operations on oesophagus 2
G16 Diagnostic fibre-optic endoscopic examination of oesophagus 1
G17 Endoscopic extirpation of lesion of oesophagus using
rigid oesophagoscope
2
G18 Other therapeutic endoscopic operations on oesophagus using
rigid oesophagoscope
2
G19 Diagnostic endoscopic examination of oesophagus using
rigid oesophagoscope
2
G21 Other operations on oesophagus 3
G23 Repair of diaphragmatic hernia 3
G24 Antireflux operations 3
G25 Revision of antireflux operations 3
G27 Total excision of stomach 4
G28 Partial excision of stomach 4
G29 Open extirpation of lesion of stomach 3
G31 Connection of stomach to duodenum 3
G32 Connection of stomach to transposed jejunum 4
G33 Other connection of stomach to jejunum 3
G34 Artificial opening into stomach 2
G35 Operations on ulcer of stomach 3
G36 Other repair of stomach 3
G38 Other open operations on stomach 3
G40 Incision of pylorus 3
G42 Other fibre-optic endoscopic extirpation of lesion of upper
gastrointestinal tract
2
G43 Fibre-optic endoscopic extirpation of lesion of upper
gastrointestinal tract
2
G44 Other therapeutic fibre-optic endoscopic operations on upper
gastrointestinal tract
2
G45 Diagnostic fibre-optic endoscopic examination of upper
gastrointestinal tract
1
G46 Therapeutic fibre-optic endoscopic operations on upper
gastrointestinal tract
2
G47 Intubation of stomach 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
G49 Excision of duodenum 4
G51 Bypass of duodenum 3
G52 Operations on ulcer of duodenum 3
G53 Other open operations on duodenum 3
G55 Diagnostic endoscopic examination of duodenum 1
G57 Other operations on duodenum 3
G58 Excision of jejunum 4
G59 Extirpation of lesion of jejunum 3
G60 Artificial opening into jejunum 2
G61 Bypass of jejunum 3
G63 Other open operations on jejunum 3
G64 Therapeutic endoscopic operations on jejunum 2
G67 Other operations on jejunum 3
G69 Excision of ileum 4
G71 Bypass of ileum 3
G72 Other connection of ileum 3
G73 Attention to connection of ileum 3
G74 Creation of artificial opening into ileum 3
G75 Attention to artificial opening into ileum 2
G76 Intra-abdominal manipulation of ileum 3
G78 Other open operations on ileum 3
G80 Diagnostic endoscopic examination of ileum 1
G82 Other operations on ileum 3
H01 Emergency excision of appendix 2
H02 Other excision of appendix 2
H03 Other operations on appendix 2
H04 Total excision of colon and rectum 4
H05 Total excision of colon 4
H06 Extended excision of right hemicolon 4
H07 Other excision of right hemicolon 4
H08 Excision of transverse colon 4
H09 Excision of left hemicolon 4
H10 Excision of sigmoid colon 4
H11 Other excision of colon 4
H12 Extirpation of lesion of colon 3
H13 Bypass of colon 3
H14 Exteriorisation of caecum 3
H15 Other exteriorisation of colon 3
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
H16 Incision of colon 3
H17 Intra-abdominal manipulation of colon 3
H18 Open endoscopic operations on colon 2
H19 Other open operations on colon 3
H20 Endoscopic extirpation of lesion of colon 2
H21 Other therapeutic endoscopic operations on colon 2
H22 Diagnostic endoscopic examination of colon 1
H24 Other therapeutic endoscopic operations on lower bowel using
fibre-optic sigmoidoscope
2
H25 Diagnostic endoscopic examination of lower bowel using
fibre-optic sigmoidoscope
1
H26 Endoscopic extirpation of lesion of sigmoid colon using rigid
sigmoidoscope
2
H27 Other therapeutic endoscopic operations on sigmoid colon using
rigid sigmoidoscope
2
H28 Diagnostic endoscopic examination of sigmoid colon using
rigid sigmoidoscope
1
H29 Subtotal excision of colon 4
H30 Other operations on colon 3
H33 Excision of rectum 4
H34 Open extirpation of lesion of rectum 3
H35 Fixation of rectum for prolapse 3
H36 Other abdominal operations for prolapse of rectum 3
H40 Operations on rectum through anal sphincter 2
H41 Other operations on rectum through anus 2
H42 Perineal operations for prolapse of rectum 2
H44 Manipulation of rectum 2
H46 Other operations on rectum 3
H47 Excision of anus 4
H48 Excision of lesion of anus 3
H49 Destruction of lesion of anus 3
H50 Repair of anus 2
H51 Excision of haemorrhoid 2
H52 Destruction of haemorrhoid 2
H53 Other operations on haemorrhoid 2
H54 Dilatation of anal sphincter 2
H55 Other operations on perianal region 2
H56 Other operations on anus 2
H57 Other operations on the anal sphincter to control continence 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
H58 Drainage through perineal region 2
H59 Excision of pilonidal sinus 2
H60 Other operations on pilonidal sinus 2
H62 Other operations on bowel 3
H68 Diagnostic endoscopic examination of enteric pouch
using colonoscope
1
H69 Diagnostic endoscopic examination of enteric pouch using
fibre-optic sigmoidoscope
1
H70 Diagnostic endoscopic examination of enteric pouch using
rigid sigmoidoscope
1
J02 Partial excision of liver 4
J04 Repair of liver 4
J08 Therapeutic endoscopic operations on liver using laparoscope 3
J09 Diagnostic endoscopic examination of liver using laparoscope 2
J10 Transluminal operations on blood vessel of liver 2
J12 Other therapeutic percutaneous operations on liver 2
J13 Diagnostic percutaneous operations on liver 2
J14 Other puncture of liver 2
J15 Transluminal insertion of prosthesis into blood vessel of liver 2
J18 Excision of gall bladder 3
J20 Repair of gall bladder 3
J21 Incision of gall bladder 2
J23 Other open operations on gall bladder 3
J24 Therapeutic percutaneous operations on gall bladder 2
J32 Repair of bile duct 3
J33 Incision of bile duct 3
J34 Plastic repair of sphincter of Oddi using duodenal approach 3
J37 Other open operations on bile duct 3
J40 Endoscopic retrograde placement of prosthesis in bile duct 2
J41 Other therapeutic endoscopic retrograde operations on bile duct 2
J42 Therapeutic endoscopic retrograde operations on pancreatic duct 2
J43 Diagnostic endoscopic retrograde examination of bile duct and
pancreatic duct
2
J47 Therapeutic percutaneous insertion of prosthesis into bile duct 2
J48 Other therapeutic percutaneous operations on bile duct 2
J50 Percutaneous examination of bile duct 2
J52 Other operations on bile duct 2
J57 Other partial excision of pancreas 4
J60 Other open operations on pancreatic duct 3
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
J67 Diagnostic percutaneous operations on pancreas 2
J68 Other operations on pancreas 3
J69 Total excision of spleen 4
J72 Other operations on spleen 4
J76 Therapeutic percutaneous operations on bile duct 2
K14 Other open operations on septum of heart 4
K47 Repair of coronary artery 4
K49 Transluminal balloon angioplasty of coronary artery 2
K60 Cardiac pacemaker system introduced through vein 2
K61 Other cardiac pacemaker system 2
K62 Therapeutic transluminal operations on heart 2
L12 Other open operations on pulmonary artery 4
L13 Transluminal operations on pulmonary artery 3
L16 Extra-anatomic bypass of aorta 4
L18 Emergency replacement of aneurysmal segment of aorta 4
L19 Other replacement of aneurysmal segment of aorta 4
L20 Other emergency bypass of segment of aorta 4
L21 Other bypass of segment of aorta 4
L22 Attention to prosthesis of aorta 4
L25 Other open operations on aorta 4
L26 Transluminal operations on aorta 3
L27 Transluminal insertion of stent graft for aneurysmal segment of aorta 3
L28 Transluminal operations on aneurysmal segment of aorta 3
L29 Reconstruction of carotid artery 3
L30 Other open operations on carotid artery 3
L31 Transluminal operations on carotid artery 3
L37 Reconstruction of subclavian artery 4
L38 Other open operations on subclavian artery 4
L39 Transluminal operations on subclavian artery 3
L41 Reconstruction of renal artery 4
L42 Other open operations on renal artery 4
L43 Transluminal operations on renal artery 2
L45 Reconstruction of other visceral branch of abdominal aorta 4
L47 Transluminal operations on other visceral branch of abdominal aorta 2
L48 Emergency replacement of aneurysmal iliac artery 4
L49 Other replacement of aneurysmal iliac artery 4
L50 Other emergency bypass of iliac artery 4
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
L51 Other bypass of iliac artery 4
L52 Reconstruction of iliac artery 4
L53 Other open operations on iliac artery 4
L54 Transluminal operations on iliac artery 2
L56 Emergency replacement of aneurysmal femoral artery 4
L57 Other replacement of aneurysmal femoral artery 4
L58 Other emergency bypass of femoral artery 4
L59 Other bypass of femoral artery 4
L60 Reconstruction of femoral artery 4
L62 Other open operations on femoral artery 4
L63 Transluminal operations on femoral artery 2
L65 Revision of reconstruction of artery 4
L66 Other therapeutic transluminal operations on artery 3
L67 Excision of other artery 4
L68 Repair of other artery 4
L70 Other open operations on other artery 4
L71 Therapeutic transluminal operations on other artery 3
L72 Diagnostic transluminal operations on other artery 3
L74 Arteriovenous shunt 2
L75 Other arteriovenous operations 3
L76 Endovascular placement of stent 3
L79 Other operations on vena cava 4
L84 Combined operations on varicose vein of leg 2
L85 Ligation of varicose vein of leg 2
L86 Injection into varicose vein of leg 2
L87 Other operations on varicose vein of leg 2
L88 Transluminal operations on varicose vein of leg 2
L89 Other endovascular placement of stent 2
L90 Open removal of thrombus from vein 2
L91 Other vein related operations 2
L92 Unblocking of access catheter 1
L93 Other open operations on vein 2
L94 Therapeutic transluminal operations on vein 2
L95 Diagnostic transluminal operations on vein 2
L96 Percutaneous removal of thrombus from vein 2
L97 Other operations on blood vessel 3
L98 Operations on microvascular vessel 2
L99 Other therapeutic transluminal operations on vein 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
M02 Total excision of kidney 4
M03 Partial excision of kidney 4
M04 Open extirpation of lesion of kidney 3
M05 Open repair of kidney 3
M06 Incision of kidney 3
M09 Therapeutic endoscopic operations on calculus of kidney 2
M10 Other therapeutic endoscopic operations on kidney 2
M11 Diagnostic endoscopic examination of kidney 2
M13 Percutaneous puncture of kidney 2
M14 Extracorporeal fragmentation of calculus of kidney 2
M15 Operations on kidney along nephrostomy tube track 2
M16 Other operations on kidney 3
M18 Excision of ureter 4
M19 Urinary diversion 3
M20 Replantation of ureter 3
M21 Other connection of ureter 3
M22 Repair of ureter 3
M23 Incision of ureter 3
M25 Other open operations on ureter 3
M26 Therapeutic nephroscopic operations on ureter 2
M27 Therapeutic ureteroscopic operations on ureter 2
M28 Other endoscopic removal of calculus from ureter 2
M29 Other therapeutic endoscopic operations on ureter 2
M30 Diagnostic endoscopic examination of ureter 2
M31 Extracorporeal fragmentation of calculus of ureter 2
M32 Operations on ureteric orifice 3
M33 Percutaneous ureteric stent procedures 2
M34 Total excision of bladder 3
M35 Partial excision of bladder 3
M37 Other repair of bladder 3
M38 Open drainage of bladder 3
M39 Other open operations on contents of bladder 3
M41 Other open operations on bladder 3
M42 Endoscopic extirpation of lesion of bladder 2
M43 Endoscopic operations to increase capacity of bladder 2
M44 Other therapeutic endoscopic operations on bladder 2
M45 Diagnostic endoscopic examination of bladder 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
M47 Urethral catheterisation of bladder 1
M48 Operations on bladder 3
M49 Other operations on bladder 3
M52 Abdominal operations to support outlet of female bladder 3
M53 Vaginal operations to support outlet of female bladder 3
M56 Therapeutic endoscopic operations on outlet of female bladder 3
M58 Other operations on outlet of female bladder 3
M61 Open excision of prostate 3
M65 Endoscopic resection of outlet of male bladder 3
M66 Other therapeutic endoscopic operations on outlet of male bladder 3
M67 Other therapeutic endoscopic operations on prostate 3
M68 Endoscopic insertion of prosthesis into prostate 2
M70 Other operations on outlet of male bladder 3
M71 Other operations on prostate 3
M72 Excision of urethra 3
M73 Repair of urethra 3
M75 Other open operations on urethra 3
M76 Therapeutic endoscopic operations on urethra 2
M77 Diagnostic endoscopic examination of urethra 1
M79 Other operations on urethra 2
M81 Operations on urethral orifice 2
M83 Other operations on urinary tract 3
M85 Diagnostic endoscopic examination of urinary diversion 1
N01 Extirpation of scrotum 2
N03 Other operations on scrotum 2
N05 Bilateral excision of testes 2
N06 Other excision of testis 2
N07 Extirpation of lesion of testis 2
N08 Bilateral placement of testes in scrotum 2
N09 Other placement of testis in scrotum 2
N10 Prosthesis of testis 2
N11 Operations on hydrocele sac 1
N13 Other operations on testis 2
N15 Operations on epididymis 1
N17 Excision of vas deferens 1
N19 Operations on varicocele 1
N20 Other operations on spermatic cord 1
N22 Operations on seminal vesicle 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
N24 Operations on male perineum 2
N26 Amputation of penis 2
N27 Extirpation of lesion of penis 2
N28 Plastic operations on penis 2
N30 Operations on prepuce 1
N32 Other operations on penis 2
O02 Transluminal balloon assisted coil embolisation of aneurysm of artery 2
O03 Transluminal stent assisted coil embolisation of aneurysm of artery 2
O05 Operations on dural arteriovenous fistula 4
O06 Hybrid prosthetic replacement of shoulder joint using cemented
humeral component
3
O07 Hybrid prosthetic replacement of shoulder joint using cemented
glenoid component
3
O08 Hybrid prosthetic replacement of shoulder joint using cement 3
O11 Other upper digestive tract 2
O12 Branch of external carotid artery 3
O14 Other lymph node 2
O15 Operations on blood vessel 2
O17 Secondary closed reduction of fracture of bone and internal fixation 3
O18 Hybrid prosthetic replacement of knee joint using cement 4
O19 Other therapeutic endoscopic operations on other joint structure 2
O20 Endovascular placement of stent graft 3
O21 Total prosthetic replacement of elbow joint using cement 4
O22 Total prosthetic replacement of elbow joint not using cement 4
O23 Total prosthetic replacement of elbow joint 4
O24 Prosthetic replacement of head of radius using cement 3
O25 Prosthetic replacement of head of radius not using cement 3
O26 Other prosthetic replacement of head of radius 3
O27 Other stabilising operations on joint 3
O29 Excision of bone 3
P01 Operations on clitoris 1
P03 Operations on Bartholin gland 1
P05 Excision of vulva 3
P06 Extirpation of lesion of vulva 2
P09 Other operations on vulva 2
P11 Extirpation of lesion of female perineum 2
P13 Other operations on female perineum 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
P14 Incision of introitus of vagina 2
P15 Other operations on introitus of vagina 2
P17 Excision of vagina 3
P18 Other obliteration of vagina 3
P19 Excision of band of vagina 2
P20 Extirpation of lesion of vagina 2
P21 Plastic operations on vagina 2
P22 Repair of prolapse of vagina and amputation of cervix uteri 3
P23 Other repair of prolapse of vagina 3
P24 Repair of vault of vagina 3
P25 Other repair of vagina 3
P26 Introduction of supporting pessary into vagina 1
P27 Exploration of vagina 1
P29 Other operations on vagina 2
P31 Operations on pouch of Douglas 3
P32 Other plastic operations on vagina 2
Q01 Excision of cervix uteri 2
Q02 Destruction of lesion of cervix uteri 2
Q03 Biopsy of cervix uteri 2
Q05 Other operations on cervix uteri 2
Q07 Abdominal excision of uterus 3
Q08 Vaginal excision of uterus 3
Q09 Other open operations on uterus 3
Q10 Curettage of uterus 2
Q11 Other evacuation of contents of uterus 2
Q12 Intrauterine contraceptive device 1
Q14 Introduction of abortifacient into uterine cavity 2
Q15 Introduction of other substance into uterine cavity 2
Q16 Other vaginal operations on uterus 2
Q17 Therapeutic endoscopic operations on uterus 2
Q18 Diagnostic endoscopic examination of uterus 2
Q20 Other operations on uterus 2
Q22 Bilateral excision of adnexa of uterus 3
Q23 Unilateral excision of adnexa of uterus 3
Q24 Other excision of adnexa of uterus 3
Q25 Partial excision of fallopian tube 3
Q27 Open bilateral occlusion of fallopian tubes 2
Q28 Other open occlusion of fallopian tube 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
Q29 Open reversal of female sterilisation 3
Q30 Other repair of fallopian tube 3
Q31 Incision of fallopian tube 2
Q32 Operations on fimbria 2
Q34 Other open operations on fallopian tube 3
Q35 Endoscopic bilateral occlusion of fallopian tubes 2
Q38 Other therapeutic endoscopic operations on fallopian tube 2
Q39 Diagnostic endoscopic examination of fallopian tube 2
Q41 Other operations on fallopian tube 2
Q43 Partial excision of ovary 3
Q45 Repair of ovary 3
Q47 Other open operations on ovary 3
Q48 Oocyte recovery 2
Q49 Therapeutic endoscopic operations on ovary 2
Q50 Diagnostic endoscopic examination of ovary 2
Q51 Other operations on ovary 3
Q55 Other examination of female genital tract 1
R01 Therapeutic endoscopic operations on fetus 2
R05 Diagnostic percutaneous examination of fetus 2
R10 Other operations on amniotic cavity 2
R12 Operations on gravid uterus 2
R14 Surgical induction of labour 2
R17 Elective caesarean delivery 3
R18 Other caesarean delivery 3
R19 Breech extraction delivery 2
R20 Other breech delivery 2
R21 Forceps cephalic delivery 2
R22 Vacuum delivery 2
R23 Cephalic vaginal delivery with abnormal presentation of head at
delivery without instrument
2
R24 Normal delivery 2
R27 Other operations to facilitate delivery 2
R28 Instrumental removal of products of conception from delivered uterus 2
R29 Manual removal of products of conception from delivered uterus 2
R30 Other operations on delivered uterus 2
R32 Repair of obstetric laceration 2
R37 Non-routine obstetric scan for fetal observations 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
R43 Ultrasound monitoring 1
S01 Plastic excision of skin of head or neck 1
S02 Plastic excision of skin of abdominal wall 1
S03 Plastic excision of skin of other site 1
S04 Other excision of skin 1
S05 Microscopically controlled excision of lesion of skin 1
S06 Other excision of lesion of skin 1
S08 Curettage of lesion of skin 1
S09 Photodestruction of lesion of skin 1
S10 Other destruction of lesion of skin of head or neck 1
S11 Other destruction of lesion of skin of other site 1
S13 Punch biopsy of skin 1
S14 Shave biopsy of skin 1
S15 Other biopsy of skin 1
S17 Distant flap of skin and muscle 3
S18 Distant flap of skin and fascia 3
S19 Distant pedicle flap of skin 3
S20 Other distant flap of skin 3
S21 Hair-bearing flap of skin 3
S23 Flap operations to relax contracture of skin 3
S24 Local flap of skin and muscle 3
S25 Local flap of skin and fascia 3
S26 Local subcutaneous pedicle flap of skin 3
S27 Other local flap of skin 3
S30 Other operations on flap of skin to head or neck 3
S31 Other operations on flap of skin to other site 3
S33 Hair-bearing graft of skin to scalp 2
S35 Split autograft of skin 2
S36 Other autograft of skin 2
S37 Other graft of skin 2
S38 Graft of mucosa 2
S39 Graft of other tissue to skin 2
S40 Other closure of skin 1
S41 Suture of skin of head or neck 1
S42 Suture of skin of other site 1
S43 Removal of repair material from skin 1
S44 Removal of other inorganic substance from skin 1
S45 Removal of other substance from skin 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
S47 Opening of skin 1
S48 Insertion of skin expander into subcutaneous tissue 1
S49 Attention to skin expander in subcutaneous tissue 1
S50 Introduction of other inert substance into subcutaneous tissue 1
S52 Introduction of therapeutic substance into subcutaneous tissue 1
S53 Introduction of substance into skin 1
S54 Exploration of burnt skin of head or neck 1
S55 Exploration of burnt skin of other site 1
S56 Exploration of other skin of head or neck 1
S57 Exploration of other skin of other site 1
S58 Larvae therapy of skin 1
S60 Other operations on skin 1
S62 Other operations on subcutaneous tissue 1
S64 Extirpation of nail bed 1
S66 Other operations on nail bed 1
S68 Excision of nail 1
S70 Other operations on nail 1
T01 Partial excision of chest wall 4
T03 Opening of chest 4
T05 Other operations on chest wall 4
T07 Open excision of pleura 4
T08 Open drainage of pleural cavity 3
T12 Puncture of pleura 2
T16 Other repair of diaphragm 4
T19 Simple excision of inguinal hernial sac 2
T20 Primary repair of inguinal hernia 2
T21 Repair of recurrent inguinal hernia 2
T22 Primary repair of femoral hernia 2
T23 Repair of recurrent femoral hernia 2
T24 Primary repair of umbilical hernia 2
T25 Primary repair of incisional hernia 2
T26 Repair of recurrent incisional hernia 2
T27 Repair of other hernia of abdominal wall 2
T28 Other repair of anterior abdominal wall 2
T29 Operations on umbilicus 2
T30 Opening of abdomen 3
T31 Other operations on anterior abdominal wall 2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
T34 Open drainage of peritoneum 3
T36 Operations on omentum 3
T37 Operations on mesentery of small intestine 3
T38 Operations on mesentery of colon 3
T39 Operations on posterior peritoneum 3
T41 Other open operations on peritoneum 3
T42 Therapeutic endoscopic operations on peritoneum 2
T43 Diagnostic endoscopic examination of peritoneum 2
T45 Image-controlled operations on abdominal cavity 2
T46 Other drainage of peritoneal cavity 3
T48 Other operations on peritoneum 3
T50 Transplantation of fascia 2
T51 Excision of fascia of abdomen 2
T52 Excision of other fascia 2
T55 Release of fascia 2
T56 Other excision of other fascia 2
T57 Other operations on fascia 2
T59 Excision of ganglion 2
T60 Re-excision of ganglion 2
T62 Operations on bursa 2
T64 Transposition of tendon 2
T65 Excision of tendon 2
T67 Primary repair of tendon 2
T68 Secondary repair of tendon 2
T69 Freeing of tendon 2
T70 Adjustment to length of tendon 2
T71 Excision of sheath of tendon 2
T72 Other operations on sheath of tendon 2
T74 Other operations on tendon 2
T76 Transplantation of muscle 3
T77 Excision of muscle 2
T79 Repair of muscle 2
T80 Release of contracture of muscle 2
T81 Biopsy of muscle 2
T83 Other operations on muscle 2
T85 Block dissection of lymph nodes 2
T86 Sampling of lymph nodes 1
T87 Excision or biopsy of lymph node 1
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
T88 Drainage of lesion of lymph node 1
T90 Contrast radiology of lymphatic tissue 1
T91 Operations on sentinel lymph node 2
T94 Operations on branchial cleft 2
T96 Other operations on soft tissue 2
T97 Repair of recurrent umbilical hernia 2
U07 Diagnostic imaging of chest 1
U08 Diagnostic imaging of abdomen 1
U09 Diagnostic imaging of pelvis 1
U11 Diagnostic imaging of vascular system 1
U16 Diagnostic imaging of hepatobiliary system 1
U20 Diagnostic echocardiography 1
U21 Diagnostic imaging procedures 1
U24 Diagnostic audiology 1
V05 Other operations on cranium 4
V06 Excision of maxilla 3
V07 Excision of bone of face 3
V08 Reduction of fracture of maxilla 2
V09 Reduction of fracture of other bone of face 2
V10 Division of bone of face 2
V11 Fixation of bone of face 2
V13 Other operations on bone of face 2
V14 Excision of mandible 3
V15 Reduction of fracture of mandible 2
V16 Division of mandible 2
V17 Fixation of mandible 2
V19 Other operations on mandible 2
V21 Other operations on temporomandibular joint 2
V22 Primary decompression operations on cervical spine 3
V24 Decompression operations on thoracic spine 3
V25 Primary decompression operations on lumbar spine 3
V26 Revisional decompression operations on lumbar spine 3
V27 Decompression operations on unspecified spine 3
V28 Insertion of lumbar interspinous process spacer 3
V29 Primary excision of cervical intervertebral disc 3
V33 Primary excision of lumbar intervertebral disc 3
V34 Revisional excision of lumbar intervertebral disc 3
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
V35 Excision of unspecified intervertebral disc 3
V37 Primary fusion of joint of cervical spine 3
V38 Primary fusion of other joint of spine 3
V39 Revisional fusion of joint of spine 3
V40 Stabilisation of spine 3
V41 Instrumental correction of deformity of spine 3
V44 Decompression of fracture of spine 3
V46 Fixation of fracture of spine 3
V47 Biopsy of spine 1
V48 Denervation of spinal facet joint of vertebra 2
V49 Exploration of spine 2
V50 Manipulation of spine 2
V52 Other operations on intervertebral disc 3
V54 Other operations on spine 3
V55 Levels of spine 1
V60 Primary percutaneous decompression using coblation to
intervertebral disc
2
V67 Other primary decompression operations on lumbar spine 2
V68 Other revisional decompression operations on lumbar spine 2
W01 Complex reconstruction of thumb 2
W02 Other complex reconstruction of hand 2
W03 Complex reconstruction of forefoot 3
W04 Complex reconstruction of hindfoot 3
W05 Prosthetic replacement of bone 4
W06 Total excision of bone 3
W07 Excision of ectopic bone 3
W08 Other excision of bone 3
W09 Extirpation of lesion of bone 3
W10 Open surgical fracture of bone 3
W12 Angulation periarticular division of bone 2
W13 Other periarticular division of bone 2
W14 Diaphyseal division of bone 2
W15 Division of bone of foot 2
W16 Other division of bone 2
W17 Other reconstruction of bone 3
W18 Drainage of bone 2
W19 Primary open reduction of fracture of bone and
intramedullary fixation
2
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
W20 Primary open reduction of fracture of bone and
extramedullary fixation
2
W21 Primary open reduction of intra-articular fracture of bone 2
W22 Other primary open reduction of fracture of bone 2
W23 Secondary open reduction of fracture of bone 2
W24 Closed reduction of fracture of bone and internal fixation 2
W25 Closed reduction of fracture of bone and external fixation 2
W26 Other closed reduction of fracture of bone 2
W27 Fixation of epiphysis 2
W28 Other internal fixation of bone 2
W29 Skeletal traction of bone 2
W30 Other external fixation of bone 2
W31 Other autograft of bone 3
W32 Other graft of bone 3
W33 Other open operations on bone 3
W35 Therapeutic puncture of bone 2
W36 Diagnostic puncture of bone 2
W37 Total prosthetic replacement of hip joint using cement 4
W38 Total prosthetic replacement of hip joint not using cement 4
W39 Other total prosthetic replacement of hip joint 4
W40 Total prosthetic replacement of knee joint using cement 4
W41 Total prosthetic replacement of knee joint not using cement 4
W42 Other total prosthetic replacement of knee joint 4
W43 Total prosthetic replacement of other joint using cement 4
W44 Total prosthetic replacement of other joint not using cement 4
W45 Other total prosthetic replacement of other joint 4
W46 Prosthetic replacement of head of femur using cement 3
W47 Prosthetic replacement of head of femur not using cement 3
W48 Other prosthetic replacement of head of femur 3
W49 Prosthetic replacement of head of humerus using cement 3
W50 Prosthetic replacement of head of humerus not using cement 3
W51 Other prosthetic replacement of head of humerus 3
W52 Prosthetic replacement of articulation of other bone using cement 3
W53 Prosthetic replacement of articulation of other bone not using cement 3
W54 Other prosthetic replacement of articulation of other bone 3
W55 Prosthetic interposition reconstruction of joint 3
W56 Other interposition reconstruction of joint 3
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
W57 Excision reconstruction of joint 3
W58 Other reconstruction of joint 3
W59 Fusion of joint of toe 3
W60 Fusion of other joint and extra-articular bone graft 3
W61 Fusion of other joint and other articular bone graft 3
W62 Other primary fusion of other joint 3
W63 Revisional fusion of other joint 3
W64 Conversion to fusion of other joint 3
W65 Primary open reduction of traumatic dislocation of joint 2
W66 Primary closed reduction of traumatic dislocation of joint 2
W67 Secondary reduction of traumatic dislocation of joint 2
W68 Primary reduction of injury to growth plate 2
W69 Open operations on synovial membrane of joint 2
W71 Other open operations on intra-articular structure 2
W72 Prosthetic replacement of ligament 2
W74 Other reconstruction of ligament 2
W75 Other open repair of ligament 2
W76 Other operations on ligament 2
W77 Stabilising operations on joint 2
W78 Release of contracture of joint 2
W79 Soft tissue operations on joint of toe 2
W80 Debridement and irrigation of joint 2
W81 Other open operations on joint 2
W82 Therapeutic endoscopic operations on semilunar cartilage 2
W83 Therapeutic endoscopic operations on other articular cartilage 2
W84 Therapeutic endoscopic operations on other joint structure 2
W85 Therapeutic endoscopic operations on cavity of knee joint 2
W86 Therapeutic endoscopic operations on cavity of other joint 2
W87 Diagnostic endoscopic examination of knee joint 2
W88 Diagnostic endoscopic examination of other joint 2
W89 Other therapeutic endoscopic operations on other articular cartilage 2
W90 Puncture of joint 2
W91 Other manipulation of joint 2
W92 Other operations on joint 2
W93 Hybrid prosthetic replacement of hip joint using cemented
acetabular component
4
W94 Hybrid prosthetic replacement of hip joint using cemented
femoral component
4
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
W95 Hybrid prosthetic replacement of hip joint using cement 4
W96 Total prosthetic replacement of shoulder joint using cement 4
W97 Total prosthetic replacement of shoulder joint not using cement 4
W98 Total prosthetic replacement of shoulder joint 4
X07 Amputation of arm 3
X08 Amputation of hand 3
X09 Amputation of leg 3
X10 Amputation of foot 3
X11 Amputation of toe 3
X12 Operations on amputation stump 3
X14 Clearance of pelvis 4
X20 Correction of congenital deformity of forearm 3
X21 Correction of congenital deformity of hand 3
X22 Correction of congenital deformity of hip 3
X23 Correction of congenital deformity of leg 3
X24 Primary correction of congenital deformity of foot 3
X25 Other correction of congenital deformity of foot 3
X27 Correction of minor congenital deformity of foot 3
X28 Intermittent infusion of therapeutic substance 1
X29 Continuous Infusion of therapeutic substance 1
X30 Injection of therapeutic substance 1
X32 Exchange blood transfusion 1
X33 Other blood transfusion 1
X35 Other intravenous injection 1
X36 Blood withdrawal 1
X37 Intramuscular injection 1
X38 Subcutaneous injection 1
X40 Compensation for renal failure 2
X41 Placement of ambulatory apparatus for compensation for renal failure 2
X42 Placement of other apparatus for compensation for renal failure 2
X45 Donation of organ 4
X46 Donation of other tissue 3
X48 Immobilisation using plaster cast 1
X49 Other external support of limb 1
X50 External resuscitation 4
X53 Extirpation of unspecified organ 4
X55 Other operations on unspecified organ 3
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
X56 Intubation of trachea 1
X59 Anaesthetic without surgery 1
X62 Assessment 1
Y02 Placement of prosthesis in organ NOC 2
Y03 Attention to prosthesis in organ NOC 2
Y05 Excision of organ NOC 4
Y06 Excision of lesion of organ NOC 3
Y07 Obliteration of cavity of organ NOC 3
Y08 Laser therapy to organ NOC 2
Y09 Chemical destruction of organ NOC 3
Y11 Other destruction of organ NOC 3
Y13 Other destruction of lesion of organ NOC 3
Y14 Placement of stent in organ NOC 2
Y15 Attention to stent in organ NOC 2
Y16 Connection of organ NOC 3
Y18 Release of organ NOC 2
Y20 Biopsy of organ NOC 2
Y22 Drainage of organ NOC 2
Y25 Suture of organ NOC 2
Y26 Other repair of organ NOC 3
Y27 Graft to organ NOC 3
Y29 Removal of foreign body from organ NOC 2
Y30 Incision of organ NOC 2
Y31 Exploration of organ NOC 2
Y32 Re-exploration of organ NOC 2
Y33 Puncture of organ NOC 2
Y35 Introduction of removable radioactive material into organ NOC 2
Y38 Injection of therapeutic substance into organ NOC 2
Y39 Injection of other substance into organ NOC 2
Y40 Dilatation of organ NOC 2
Y41 Examination of organ NOC 2
Y42 Manipulation of organ NOC 2
Y44 Other methods of operation on organ NOC 2
Y48 Approach to spine through back 2
Y49 Approach through thoracic cavity 4
Y50 Approach through abdominal cavity 3
Y51 Approach to organ through artificial opening into
gastrointestinal tract
3
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TABLE 30 Operative Severity Score classification (continued )
OPCS subsection code OPCS subsection description
Operative Severity
Score
Y52 Approach to organ through other opening 2
Y53 Approach to organ under image control 2
Y58 Harvest of skin for graft 2
Y59 Harvest of flap of skin and fascia 3
Y60 Other harvest of fascia 2
Y61 Harvest of flap of skin and muscle of trunk 3
Y63 Harvest of flap of muscle of trunk 3
Y65 Harvest of tendon 2
Y66 Harvest of bone 3
Y67 Harvest of other multiple tissue 3
Y69 Harvest of other tissue 2
Y70 Early operations NOC 1
Y71 Late operations NOC 1
Y74 Minimal access to thoracic cavity 3
Y75 Minimal access to abdominal cavity 2
Y76 Minimal access to other body cavity 2
Y78 Arteriotomy approach to organ under image control 2
Y80 General anaesthetic 2
Y81 Spinal anaesthetic 1
Y82 Local anaesthetic 1
Y96 In vitro fertilisation 1
Y99 Donor status 1
NOC, not otherwise classified; OPCS, Office of Population Census and Surveys.
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Appendix 2 Variable relationships with acute
kidney injury
Alanine transaminase
Alanine transaminase is a liver enzyme. It is often measured clinically to determine liver function. In the
event of acute hepatocellular injury the ALT level rises. In cases of chronic liver damage and cirrhosis there
may, however, be a reduced level of ALT as production of the enzyme is decreased. The relationship
between ALT and AKI in this data set (Figure 25), suggest that only a low ALT level is associated with an
increased risk of AKI.
Normal range (laboratory)= 0–70 U/l.
Range determined as normal for risk modelling=≤ 50 U/l.
Amylase
Amylase is an enzyme produced in the pancreas that aids the digestion of carbohydrates. A raised level of
AMY can signify the presence of pancreatitis, which we believe may carry a risk of AKI. However, as
shown in Figure 26, the relationship between AMY level and AKI in this data set suggests that only a low
AMY level is associated with an increased risk of AKI.
Normal range (laboratory)= 0–125 U/l.
Range determined as normal for risk modelling=≤ 125 U/l.
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FIGURE 25 Relationship between ALT level and AKI.
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Brain natriuretic peptide
Brain natriuretic peptide is an amino acid produced by the cardiac myocytes when they are under strain,
and, in this way, BNP is associated with heart failure. Heart failure may result in reduced perfusion of the
kidneys and thus carry a risk of AKI. The relationship between BNP level and AKI in this data set (Figure 27)
suggests that, above a BNP of 25 ng/l, with a rising BNP value there is an increasing risk of AKI.
Normal range (laboratory)= 0–99 ng/l.
Range determined as normal for risk modelling=≤ 25 ng/l.
Corrected calcium
Corrected calcium is the calcium, a mineral in the blood, corrected for the albumin level in the blood.
Raised calcium levels can lead to dehydration, which can result in AKI. Low calcium levels can signify acute
disease, which may have a risk of AKI. The relationship between calcium level and AKI in this data set
(Figure 28) suggests that both low calcium and high calcium levels signify an increased risk of AKI, and
that the risk increases the further away the value is from the normal range.
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FIGURE 26 Relationship between AMY level and AKI.
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FIGURE 27 Relationship between BNP level and AKI.
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Normal range (laboratory)= 2.2–2.6 mmol/l.
Range determined as normal for risk modelling= 2.1–2.6mmol/l inclusive.
C-reactive protein
C-reactive protein is a marker of infection or inflammation. Infection and, importantly, sepsis carry a
significant risk of AKI. The higher the CRP level the greater the severity of the infection and, it would be
expected, the higher the risk of AKI. The relationship between CRP level and AKI in this data set
(Figure 29) suggests that the risk of AKI increases with rising CRP levels.
Normal range (laboratory)=≤ 10mg/l.
Range determined as normal for risk modelling=≤ 10mg/l.
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FIGURE 28 Relationship between calcium and AKI.
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FIGURE 29 Relationship between CRP level and AKI.
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Haemoglobin
Haemoglobin is the iron-containing oxygen transport metalloprotein in red blood cells. A low Hb level is a
marker of acute or chronic disease, and we would therefore expect it to be associated with AKI. The
relationship between Hb level and AKI in this data set (Figure 30) suggests that both low and high
Hb levels signify an increased risk of AKI and that risk increases the further away the value is from the
normal range.
Normal range (laboratory)= 11–15 g/l (women); 13–18 g/l (men).
Range determined as normal for risk modelling= 11–15 g/l inclusive if female, 13–18 g/l inclusive if male.
Glycated haemoglobin
Glycated haemoglobin gives an average of blood sugar readings over the last 120 days. A value of > 6.5%
indicates a patient with diabetes. Patients with diabetes have an increased risk of AKI. A value of > 7.5%
indicates that the diabetes is not well controlled; it would be expected that the higher the value, the worse
the diabetic control and, therefore, the higher the risk of AKI. The relationship between HbA1c and AKI in
this data set (Figure 31) suggests that having HbA1c tested (as probably defining diabetes) indicates an
increased risk of AKI. This risk increases with rising HbA1c up to a value of approximately 12%, at which
point the risk starts to decrease.
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FIGURE 31 Relationship between HbA1c and AKI.
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FIGURE 30 Relationship between Hb and AKI.
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Normal range (laboratory)= 4–6.5% (Diabetes Control and Complications Trial).*
Range determined as normal for risk modelling=≤ 7.5% (Diabetes Control and Complications Trial116).*
*The International Federation of Clinical Chemistry (www.ifcc.org) recommended standardisation of HbA1c
following extraction of this data set.
Potassium
Potassium is an electrolyte that is essential for the normal functioning of cells, importantly cardiac cells.
Maintaining the gradient across the cellular membrane is essential, and changes in this can lead to cardiac
arrhythmias. K level itself in blood would not be expected to have a causal relationship with the
development of AKI, but may be a reflection of acute illness and changes in electrolyte and fluid balance.
The relationship between K level and AKI in this data set (Figure 32), suggests that both a low and a
high K level indicates an increased risk of AKI and that risk increases the further away the value is from the
normal range.
Normal range (laboratory)= 3.5–5.3 mmol/l.
Range determined as normal for risk modelling= 3.5–5.3mmol/l, inclusive.
Magnesium
Magnesium is an electrolyte that is essential for the normal functioning of cells. The magnesium (Mg) level
itself in blood would not be expected to have a causal relationship with the development of AKI, but may
be a reflection of acute illness and changes in electrolyte and fluid balance. The relationship between
Mg level and AKI in this data set (Figure 33), suggests that both a low and a high Mg level indicates an
increased risk of AKI and that risk increases the further away the value is from the normal range.
Normal range (laboratory)= 0.70–1.05mmol/l.
Range determined as normal for risk modelling= 0.7–1.0mmol/l, inclusive.
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FIGURE 32 Relationship between K and AKI.
DOI: 10.3310/hsdr04060 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 6
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Bedford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
Sodium
Sodium is an electrolyte that is essential for the normal functioning of cells. The Na level itself in blood
would not be expected to have a causal relationship with the development of AKI, but may be a reflection
of acute illness and changes in electrolyte and fluid balance. A low Na level may also signify diuretic
medication use. The relationship between Na and AKI in this data set (Figure 34) suggests that both low
and high Na levels indicate an increased risk of AKI, and that risk increases the further away the value is
from the normal range.
Normal range (laboratory)= 136–145mmol/l.
Range determined as normal for risk modelling= 136–145mmol/l, inclusive.
Platelet count
Platelet count is a measure of the number of platelets in the blood. Platelets are essential for the clotting
of the blood. The platelet level itself in blood would not be thought to have a causal relationship with the
development of AKI. However, a low PLT may be related to haematological disease or acute illness,
and a high PLT may also signify acute illness, specifically inflammation/infection.
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FIGURE 33 Relationship between Mg and AKI.
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The relationship between PLT and AKI in this data set (Figure 35) suggests that both a low and a high PCT
indicates an increased risk of AKI, and that risk increases the further away the value is from the
normal range.
Normal range (laboratory)= 150–400 × 109/l.
Range determined as normal for risk modelling= 150– 400 × 109/l, inclusive.
White blood cell count
White blood cell count is a direct marker of infection. A low (< 4 × 109/l) or high (> 11 × 109/l) WBC can
signify infection, and an infection brings a risk of AKI. The relationship between WBC and AKI in this data
set (Figure 36) suggests that both a low and a high WBC indicates an increased risk of AKI, and that risk
increases the further away the value is from the normal range.
Normal range (laboratory)= 4–11 × 109/l.
Range determined as normal for risk modelling= 1–11 × 109/l, inclusive.
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FIGURE 36 Relationship between WBC and AKI.
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FIGURE 35 Relationship between PLT and AKI.
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Creatinine kinase
Creatinine kinase is a product of muscle breakdown. When excess muscle breakdown occurs, high levels
of CK can cause damage to the kidneys and result in AKI. It would therefore be expected that the greater
the CK the greater the risk of AKI. However, the relationship between creatinine kinase level and AKI in
this data set (Figure 37) suggests that the fact that CK has been tested defines a patient with a higher risk
of AKI; however, lower levels of CK seem to be related to higher risk of AKI.
Normal range (laboratory)= 0–142 U/l.
Range determined as normal for risk modelling=≤ 1000 U/l.
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FIGURE 37 Relationship between CK and AKI.
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Appendix 3 Quantitative univariable analysis
results
TABLE 31 Results of the univariable ordinal logistic regression analysis to examine factors associated with AKI on
admission: risk model 1
Variable Category/term Odds ratio (95% CI) p-value
Agea Linear term 0.85 (0.51 to 1.41) < 0.001
Quadratic term 1.08 (0.99 to 1.18)
Cubic term 0.996 (0.991 to 1.000)
Sex Male 1 < 0.001
Female 0.78 (0.73 to 0.84)
Admissions (last 30 days) No 1 0.002
Yes 1.13 (1.05 to 1.21)
Admissions (last 2–12 months) 0 1 < 0.001
1–2 1.64 (1.52 to 1.77)
3–5 2.24 (2.03 to 2.46)
6+ 2.80 (2.43 to 3.22)
Outpatients appointments (last 12 months) 0 1 < 0.001
1–2 1.10 (1.01 to 1.20)
3–5 1.29 (1.17 to 1.41)
6+ 1.67 (1.52 to 1.84)
Primary diagnosis Neoplasms 1 < 0.001
Infectious diseases 1.47 (1.13 to 1.90)
Blood diseases 0.62 (0.43 to 0.87)
Circulatory system 0.71 (0.59 to 0.86)
Digestive system 0.66 (0.55 to 0.80)
Diseases of head/neck 0.19 (0.09 to 0.40)
Genitourinary system 1.57 (1.30 to 1.91)
Musculoskeletal 0.33 (0.26 to 0.41)
Nervous system 0.44 (0.33 to 0.60)
Respiratory system 1.02 (0.85 to 1.23)
Skin 0.84 (0.65 to 1.08)
Endocrine/metabolic 1.74 (1.47 to 2.23)
Injury/poisoning 0.47 (0.38 to 0.57)
Mental disorders 0.59 (0.42 to 0.83)
Symptoms/signs 0.44 (0.37 to 0.53)
Other 0.35 (0.16 to 0.73)
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TABLE 31 Results of the univariable ordinal logistic regression analysis to examine factors associated with AKI on
admission: risk model 1 (continued )
Variable Category/term Odds ratio (95% CI) p-value
Calcium Not measured 1 < 0.001
Normal (2.2–2.6mmol/l) 1.24 (1.13 to 1.36)
Abnormal 1.89 (1.34 to 2.66)
CRP Not measured 1 < 0.001
Normal (≤ 10mg/l) 0.86 (0.78 to 0.96)
Abnormal 1.49 (1.36 to 1.62)
Hb Not measured 1 < 0.001
Normal
(female: 11–15 g/dl)b
0.77 (0.71 to 0.84)
Abnormal 1.76 (1.62 to 1.91)
HbA1c (12-month average) Not measured 1 < 0.001
Normal (≤ 7.5%) 1.43 (1.31 to 1.56)
Abnormal 1.93 (1.71 to 2.17)
K Not measured 1 < 0.001
Normal (3.5–5.3mmol/l) 1.17 (1.09 to 1.25)
Abnormal 1.79 (1.52 to 2.10)
Na Not measured 1 < 0.001
Normal (136–145) 1.11 (1.04 to 1.20)
Abnormal 1.50 (1.36 to 1.65)
K/Na combined Not measured 1 < 0.001
Both normal 1.07 (1.00 to 1.16)
Na only abnormal 1.44 (1.31 to 1.60)
K only abnormal 1.66 (1.35 to 2.05)
Both abnormal 1.96 (1.50 to 2.55)
PLT Not measured 1 < 0.001
Normal (150–400× 109/l) 1.08 (1.01 to 1.16)
Abnormal 1.44 (1.28 to 1.62)
Troponin 0 1 < 0.001
1 2.33 (2.07 to 2.62)
2+ 3.38 (2.72 to 4.19)
WBC count Not measured 1 < 0.001
Normal (1–11 × 109/l) 1.13 (1.05 to 1.21)
Abnormal 1.26 (1.12 to 1.41)
Blood culture Not taken 1 < 0.001
Not significant 1.95 (1.70 to 2.22)
Significant 4.67 (3.61 to 6.04)
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TABLE 31 Results of the univariable ordinal logistic regression analysis to examine factors associated with AKI on
admission: risk model 1 (continued )
Variable Category/term Odds ratio (95% CI) p-value
Charlson score ≤ 0 1 < 0.001
1–10 1.55 (1.40 to 1.72)
11+ 3.11 (2.84 to 3.41)
Not recorded 1.04 (0.91 to 1.19)
Baseline eGFRc Linear term 0.63 (0.43 to 0.94) < 0.001
Quadratic term 0.93 (0.84 to 1.03)
Cubic term 1.01 (1.00 to 1.02)
Drugs takend 0 1 < 0.001
1 1.30 (1.18 to 1.43)
2 or 3 1.93 (1.71 to 2.18)
Not recorded 0.62 (0.57 to 0.67)
Faeces Not taken 1 < 0.001
Taken 1.74 (1.32 to 2.30)
MSU or CSU Not taken 1 < 0.001
Not significant 1.20 (0.95 to 1.52)
Significant 1.75 (1.54 to 2.00)
Proteinuria (worst result) Not done 1 < 0.001
1 1.39 (1.27 to 1.53)
2 or 3 2.66 (2.42 to 2.91)
Sputum Not taken 1 0.90
Taken 1.02 (0.71 to 1.48)
Wound swab/fluid aspirate Not taken 1 0.07
Not significant 0.62 (0.39 to 0.99)
Significant 1.14 (0.91 to 1.44)
a Odds ratio given for a 10-unit increase in age.
b Normal range 13–18 g/l for males.
c Odds ratio given for a 20-unit increase in baseline GFR.
d Number of the following drugs taken: angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory
drugs, diuretics.
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TABLE 32 Results of the univariable ordinal logistic regression analysis to examine factors associated with new AKI
at 72 hours: risk model 2
Variable Category/term Odds ratio (95% CI) p-value
Agea Linear term 1.28 (1.21 to 1.35) < 0.001
Sex Male 1 0.27
Female 0.91 (0.78 to 1.07)
Admissions (last 30 days) No 1 0.56
Yes 0.95 (0.79 to 1.14)
Admissions (last 2–12 months) 0 1 < 0.001
1–2 1.31 (1.09 to 1.58)
3–5 1.55 (1.22 to 1.97)
6+ 1.88 (1.37 to 2.58)
Outpatients appointment (last 12 months) 0 1 0.07
1–2 1.03 (0.84 to 1.28)
3–5 1.25 (1.00 to 1.55)
6+ 1.28 (1.02 to 1.62)
Primary diagnosis Neoplasms 1 < 0.001
Infectious diseases 1.80 (1.08 to 3.00)
Blood diseases 0.63 (0.28 to 1.43)
Circulatory system 1.09 (0.73 to 1.62)
Digestive system 0.71 (0.47 to 1.08)
Genitourinary system 1.54 (0.98 to 2.42)
Musculoskeletal 0.74 (0.37 to 1.47)
Nervous system 0.53 (0.23 to 1.22)
Respiratory system 0.78 (0.52 to 1.19)
Skin 0.89 (0.47 to 1.69)
Endocrine/metabolic 0.70 (0.34 to 1.43)
Injury/poisoning 0.97 (0.64 to 1.48)
Mental disorders 0.14 (0.02 to 1.04)
Symptoms/signs 0.72 (0.46 to 1.14)
Other 1.02 (0.29 to 3.65)
ALT Not measured 1 0.84
Normal (≤ 50U/l) 1.06 (0.86 to 1.32)
Abnormal 1.08 (0.79 to 1.48)
AMY Not measured 1 0.55
Normal (≤ 125U/l) 0.90 (0.73 to 1.10)
Abnormal 1.05 (0.62 to 1.79)
BNP (12-month average) Not measured 1 0.49
Measured 1.19 (0.73 to 1.96)
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TABLE 32 Results of the univariable ordinal logistic regression analysis to examine factors associated with new AKI
at 72 hours: risk model 2 (continued )
Variable Category/term Odds ratio (95% CI) p-value
Calcium Not measured 1 0.45
Normal (2.2–2.6mmol/l) 1.09 (0.92 to1.30)
Abnormal 1.24 (0.75 to 2.03)
CRP Not measured 1 < 0.001
Normal (≤ 10mg/l) 0.81 (0.59 to 1.10)
Abnormal 1.16 (0.87 to 1.53)
Hb Not measured 1 < 0.001
Normal
(female: 11–15 g/dl)b
0.65 (0.41 to 1.01)
Abnormal 0.94 (0.60 to 1.47)
HbA1c (12-month average) Not measured 1 < 0.001
Normal (≤ 7.5%) 1.51 (1.24 to 1.85)
Abnormal 1.52 (1.13 to 2.02)
K Not measured 1 0.003
Normal (3.5–5.3mmol/l) 0.67 (0.50 to 0.91)
Abnormal 0.94 (0.65 to 1.37)
Mg Not measured 1 0.008
Normal (0.7–1.0mmol/l) 0.87 (0.66 to 1.15)
Abnormal 1.72 (1.19 to 2.48)
Na Not measured/normal 1 0.46
Abnormal 1.06 (0.90 to 1.25)
PLT Not measured/normal 1 0.10
Abnormal 1.17 (0.97 to 1.41)
Troponin 0 1 < 0.001
1 1.35 (1.10 to 1.66)
2+ 2.33 (1.86 to 2.93)
WBC Not measured/normal 1 0.03
Abnormal 1.20 (1.02 to 1.40)
CK Not measured 1 0.67
Normal (≤ 1000U/l) 0.96 (0.63 to 1.47)
Abnormal 1.35 (0.68 to 2.67)
Blood culture Not taken 1 0.02
Taken 1.28 (1.03 to 1.59)
Charlson score ≤ 0 1 < 0.001
1–10 1.45 (1.12 to 1.87)
11+ 2.33 (1.86 to 2.93)
Not recorded 1.39 (1.03 to 1.88)
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TABLE 32 Results of the univariable ordinal logistic regression analysis to examine factors associated with new AKI
at 72 hours: risk model 2 (continued )
Variable Category/term Odds ratio (95% CI) p-value
Number of contrast radiology scans 0 1 0.82
1+ 1.03 (0.78 to 1.37)
Baseline eGFRc Linear term 0.54 (0.40 to 0.74) < 0.001
Quadratic term 1.03 (1.00 to 1.08)
Drugs takend 0 1 < 0.001
1 1.25 (1.00 to 1.58)
2 or 3 1.92 (1.42 to 2.59)
Not recorded 0.85 (0.71 to 1.03)
Faeces (pre admission) Not taken 1 0.30
Taken 1.36 (0.76 to 2.43)
Faeces (admission) Not taken 1 0.42
Taken 0.78 (0.43 to 1.42)
MSU or CSU (pre admission) Not taken 1 0.07
Not significant 0.63 (0.29 to 1.36)
Significant 1.40 (1.00 to 1.96)
MSU or CSU (admission) Not taken 1 0.001
Taken 1.43 (1.15 to 1.78)
Operation score at 12 hours 0 1 0.13
Score 1–2 0.99 (0.68 to 1.44)
Score 3–4 1.47 (1.01 to 2.13)
Proteinuria (worst result) Not done 1 < 0.001
1 1.27 (1.01 to 1.60)
2 or 3 2.56 (2.08 to 3.15)
Sputum (pre admission) Not taken 1 0.73
Taken 1.14 (0.54 to 2.42)
Sputum (admission) Not taken 1 0.12
Taken 0.54 (0.24 to 1.17)
Wound swab/fluid aspirate (pre admission) Not taken 1 0.42
Taken 0.81 (0.48 to 1.36)
Wound swab/fluid aspirate (admission) Not taken 1 0.55
Taken 1.11 (0.80 to 1.53)
a Odds ratio given for a 10-unit increase in age.
b Normal range 13–18 g/l for males.
c Odds ratio given for a 20-unit increase in baseline GFR.
d Number of the following drugs taken: angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs,
and diuretics.
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TABLE 33 Results of the univariable ordinal logistic regression analysis to examine factors associated with
worsening AKI at 72 hours: risk model 3
Variable Category/term Odds ratio (95% CI) p-value
Agea Linear term 0.94 (0.86 to 1.04) 0.26
Sex Male 1 0.32
Female 1.18 (0.86 to 1.61)
Admissions (last 30 days) No 1 0.53
Yes 0.89 (0.61 to 1.129)
Admissions (last 2–12 months) 0 1 0.92
1–2 0.89 (0.61 to 1.29)
3–5 0.88 (0.56 to 1.38)
6+ 0.98 (0.54 to 1.78)
Outpatients appointment (last 12 months) 0 1 0.42
1–2 0.86 (0.57 to 1.33)
3–5 0.69 (0.42 to 1.11)
6+ 1.00 (0.66 to 1.52)
Primary diagnosis Neoplasms 1 < 0.001
Infectious diseases 6.39 (1.88 to 21.7)
Circulatory system 1.90 (0.63 to 5.69)
Digestive system 1.46 (0.47 to 4.57)
Genitourinary system 2.60 (0.85 to 7.94)
Musculoskeletal 1.67 (0.27 to 10.3)
Nervous system 0.82 (0.08 to 8.08)
Respiratory system 1.46 (0.48 to 4.42)
Skin 1.15 (0.27 to 4.99)
Endocrine/metabolic 1.06 (0.28 to 4.02)
Injury/poisoning 2.70 (0.84 to 8.66)
Symptoms/signs 0.92 (0.26 to 3.29)
Other 0.43 (0.04 to 4.12)
ALT Not measured 1 0.07
Normal (≤ 50U/l) 1.05 (0.69 to 1.63)
Abnormal 1.73 (0.98 to 3.05)
AMY Not measured 1 0.24
Measured 1.25 (0.86 to 1.82)
BNP (12-month average) Not measured 1 0.86
Measured 1.09 (0.45 to 2.62)
Calcium Not measured 1 0.92
Normal (2.2–2.6mmol/l) 0.93 (0.66 to 1.32)
Abnormal 1.01 (0.47 to 2.19)
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TABLE 33 Results of the univariable ordinal logistic regression analysis to examine factors associated with
worsening AKI at 72 hours: risk model 3 (continued )
Variable Category/term Odds ratio (95% CI) p-value
CRP Not measured 1 0.05
Normal (≤ 10mg/l) 0.80 (0.32 to 1.96)
Abnormal 1.40 (0.62 to 3.17)
Hb Not measured 1 0.73
Normal
(female: 11–15 g/dl)b
1.02 (0.38 to 2.70)
Abnormal 0.89 (0.34 to 2.37)
HbA1c (12-month average) Not measured 1 0.85
Normal (≤ 7.5%) 1.06 (0.72 to 1.58)
Abnormal 1.14 (0.71 to 1.83)
K Not measured 1 0.76
Normal (3.5–5.3mmol/l) 0.89 (0.43 to 1.86)
Abnormal 1.03 (0.47 to 2.27)
Mg Not measured 1 < 0.001
Normal (0.7–1.0mmol/l) 1.29 (0.80 to 2.11)
Abnormal 2.92 (1.71 to 4.98)
Na Not measured/normal 1 0.55
Abnormal 1.10 (0.80 to 1.52)
PLT Not measured/normal 1 0.05
Abnormal 1.43 (1.00 to 2.05)
Troponin 0 1 0.66
1 0.90 (0.58 to 1.39)
2+ 1.16 (0.75 to 1.78)
WBC Not measured/Normal 1 0.02
Abnormal 1.51 (1.08 to 2.11)
CK Not measured 1 0.008
Normal (≤ 1000U/l) 1.49 (0.73 to 3.04)
Abnormal 4.90 (1.73 to 13.9)
Blood culture Not taken 1 0.04
Taken 1.47 (1.03 to 2.12)
Charlson score ≤ 0 1 0.44
1–10 1.40 (0.82 to 2.39)
11+ 1.10 (0.68 to 1.78)
Not recorded 1.45 (0.76 to 2.79)
Number of contrast radiology scans 0 1 0.05
1+ 1.77 (1.01 to 3.09)
Baseline eGFRc Linear term 1.18 (1.040 to 1.32) 0.007
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TABLE 33 Results of the univariable ordinal logistic regression analysis to examine factors associated with
worsening AKI at 72 hours: risk model 3 (continued )
Variable Category/term Odds ratio (95% CI) p-value
Drugs takend 0 1 0.23
1 1.09 (0.69 to 1.72)
2 or 3 1.53 (0.90 to 2.61)
Not recorded 1.41 (0.96 to 2.07)
Faeces (pre admission) Not taken 1 0.69
Taken 1.24 (0.42 to 3.66)
Faeces (admission) Not taken 1 0.22
Taken 1.57 (0.78 to 3.20)
MSU or CSU (pre admission) Not taken 1 0.50
Taken 1.20 (0.71 to 2.04)
MSU or CSU (admission) Not taken 1 0.20
Taken 1.28 (0.88 to 1.85)
Operation score at 12 hours 0 1 < 0.001
Score 1–2 1.55 (0.68 to 3.52)
Score 3–4 4.65 (2.24 to 9.67)
Proteinuria (worst result) Not done 1 0.84
1 1.00 (0.65 to 1.55)
2 or 3 1.12 (0.76 to 1.65)
Sputum (pre admission) Not taken 1 0.68
Taken 0.65 (0.08 to 5.17)
Sputum (admission) Not taken 1 0.02
Taken 2.95 (1.17 to 7.42)
Wound swab/fluid aspirate (pre admission) Not taken 1 0.10
Taken 1.95 (0.87 to 4.34)
Wound swab/fluid aspirate (admission) Not taken 1 < 0.001
Taken 3.16 (1.94 to 5.13)
a Odds ratio given for a 10-unit increase in age.
b Normal range 13–18 g/dl for males.
c Odds ratio given for a 20-unit increase in baseline GFR.
d Number of the following drugs taken: angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs,
and diuretics.
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Appendix 4 Qualitative analysis documentation
Data analysis framework
Introducing the AKI alert system
Analytical construct Quote and code
Coming to know about the AKI alert system
Introduction to the system, how this happened
Preparation for use, training
Length of time system used
How introduction could be improved
Other
Using the technology
General experiences of using the technology
Accessibility
Ease of navigation
Visual impact
Opinions of information on the system
Ease of identifying cohort
Relevance of information
Accuracy
Sufficiently up to date
How information is used
Accessing information
Communicating information
Monitoring behaviour
Influencing treatments/interventions
Communicating to clinician looking after the patient
Strengths of technology
Weaknesses of technology
Improvements to technology
Other
Impacts on clinical practice and patients: consultants
Changes to clinical practice from the AKI alert system
Positive changes
Negative changes
Communicating to teams
Team’s understanding of AKI
Difference to patient care
Positive differences
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Introducing the AKI alert system
Negative differences
Added value, cost-effectiveness
Other
Impacts on clinical practice and patients: nurses
Changes to clinical practice from the AKI alert system
Positive changes
Negative changes
Assessment behaviour
Explanation of disparities between areas
Working with medical teams
Communication issues
Reactions to requests
Response to referrals
Other
Comments/suggestions for improvement/other
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Appendix 5 Consultant interview schedule
Evaluation of the AKI Alert System to identify and monitor patients 
with Acute Kidney Injury (AKI): Consultant Interview 
 
1 Introducing the AKI Alert System 
a) How did you first come to know about the AKI Alert System? 
Prompts: who introduced the system, where, preparation for use/training 
received, how long using it? 
b) What were your initial reactions? 
 
c) How could your introduction to the system have been improved? 
 
 
2 Using the technology 
a) Describe to me your experiences of using the technology 
Prompts: accessibility, ease of navigation, visual impact, strengths and 
weaknesses   
 
b) Tell me about your opinions of the information on the system. 
Prompts: ease of identifying cohort, relevance of information, accuracy, 
sufficiently up-to-date, strengths and weaknesses? 
 
c) How do you use this information? 
Prompts: how often accessed, communication of information, monitoring 
behaviour, treatment/interventions? Communicating to clinician looking after 
the patient? 
 
d) Do you have any suggestions for how the technology could be improved? 
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 3 Impacts on clinical practice and patients 
a) Does the AKI Alert System change clinical practice?  
Prompts: examples of positive and negative changes to clinical practice. 
 
b) Tell me about how you communicate with the clinical teams looking after the 
patient. 
Prompts: What do they know about AKI? Any difficulties with 
communication? 
 
a) Can you think of any ways that it makes a difference to patient care? 
Prompts: positive and negative differences, does it add value, is it cost-
effectiveness? 
 
 
4 Any other comments or suggestions for improvement? 
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Appendix 6 Outreach nurse focus group schedule
Evaluation of the AKI Alert System to identify and monitor patients 
with Acute Kidney Injury (AKI): Outreach Nurse Focus Group 
 
1 Introducing the AKI Alert System 
a) How did you first come to know about the AKI Alert System? 
Prompts: who introduced the system, where, preparation for use/training 
received? 
b) What were your initial reactions? 
 
c) How could your introduction to the system have been improved? 
 
 
2 Using the technology 
a) Describe to me your experiences of using the technology 
Prompts: accessibility, ease of navigation, visual impact, strengths and 
weaknesses   
 
b) Tell me about your opinions of the information on the system. 
Prompts: ease of identifying cohort, relevance of information, accuracy, 
sufficiently up-to-date, strengths and weaknesses? 
 
c) How do you use this information? 
Prompts: how often accessed, communication of information, monitoring 
behaviour, treatment/interventions? 
 
d) Do you have any suggestions for how the technology could be improved? 
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3 Impacts on clinical practice and patients 
a) Has the AKI Alert System changed the way you work?  
Prompts: examples of positive and negative changes to clinical practice, 
assessment behaviour (disparity in assessments per area – why?) 
 
b) Tell me about your experiences of working with members of the medical 
team. Prompts: communication issues, reactions, responding to referrals? 
 
c) Are there any specific impacts from a professional viewpoint? 
Prompts: should patients with AKI be a focused part of the job, or just an 
addition to support the renal team? Will this become embedded in the future 
role of outreach nurses? 
 
d) Can you think of any ways that it makes a difference to patient care? 
Prompts: positive and negative differences, added value, cost-effectiveness? 
 
4 Any other comments or suggestions for improvement?
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